Structural and functional investigation of Na+, K+-ATPase regulators : FXYD proteins and cardiac glycosides by Whittaker, Christopher Andrew Paul
STRUCTURAL AND FUNCTIONAL 
INVESTIGATION OF NA+, K+-ATPASE 
REGULATORS: FXYD PROTEINS AND CARDIAC
GLYCOSIDES
Thesis submitted in accordance with the requirements of 
the University of Liverpool for the degree of Doctor in 
Philosophy
by
Christopher Andrew Paul Whittaker
September 2011
ABSTRACT
The Na+, K+-ATPase is an integral membrane protein that is essential for maintaining the ionic gradient in 
eukaryotes which is required for many important cellular processes including maintaining cell volume and 
the secondary transport of solutes. This project investigates the structure, function and physical properties 
of two classes of inhibitors of the Na+, K+-ATPase, FXYD proteins and the cardiac glycosides. This was 
achieved with a range of biophysical methods including solid-state NMR.
The FXYD proteins are a family of seven physiological inhibitors of the Na+, K+-ATPase named after a 
shared PFXYD domain. They are transmembrane proteins of 64-178 amino acids which share sequence 
homology in their transmembrane domains but are sequentially diverse in their cytoplasmic domains. As 
the members of the FXYD family are tissue specifically expressed and they affect the activity of the Na+, 
K+-ATPase in different ways it is thought that the variable cytoplasmic domains of these proteins are 
responsible for the unique functional features of each FXYD protein. This work focuses on two FXYD 
proteins: phospholemman (PLM) which has been linked to cardiac arrhythmia and Mat-8, a marker for 
several forms of cancer which has two isofonns varying in the lengths of their cytoplasmic domains (short 
form and long form). The initial hypothesis is that the cytoplasmic region of PLM interacts with the Na+, 
K+-ATPase at one or more specific sites which causes a reduction of ATPase activity. This interaction is 
likely regulated by Ser 68 and/or Ser 63 phosphorylation and occurs in close proximity of the cell 
membrane surface due to the affinity of the cytoplasmic region of PLM for negatively charged lipid 
bilayers. This feature is unlikely shared with short form Mat-8 as it does not have any identified 
phosphorylation sites but due to lack of data on long form Mat-8 it is not clear whether or not its 
cytoplasmic region interacts with the Na+, K+-ATPase in a similar way to PLM.
Initially, work was undertaken to develop a system to express and purify PLM and Mat-8. An existing 
method based on the expression of inclusion bodies was first investigated but was found to be inefficient. 
A new system was therefore developed which successfully enabled the expression and purification of the 
short form of Mat-8. Further optimisation of this procedure will allow the expression and purification of 
isotopically labelled Mat-8 suitable for analysis by NMR.
Synthetic peptides corresponding to the cytoplasmic domains of PLM and Mat-8 were studied in isolation 
of the transmembrane domains in order to investigate their interactions with Na+,K+-ATPase and with 
phospholipid membrane surfaces. The cytoplasmic domain of PLM has been found to interact with 
negatively charged phospholipid membrane surfaces and inhibit the Na+, K+-ATPase. These effects are 
reduced upon phosphorylation of Ser 68 suggesting phosphorylation has a role in regulating inhibition of 
the Na+, K+-ATPase by PLM. It was found here that the short isoform of Mat-8 neither interacts with 
membrane surfaces nor inhibits Na+,K+-ATPasc whereas the long isofonn of Mat-8, which has an 
additional 26 amino acids in the cytoplasmic region, also binds to negatively charged cell membranes and 
inhibits the Na+, K+-ATPase albeit to a smaller extent. Motivated by these results, bioinformatic analysis 
identified a potential small linear Na+, K+-ATPase binding motif; SxxRxS, which is present in PLM, long 
form Mat-8, several other binding partners of the Na+, K+-ATPase but not any other FXYD proteins. This 
motif in PLM was modelled onto a binding site predicted by Anchorsmap, showing both electrostatic and 
steric compatibility and favouring a site of interaction of the PLM cytoplasmic domain situated close to the 
membrane surface where interactions with lipid headgroups are possible.
The cardiac glycosides are drugs used in heart failure and cardiac arrhythmia which are potent inhibitors of 
the Na+, K+-ATPase. Solid-state NMR methods were developed to investigate the position of cardiac 
glycosides in the high-affinity site within native membranes, by exploiting ouabain derivatised in the 
steroid moiety with a l3C-labelled acetonide bridge. By using the solid-state NMR technique of cross­
polarisation, the natural abundance 13C nuclei from lipid headgroups and protein side chains can be 
observed together with a signature peak from the bound ouabain derivative. The paramagnetic broadening 
agent manganese was titrated into the membranes to probe the depth of the ouabain binding site. 
Paramagnetic broadening agents shorten the T2 times of local nuclei causing peak broadening with a 
distance-dependent relationship, thereby having greater effects on more accessible nuclei. The reduction of 
the ligand peak intensity was compared to the natural abundance 13C signals to estimate the depth of the 
acetonide bridge. The results suggest that (he acetonide group attached to the steroid moiety is close to the 
surface of the protein. This methodology can now be used with double 13C-labelled ouabain to determine 
the orientation of the ligand in the binding site. The work presented here provides a range of insights into 
the structure function relationship of FXYD proteins and reveals a novel method for probing the depths of 
ligands within transmembrane proteins which can be applied to other systems.
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Chapter 1
1.1. Introduction
The Na+, K+-ATPase is a membrane embedded ion pump. The importance 
of the Na+, K+-ATPase is highlighted by the fact that it consumes 20-30% 
of ATP production at rest in all mammalian cells (Jorgensen et aL, 2003). 
The electrochemical gradient induced by the Na+, Kf-ATPase is vital for 
many important cellular processes. These include maintaining membrane 
potentials, maintaining cell volume and the secondary transport of other 
solutes in all eukaryotes.
1.1.2. History - Sodium Pump
In the 1930s it was generally accepted that the cell membrane could 
actively transport nutrients such as sugar but it was not widely accepted 
that small ions like Na+ could enter or leave the cell in a similar manner. 
This all changed when techniques were developed to produce radioactive 
isotopes of hydrogen, nitrogen, carbon and oxygen (Hevesy, 1938). Dean 
noted (Dean, 1941) from his own experiments and the work of others 
(Heppel and Schmidt, 1938; Heppel, 1939; Steinbach, 1940) that Na+was 
found in high concentrations in muscle cells and this Na+ was rapidly 
replaced by K+ ions when they were made available. He theorised that as 
the muscle can actively move potassium and sodium ions against 
concentration gradients there must be some sort of an energy requiring
1
pump, possibly located in the fibre membrane, which can pump out the 
sodium or, conversely, pump in the potassium. As the notion of such a 
system was so radical there was no significant response to the work of 
Dean until 1957 when Skou discovered the biochemical mechanism 
responsible for the exchange of Na+ and K+ ions across the cell membrane 
(Skou, 1957). It was described as a membrane embedded ATPase with 
catalytic properties. This work followed the discovery of an ATPase in the 
sheath part of the giant axon in crab nerves (Libet, 1948). ATP hydrolysis 
is used frequently in nature to provide energy for non-passive processes so 
it was hypothesised this ATPase must provide an active function. Skou 
analysed these crab nerves further in order to discover what this function 
was. He observed that the membranes have a small Mg2+ induced ATPase 
activity. When Mg2+ was added with Na+ it generated a small increase in 
activity, which was not obseived when Mg2+ was added with K+. However 
upon addition of both Na+ and K+ in the presence of Mg2+ there was a 
significant combined positive effect on activity. This result and those of 
later experiments from other laboratories lead to the identification and 
characterisation of Na+, K+-ATPase (Skou, 1965) and as a result in 1997 
Skou received share of the Nobel prize for chemistry for “the first 
discoveiy of an ion-transporting enzyme, Na+, K+ -ATPase”.
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1.1.2. Mechanism
The Na+, K+-ATPase has two major subunits. The a-subimit is the catalytic 
subunit where all the ions are bound and exchanged whereas the (3-subunit 
alters the a-subunit to give it affinity for Na+ and K1. The Na+, K+-ATPase 
operates in a cyclic mechanism, exchanging three Na+ ions from inside the 
cell with two K+ ions from the extracellular matrix. The cytoplasm has a 
veiy high concentration of proteins which have a negative charge 
neutralised by the K! pumped into the cell. This electrogenic translocation 
generates an ionic gradient as the extracellular matrix is more positively 
charged than the cytoplasm. Under equilibrium conditions intracellular 
concentrations of Na+ and K1 are 10-20 mM and about 150 mM 
respectively. Na+ activation of the Na+, K+-ATPase occurs when 
intracellular Na+ ion concentration goes beyond the threshold at 15-20% 
above the maximum. Extracellular concentrations are typically around 
4 mM K+ and 140 mM Na+. K+ activation of the Na+, K+-ATPase 
occurring when going beyond the threshold at approximately 85% above 
the typical extracellular K+ ion concentration. Ionic translocation by the 
Na+, K+-ATPase induces many conformational transitions of the protein 
that are dependent on the energy released from ATP hydrolysis. The Na+, 
K+-ATPase is a P-type ATPase and like other P-type ATPases the Na+, 
K+-ATPase has two major conformations known as Ei and E2 which have 
different affinities for Na+ and K+ and changes between these two 
conformations are induced by phosphorylation and dephosphorylation.
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Figure LI shows a schematic representation of the how these 
conformational changes occur and their implications. At rest (when Na+ 
and K+ are below activation thresholds) the Na+, K+-ATPase appears to be 
in the phosphorylated E2 conformation (E2P) as it has been shown to be in 
the absence of NaH and K1 ions (Skou and Esmami, 1983). E2P will bind 
two K+ ions with low affinity (giving E2P.2K+) and this in turn induces a 
change into a K+ occluded form (E2P(2K+)) (Glynn and Richards, 1982). 
The equilibrium between E2P.2K+ and E2P(2K+) is shifted far towards the 
latter and thus the apparent E2P affinity for K+ is in fact very high with K0.5 
just a few pM. The transformation from high K+ affinity (E2P(2K+)) to 
high Na+ affinity (Ei.3Na+) is veiy slow in the absence of ATP but upon 
ATP binding the rate of this transition is increased to form Ei.3Na+.ATP; 
the conformation where both 3 sodium ions and 1 ATP molecule is bound 
to the Na+, K+~ATPase. This causes a loss of affinity for K+ ions and they 
are released into the cytoplasm. It is important to note that ATP is not 
hydrolysed at this point so this increase in transitional rate is passive, i.e. 
down the free energy gradient. The hydrolysis of ATP is induced after the 
binding of the Na+ ions where Na+ bestows catalytic activity to the system. 
The released phosphate transfers to Asp 369 of the a-subimit which leads 
to Na+ occlusion (Ej.P (3Na+)). De-occlusion of these Na+ ions has only 
recently been fully understood. This is because much of the knowledge for 
the mechanism of the Na+, fC'-ATPase has been obtained from the 
sarcoplasmic reticulum Ca2+-ATPase (SERCA), which has 65% similarity
4
to the a-subunit of the Na+, K+-ATPase (Sweadner and Donnet, 2001). 
SERCA has two cation (Ca2+) binding sites with the corresponding sites in 
Na+, K+-ATPase alternatively occupied by Na+ and K+. The third Na+ 
binding site is unique to the Na+, K+-ATPase so there is no corresponding 
data from SERCA to compare to. As a result of this the third Na+ binding 
site is not veiy well understood. The simplest explanation would be that all 
three Na+ ions are released at once; however, there is no significant 
corresponding binding event unlike the de-occlusion of K+ ions induced by 
the binding of ATP. This suggests de-occlusion of Na1 could happen in a 
veiy different maimer to de-occlusion of K+. A more refined model is 
shown in Figure 1.2. This is based on observations using high-time- 
resolution measurements (Hilgemann, 1994; Holmgren et ah, 2000). 
Initially all three Na1 ions are occluded (EiP3Na+). The third binding site 
likely releases its Na1 ion first (EzPSNa*) which would explain the quick 
large charge movement (around 100 ps). This observation is much like 
what is observed in an ion channel. This, in turn causes the remaining two 
Na1' binding sites to reorganise thus causing a relatively slow de-occlusion 
(4 ms) of the remaining Na+ ions (E2P2Na+). This returns the Na1*, K+- 
ATPase to E2P conformation and thus a cycle is completed.
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Figure 1.2. Refined mechanism of the Na+, K+-ATPase. The de-occlusion of Na 
remains unclear; it appears to be a two step process where one specialised Na4 site unique 
to the Na+, K -ATPase releases its ion first causing a rearrangement of the enzyme 
allowing the remaining two cation binding sites to release their Na4 ions, allowing 
subsequent binding ofK' ions (Hilgemann, 1994).
Further insight into the third Na4 binding site was gained upon solving the 
structure of the Na+, K4-ATPase (Morth et al., 2007) which is discussed 
later.
1.1.3. Structure
The minimal functional enzyme unit of the Na4 , K4-ATPase is made up of 
a large a-subunit of around 1012 amino acids and a smaller (Tsubunit of 
around 300 amino acids both primary sequences of which were first 
determined in sheep (Shull et al., 1985). There are four a-subunit (al-a4) 
and three P-subunit (pl-p3) isoforms in mammalian cells potentially giving 
twelve different isozymes with different functional properties (Blanco and 
Mercer, 1998). Until recently much of the structural information about the 
a-subunit was obtained from modelling it to the x-ray crystal structure of 
SERCA (Toyoshima et al, 2000). However subsequently x-ray structures 
have been solved in the E2P.(2K+) conformation of Na4, Kf-ATPase from
7
pig kidney published in 2007 (Moith et ah, 2007) and then shark rectal 
gland published in 2009 (Shinoda et aL, 2009). SERCA and the a-subunit 
of the Na+, K+-ATPase are sequentially and structurally veiy similar as 
shown in the sequence alignment (Appendix A) and the structural 
alignment (Figure 1.3.). Both are P-Type ATPases (type II) which means 
they both undergo conformational changes between El and E2 forms 
which are dependent on phosphorylation and dephosphorylation. (Chan et 
aL, 2010). Both proteins contain ten transmembrane helices (M1-M10) 
which make up the cation transport path. They also have three cytoplasmic 
domains; the A-domain (actuator), P-domain (phosphorylation) and 
N-domain (nucleotide-binding) (Toyoshima et aL, 2000; Morth et aL, 
2007). The P-domain is the central part of the protein and contains the 
phosphorylation site (Asp 351 in the Na+, K+-ATPase) in a negatively 
charged pocket, key in the mechanism described earlier. It is made up of 
two segments vastly separated in the amino-acid sequence. The N-terminal 
part (ranging approximately between Asn 330 and Asn 359 in the 
Na+, K+-ATPase) is comiected to helix M4 and the C-terminal part 
(approximately from Lys 605 to Asp 737 in the Na+, K'-ATPase) to helix 
M5. The N-domain is the largest domain and contains the ATP binding 
pocket which is positively charged (surrounds Phe 487 in the 
Na+, K+-ATPase). It is made up of the amino acids that are inserted in- 
between the two P-domain parts. The A-domain is the smallest and is made 
up of the cytoplasmic N-tenninus (two short a-helices) and an insertion
8
between M2 and M3 (these helices in the Na+, K+-ATPase can be seen in 
Figure 1.4.) It is connected to the transmembrane region by long loops 
leaving it virtually isolated. These 3 large regions are able to move in a 
concerted fashion which is vital in the conformational changes described in 
the earlier mechanism. The N-domain is particularly mobile in the presence 
of ions (Toyoshima et ah, 2000; Morth et al, 2007) a property conferred 
by a hinge region, the presence of which is indicated by the ease of 
isolating the N domain with several proteases (Champeil et a!., 1998). 
Phosphorylation of the P-domain by hydrolysis of the bound ATP brings 
the N-domain closer to the P-domain (Nakamoto and Inesi, 1984) allowing 
the phosphorylation signal to be passed on.
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As stated earlier the structure of the Na' , K+-ATPase gave further insight 
into the third Na+ binding site (Morth et aL, 2007). It was noted the helix 
M10 ends with three arginine residues (Arg 1003-1005 which are highly 
electropositive), a PGG motif and an eight-residue extension relative to the 
C-terminus of SERCA. A five-residue truncation of the C-terminus of the 
Na+, K+-ATPase results in a 26-fold reduction in Na+ affinity compared to 
wild type, yet the truncation had no effect on K+ affinity. This is similar to 
what was observed when Tyr 771 (helix MS (Vilsen et ah, 1997) and Thr 
807 (helix M6 (Vilsen, 1995)) were mutated. These two residues along 
with Glu 954 (helix M9) have been suggested to make up the third Na+ 
binding site (Li et aL, 2005) and the structure has since revealed these three 
residues cluster and bridge to the second NaVfC1’ binding site. Due to the 
effects of the C-terminal truncation it was proposed the direct contact the 
C-terminus has with alpha M5 optimises Na+ binding at the third site.
The arginine cluster at the C-terminus of helix M10 could act as a voltage 
sensor as observed in voltage-dependant ion channels (ref) that move in 
response to membrane depolarisation. This would activate a C-terminus 
switch that alters the relationship of the C-terminus with the third Na+ 
binding site during depolarisation/repolarisation with consequences on Na+ 
affinity.
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When the shark rectal gland Na+, K+ -ATPase structure was solved at a 
higher resolution (2.4 A) in the E2P (2K+) conformation (Shinoda et al., 
2009) it validated the assumption that its tertiary structure is veiy similar to 
SERCA. In fact four out of five residue positions were virtually identical 
even down to side chain conformations. Many key differences between the 
two structures were found, however, helping understand how subtle 
changes can give very different functions. Firstly the N-domain of the Na+, 
K+-ATPase is ~20° further from the P-domain than that of SERCA in the 
equivalent E2P (2Ca2+). This could well explain the much faster ATPase 
turnover (the Na+, K+-ATPase is nearly seven times faster than SERCA). 
The transmembrane helices M5 and M7 (Figure 1.4.) have unwound 
regions in the Na+, K+-ATPase which are not present in SERCA. hr M7 
this gives a distinct kink of -18° which has a distinct role in K+ binding. 
The M5 helix straightens in the E2P>E2>Ei.2Ca2+ transition in SERCA 
(Toyoshima et aL, 2000). If a similar event happened in the Na+, K+- 
ATPase it would cause M7 to push towards M10 inducing large scale 
structural changes in the P-domain, M3 and the carboxy-terminal segment 
of the a and p subunits. This gives M7-M10 a much bigger role in the Na+, 
K+-ATPase than SERCA and might change the position of the p-subunit 
(which does not associate with SERCA) cytoplasmic domain.
Indeed, the p-subunit is only found in two P-type ATPases the Na+, K+- 
ATPase and the gastric IT1, K+-ATPase. It has long been strongly
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suggested that the j3-subimit plays a key role in altering the a-subunit 
allowing it to transport K+ (Geering, 2001). By completely solving the 
structure of the p-subunit insights into how this may occur have been 
proposed (Shinoda et at, 2009). Although the single transmembrane helix 
of the P-subunit is quite detached from the transmembrane helices of the a- 
subunit in this solved structure it does form key interactions with M7 and 
M10. Two aromatic clusters involving these helices and aromatics in the 
P-subunit form complex hydrogen bonds and salt bridges. These intricate 
interactions could well explain how the P-subunit alters the Na+, K+- 
ATPase to have an affinity for K+.
1.1.4. Regulation
The Na+, K+-ATPase is clearly a critical and complex system so 
understandably requires strict regulatory control. There are several 
different ways this is achieved. These either affect the regulation of gene 
expression of the Na+, K+-ATPase or affect the rate of reaction. The 
simplest of the latter type is already clear from the mechanism; increased 
intracellular Na+ or extracellular K+ increase Na+, K+-ATPase activity. 
More complex mechanisms of regulation are discussed below.
Thyroid hormones induce an increase in Na+, K+-ATPase expression and 
thus its concentration in the cell membrane. Studies on rat thyroidectomies 
(Asano et ah, 1976), showed a 35% decrease in NaH', K+-ATPase activity
14
after thyroidectomy and a 54% increase when pre treated with the thyroid 
hormone triiodothyronine (T3). Further studies with the radioactive labelled 
[3H]ouabain could quantify this effect of thyroid hormones via liquid 
scintillation counting. Ouabain is a highly specific and high affinity 
inhibitor of the Na'", K+-ATPase (discussed later), binding at 1:1 
stoichiometry allowing Na+, K1 -ATPase concentration to be determined by 
bound [3H]ouabain. [3H]ouabain reveals Na+, K+-ATPase concentration to 
be largest in the brain, intermediate in the skeletal muscle, lower in the 
kidney, and at its lowest in the liver (Lin and Akera, 1978). T3 heated rats 
had a largely increased Na+, K'-ATPase concentration in skeletal muscle, 
kidney and liver but not in brain. This has been confirmed with increased 
Na+, K+-ATPase mRNA upon addition of T3 in rats (Yalcin et al, 1999).
Insulin appears to have a role in altering rate of reaction of the Na+, K+- 
ATPase. Diabetes is a condition where either insulin is no longer produced 
(type 1) or no longer recognised by receptors (type 2). Diabetes patients 
often suffer from a condition known as diabetic retinopathy. This is due to 
abnormalities such as reduced endothelial cell density and increased 
endothelial pleomorphism (Olsen and Busted, 1981; Roszkowska et al, 
1999; Inoue et al, 2002). It is caused by decreased Na+, K+-ATPase 
activity in the corneal endothelium (Herse, 1990; Herse and Adams, 1995) 
which is in turn caused by the reduced insulin levels in the condition 
(Hatou et al, 2010).
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These systems are both veiy general as they affect so many other processes 
in the cell. There are also specific regulatory molecules of the 
Na1', K+-ATPase which alter the rate of ATP hydrolysis and ionic transport. 
Two such mechanisms are the focus of this project. A family of proteins 
called FXYD proteins are physiological regulators of the Na1, K+-ATPase 
and form part of the complex whereas cardiac glycosides are 
pharmacological regulators and bind to a specific region in the a-subunit. 
Both are discussed in detail below.
1.2. FXYD Proteins
The FXYD proteins are a family of short polypeptides each having a single 
helical transmembrane domain localised in the plasma membrane (Garty 
and Karlish, 2005). They were classified as a single family after the Na+, 
K+-ATPase y-subunit and the proteins phospholemman (PLM), Mat-8, and 
corticosteroid-induced factor (CHIF) showed sequence similarity following 
analysis despite no clear related function. (Sweadner and Rael, 2000). 
These proteins have a signature sequence (Figure 1.5.) of 35 amino acids 
where sequence similarity is high. Contained within the signature sequence 
is the Phe-X-Tyr-Asp (FXYD) motif in the extracellular region after which 
the family was named. The function of this motif remains unclear as it has 
been shown to be important for a stable interaction with the a- subunit of 
the Na+, K+-ATPase in CHIF and Na+, K+-ATPase y-subunit (Beguin et ah, 
2001) but not in a later identified FXYD7 (Crambert et aL, 2004).
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Sequence similarity between members is generally poor outside the 
signature sequence. With this information the protein “related to ion 
channel” (RIC) was identified as a fifth member of the family (previously 
not identified due to it having a much longer N-terminal segment) and 
further bioinformatics revealed two more un-named proteins (Sweadner 
and Rael, 2000). Since this paper FXYD proteins have been named in 
order of discoveiy; FXYD1 (PLM), FXYD2 (y-subimit), FXYD3 (Mat-8), 
FXYD4 (CFIIF), FXYD5 (RIC) and FXYD6/FXYD7 (the two unnamed 
members although FXYD6 has since been given the alternative name 
phosphohippolin). In this thesis all proteins will be referred to by their 
original names (e.g. PLM and Mat-8). No subsequent FXYD proteins have 
been discovered in mammals since this study. However additional 
members FXYD8-12 (Tipsmark, 2008) have been discovered in fish. 
FXYD 10 is noteworthy as it has its structure solved in complex with the 
Na+, K+-ATPase (Figure 1.4.). All 7 mammalian members have been 
shown to interact with and regulate the Na+, K+-ATPase. PLM (Crambert 
et ai, 2002), y-subunit (Beguin et al, 1997; Pu et al, 2001), Mat-8. 
(Crambert et al., 2005; Arimochi et al, 2007), CHIP (Garty et al, 2002) 
and FXYD7 (Beguin et al, 2002) all reduce the affinity of the 
Na+, K+-ATPase for Na+ and/or K+ ions although their effect can depend 
on which Na+, K+-ATPase a-subunit isofomi it interacts with. For 
example, RIC increases affinity for Na+ and/or K+ ions in an al pi complex 
(Lubarski et al, 2005) whereas FXYD6 slightly decreases apparent K+
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affinity and significantly decreases the apparent Na+ affinity of the 
Na+, K+-ATPase al-pl isozymes, hr contrast when FXYD6 associates with 
al~p2 isozymes it in fact increases apparent K+ and Na+ affinity (Delprat et 
al, 2007). What is interesting is that not only do the FXYD proteins have 
different regulatory effects on the Na+, K’-ATPase, they are also tissue 
specifically expressed. Table 1.1 shows the tissues in which each member 
is expressed. This suggests that FXYD proteins alter the activity of the 
Na+, K+-ATPase to match the specific needs of individual tissue types. The 
specificity of expression suggests they are specifically designed to meet the 
needs of specific tissues. The signature sequence (highlighted in Figure 
1.5.) suggests they may share some kind of functions) or membrane 
targeting.
1.2.1. Comparing FXYD Proteins
As mentioned the FXYD proteins have homology in the 35 amino acid 
signature sequence but poor homology outside of this. Fig 1.5 shows a 
comparison of the human FXYD proteins. The alignment (Figure 1.5a) 
shows sequence similarity is poor outside the signature sequence between 
all seven members. However certain pairs of FXYD proteins have high 
sequence similarity outside the signature sequence that is related to their 
evolutionary path highlighted by the phylogenetic tree (Figure 1.5b). Table
1.1. shows where FXYD proteins are expressed in humans.
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Table 1.1: The FXYD family. The table below shows the FXYD proteins, where 
they are expressed in mammals, and also FXYD10 from shark the structural 
information available
Protein Common name(s) Expressed in Structural information
FXYD1 Phospholemman Heart, liver, skeletal muscle Solution state NMR
(Teriete et al, 2007)“
FXYD2 The y subunit of Kidney, heart, stomach Structure as part of
Na+,K+-ATPase Na+, K+-ATPase in pig 
kidneyb
FXYD3 Mat-8 Colon, stomach, uterus Limited structure known
(human)(Franzin et al., 
2007a)b
FXYD4 CHIP Kidney collecting duct, Solution state NMR (rat)
distal colon (Franzin et al, 2007d)b
FXYD5 RIC, dysadherin Heart, brain, spleen, lung,
liver, skeletal muscle,
kidney, testis
None
FXYD6 Phosphohippolin Brain and kidney None
FXYD7 Brain (cerebellum,
cerebrum, hippocampus and
stem)
None
FXYD 10 Shark rectal gland Structure as part of 
Na+, K+-ATPase in shark
rectal gland (Shinoda et
al, 2009)a
“Solution state NMR (in micelles) 
bX-Ray crystallography
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1.2.3. The Na+, K -ATPase is regulated by FXYD proteins
As stated earlier, it appears the FXYD proteins have a major role in
regulating the Na+, K^'-ATPase in a specific way to dependent on tissue 
type. There are methods which have confirmed that all seven FXYD 
proteins regulate the Na+, K+-ATPase. These include 
co-immunoprecipitation (Bibert et al., 2006; Fuller et al., 2009) and 
distinct modulation of Na+, K+-ATPase activity by different FXYD 
proteins and FXYD protein silencing (Han et al., 2006; Bibert et al., 2009) 
(discussed for PLM and Mat-8 later). The region of interaction appears to 
be the transmembrane region (veiy common for two interacting membrane 
proteins) but it is speculated the non-conserved regions of FXYD proteins 
which are largely in the cytoplasmic region confer the tissue specific 
effects of FXYD proteins on Na+, K+-ATPase. Indeed in PLM there is 
evidence for the cytoplasmic region having an inhibitory effect on the 
Na+, K+-ATPase (discussed later).
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1.2.4. Phospholemman (FXYD1)
PLM was originally referred to as simply “15-kDa protein” when first 
discovered but was renamed phospholemman (Palmer et al, 1991) as it is 
located on the plasma membrane and its two phosphorylation sites in the 
cytoplasmic region that may regulate its function. Immunoprecipitation 
experiments (Crambert et al, 2002) have shown PLM interacts with the 
Na+, K+-ATPase and decreases the apparent Na+ affinity and also the 
apparent K+ affinity (to a smaller degree). It also interacts with the Na+- 
Ca2+ exchanger (NCX1) in muscle cells (Dostanic et al, 2004). 
Experiments with PLM-knockout mice (Jia et al., 2005) contradict other 
data as ATPase assays of Na+, K -ATPase purified from wild type and 
PLM knock out mice showed a 50% decrease in activity when PLM is 
knocked out, despite no change in Na+, K+-ATPase expression levels 
revealed by immunoprecipitation. This suggests PLM in fact stimulates the 
Na+, K+-ATPase. However these contradictions may in fact be evidence 
that PLM has two conformations, and in some way whilst interacting with 
the Na1', K+-ATPase, its functional effect can change from a positive to a 
negative effect.
1.2.5. Mat-8 (FXYD3)
Mat-8 was discovered in 1994 in murine breast tumours (Morrison and 
Leder, 1994) as a novel gene induced by Ras and Neu oncogenes. It has
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since been linked to many other cancers including human breast tumour 
cell lines (Morrison et al., 1995), colorectal cancer cell lines (Arimochi et 
al.t 2007) and pancreatic cancer cell lines (Kayed et al., 2006). The first 
real evidence for an interaction between Mat-8 and the Na+, K+-ATPase 
was discovered as recently as 2005 (Crambert et al, 2005). Several 
proteins including rat Mat-8, Na+, K+-ATPase, colonic H'^K’-ATPase and 
SERCA were variously co-expressed in Xenopus oocytes. 
Immimoprecipitation experiments performed on these proteins showed that 
Mat-8’s strongest co-immunoprecipitation was Na+, K+-ATPase. Mat-8 
also associated with colonic H+, K+-ATPase (although to a lesser extent) 
but showed no interaction with SERCA. These experiments also revealed 
that Mat-8 induces a small yet significant reduction in the affinity of 
Na+, K+-ATPase for external K+ (15-40% depending on membrane 
potential) and also an approximately 20% reduction of affinity for Na+ (as 
opposed to sequentially similar CHIP, which increases affinity). More 
recently it has been discovered these affinity changes were actually only 
caused by one isoform of Mat-8. There is in fact a longer isoform with a 
26-amino acid insertion after the transmembrane domain (Figure 1.6.) 
(Bibert et al, 2006).
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>Mat"8 Short Form cytoplasmic region
S-------------------------- AKCKCKFGQKSGHHPGETPPLITPGSAQS
>Mat-8 Long Form cytoplasmic region
SEWRSSGEQAGRGWGSPPLTTQLSPTGAKCKCKFGQKSGHHPGETPPLITPGSAQS
Figure 1.6. Comparison of cytoplasmic regions of Mat-8 isoforms. Both isofonns are 
identical in the transmembrane and extracellular region (not shown) but the long isoform 
has an extra 26 amino acids in the cytoplasmic region.
Functional information on the long isofonn is limited but unlike the short 
form Na+, K+-ATPase affinity for external K+ decreases to a larger extent 
(up to 50%) but affinity for Na+ actually increases (~15%) Differences in 
expression levels of the Mat-8 isoforms have been difficult to analyse due 
to their high similarity and small size but the short form does seem to have 
much higher levels of expression in cancer than long form (Yamamoto et 
al., 2009). The Na+, K+-ATPase interaction with Mat-8 was then further 
studied with fluorescence tags in colorectal cancer cells (Arimochi et ah, 
2005), which showed the distribution of Mat-8 in cells. Using GFP and 
Myc tags it was revealed that Mat-8 was found to co-localise with the 
Na+, K+-ATPase on intracellular membranes. These membranes were then 
prepared and immunoprecipitation confirmed that the Na+, K+-ATPase a- 
subunit and Mat-8 co precipitate, further suggesting an important 
interaction between the two. Recently, Mat-8 silencing experiments in 
human colon adenocarcinoma cells have shown an increased affinity of the 
Na+, K+-ATPase for Na! and K+ ions strengthening the argument that Mat- 
8 decreases the affinity of the Na+, K+-ATPase for ions (Bibert et al.
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2009). Despite this increase of ion affinity the rate of reaction of the 
Na+, K+-ATPase actually decreases whilst total a-subunit levels expressed 
and present at the membrane are unchanged. This could be explained by 
differential isoform expression as in Mat-8 deficient cells there is a 
reduction of the Na+, K+-ATPase a 1-subunit and an increase in a3-subunit 
(Mat-8 associates with a 1-subunit). Difficulties arose in detecting (3- 
subimit isofomis by western blot, however it was observed that (31-subunit 
expression was downregulated in Mat-8 deficient cells which causes the 
cell to be poorly differentiated. Aside from this, mechanistic information 
details on the Mat-8/Na+, K+ -ATPase are scarce.
A large amount of the experimental work presented in this thesis shows the 
results of experiments to analyse the effects of FXYD proteins on the Na+, 
K+-ATPase. The source of the Na+, K+-ATPase used is pig kidney 
(Jorgensen, 1974) and spiny dogfish rectal gland (Esmami et al, 1979) as 
they are the most effective known methods of obtaining the enzyme. The 
isofomis purified by these methods are a 1(31 from pig kidney and a3pl 
from spiny dogfish rectal gland. These are physiologically relevant 
isoforms to use as PLM interacts with all al-3/p 1-2 and both isoforms of 
Mat-8 associate stably with all al-4/pi complexes (Bibert et al, 2006)
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1.2.6. Structures of FXYD proteins
The structures of FXYD proteins, PLM and CHIP have been solved by 
NMR (Franzin et al, 2007c; Teriete et al, 2007). There is also limited 
structural information for Mat-8 which shows locations of secondary 
structure on the sequence, as determined by heteronuclear single quantum 
coherence (HSQC) experiments (Franzin et ah, 2007b). Figure 1.7. shows 
these two solved structures. These structures were solved using solution 
state NMR in detergent micelles and not bilayers. Micelles are a relatively 
poor model for a cell membrane as they do not consist of a bilayer unlike 
native membranes. It appears structural similarity is good inside and poor
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outside of the transmembrane domain which is supported by the sequence 
as outside of the signature sequence (predominantly comprising the 
transmembrane domain), sequence similarity is veiy poor. This further 
suggests that the unique functions of FXYD proteins are regulated by the 
extracellular and cytoplasmic regions of the FXYD proteins. These unique 
features are either unknown or poorly understood but usefully these 
regions are soluble so when produced as small peptide fragments can be 
used in solution in assays (Pavlovic et al, 2007). A large focus of this 
project will be to attempt to find possible roles for these fragments and to 
see if differences in structure could be could be related to function.
1.2.7. Roles of Mat-8 and PLM in disease
In order to improve treatments of diseases it is important to understand the 
proteins involved in them. This can lead to targeted drug design. Mat-8 
appears to have a role in many cancers. It was discovered to be 
overexpressed in murine breast tumours (Morrison and Leder, 1994) and 
has since been discovered to be a marker for other cancers including 
prostate (Grzmil et al., 2004), pancreatic (Kayed et al, 2006) and 
colorectal (Arimochi et al, 2007). It is unclear if the upregulation of Mat-8 
has an effect on cancer or is just a consequence although evidence for the 
former is increasing. For example Mat-8 has been shown to be linked to 
tumour protein 53 (p53) as it is upregulated by 5-Fluorouracil treatment of
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breast cancer cells in a manner dependent on p53 (Jorgensen et al, 2003). 
Inhibition of Mat-8 expression reduces cell proliferation (Grzmil et al, 
2004), so it could be that, again like p53, the role of Mat-8 is in cell 
proliferation and not antiproliferation. Perhaps p53 induces genes including 
Mat-8 that are involved in cell proliferation as part of a negative feedback 
loop. Recently, Mat-8 silencing in human colon adenocarcinoma cells 
showed impeded cell differentiation and a small increase in cell apoptosis, 
which in contrast to the previous work does not translate into decreased 
cell proliferation (Bibert et al, 2009). However, Mat-8 was actually shown 
to be down-regulated in colon and kidney cancer (Kayed et al, 2006), 
which would support results that Mat-8 perhaps does not have an effect on 
Caco-2 cell proliferation. It is possible that Mat-8 has two different roles in 
cancer. In cancer cells that are unable to differentiate, Mat-8 could 
encourage cell proliferation, whereas in differentiation-competent cells like 
human colon adenocarcinoma cells, Mat-8 may have no effect on cell 
proliferation but in fact decreases cell apoptosis and promotes cell 
differentiation. This is all still quite speculative but it seems increasingly 
likely that Mat-8 is more than a mere marker for cancers and has its own 
distinct role.
PLM has a role in cardiac disease although it is also poorly understood. 
However there is increasing evidence that the Na1', K'-ATPase -PLM
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interaction could be a valid drag target. When PLM is knocked out in 
mouse hearts there is depression of contractile function which was 
associated with mild hypertrophy (Chan et a!., 2010). Intracellular Na+ ion 
concentration is up to 3 mM higher during heart failure, which can greatly 
affect Na+/Ca+ exchange and effect cardiac contractile function. As 
mentioned earlier, the Na+, K!-ATPase exports three Na+ ions per cycle 
and is in fact the main method of Na+ extrasion. Importantly cardiac 
Na+, K'!-ATPase activity decreases after a myocardial infarction (Zhang et 
al, 2006) and in heart failure (Dixon et al., 1992). FXYD proteins are 
expressed tissue specifically and the predominant FXYD protein in heart 
tissue is PLM. Overexpression of PLM appears to cause both reduced 
Na+, K+-ATPase function and a reduced Na1, K'-ATPase 
expression(Zhang et al, 2006). It was recently highlighted (Shattock, 
2009), that drugs that decrease Na+ influx protect against ischaemic injury 
and arrhythmias in animal models. This suggests that drugs that increase 
Na+ efflux by stimulating the Na+, K+ -ATPase could provide a novel 
method of clearing intracellular Na+ in heart failure. PLM has been shown 
to inhibit the Na+, K+-ATPase so altering its activity via drag targeting 
could stimulate the Na+, K' -ATPase to give the desired treatment.
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1.3. Cardiac Glycosides
Cardiac glycosides were first used as drugs over 200 years ago (Withering, 
1785), with extracts of digitalis purpurea (foxglove) used to treat heart 
disorders. As this was a long time before modem biology there was no 
understanding of how this drug worked. In fact the mechanism of cardiac 
glycosides did not begin to be understood until 1965 when another cardiac 
glycoside known as ouabain was shown to specifically inhibit the 
Na+, K+-ATPase (Schatzmann HJ, 1965).
1.3.1. Characteristics and structure of Cardiac Glycosides
The cardiac glycosides all have a characteristic structural motif comprised
of a steroid nucleus, a sugar moiety and a lactone moiety (Figure 1.8). The 
steroid nucleus only varies in its side chains between members. The 
lactone moiety is what defines the subclass of cardiac glycoside. A 
cardenolide has a five-membered unsaturated butyrolactone ring in this 
position whereas a bufadienolide has a six-membered unsaturated pyrone 
ring. Finally, the sugar moiety can be any of a range of sugars such as 
glucose, galactose, mannose, rhamnose and digitalose. The sugar itself has 
no active role but they do affect the pharmacodynamics and 
pharmacokinetics of the cardiac glycosides (Prassas and Diamandis, 2008). 
These effects include the speed of absorption and potency. This variation 
has allowed over one hundred cardiac glycosides to be extracted from 
vegetal sources (Melero et al, 2000).
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Due to a veiy specific site for plant derived cardiac glycosides being 
present in the animal protein complex of the Na+, K+-ATPase, it seemed 
likely that animal produced equivalent cardiac glycosides must also exist. 
This would give cardiac glycosides both a pharmacological and a 
physiological role. Many cardiac glycosides have been extracted from 
animals, most of which have been from frogs (Pieter and Fanie, 1998). 
Endogenous ouabain has been extracted from mammal sources including 
human plasma (Hamlyn et al., 1991; Mathews et al, 1991), bovine adrenal 
cortex (Schneider et al., 1998) and bovine hypothalamus (Kawamura et al, 
1999). Differences between endogenous and exogenous ouabain are veiy 
discreet and have made it difficult to prove that animals naturally produce 
ouabain. However increased levels of ouabain in conditions like 
hypertension and detection of a marinobufagenin-like cardiac glycoside in 
urine after acute myocardial infarction (Bagrov et al., 1998) suggest 
cardiac glycosides are produced by the animals themselves.
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Lactone moiety (R) 
o
Figure 1.8. Signature cardiac glycoside motif. The backbone of the cardiac glycosides is 
the steroid nucleus common to all members. R represents the lactone moiety which defines 
its subtype. R’ represents the sugar moiety (e.g. rhamnose), which may control the 
pharmacodynamic and pharmacokinetic properties.
1.3.2. Mechanism
As described earlier the Na+, K+ -ATPase goes through a dephosphorylation 
step which changes the cation affinity from K+ to Na+. Cardiac glycosides 
block this event from occurring stopping the cycle from completing and 
completely inactivating the enzyme (Godfraind, 1984). It appears that this 
occurs primarily in the E2P conformation (as opposed to the E2P.2K+ 
conformation) as ouabain affinity for the Na+, K+-ATPase decreases in the 
presence of K+ (Sachs, 1974; Hobbs and Dunham, 1978). The site at which
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this occurs is not fully clear. Mutagenesis studies have revealed that when 
Cys104, Tyr108 (Canessa et al, 1992), Gin111 (Price and Lingrel, 1988), 
Pro118 (Schultheis and Lingrel, 1993), Asp121 (Price et al., 1989), Asn122 
(Lingrel et al, 1991), Tyr308 (Canessa et al, 1993), Leu330, Ala331, Tin338 
(Croyle et al, 1997b), Phe786, Leu793, Phe863 (Palasis et al, 1996), Thr797 
(Burns and Price, 1993), Arg880 (Schultheis et al, 1993) and Phe982 (Croyle 
et al, 1997a; Sweadner and Donnet, 2001) are substituted there were 
negative effects on the binding of ouabain to the Na+, K ' -ATPase. As seen 
in Figure 1.9. most of these are found in the transmembrane region in close 
proximity of the FXYD protein.
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Figure 1.9. Residues that affect ouabain binding. In this structure (Morth et ai, 2007) 
of the Na+, K+-ATPase the a-subunit is shown in green, the p-subunit is show in cyan and 
the y-subunit is shown in pink. The red spheres indicate locations of residues that reduce 
ouabain binding when replaced with other amino acids by mutagenesis.
To understand this interaction better, NMR and modelling studies were 
performed (Middleton et al, 2000). By studying isotopically labelled 
ouabain derivatives bound to unlabelled Na+, K-ATPase it was shown that
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the majority of the interactions between ouabain and the Na+, K+-ATPase 
appeared to be due to the steroid nucleus lying across the surface of the a- 
submiit seemed most likely by hydrogen bonds. In this conformation the 
sugar moiety faces away from the surface of the membrane and is free to 
move into contact with one or more aromatic residues. Recent full Na+, K+- 
ATPase structures have disputed this. Two x-ray crystallography structures 
of the Na+, K+-ATPase with bound ouabain have been solved, the first 
structure is from shark rectal fin Na+, K+-ATPase with ouabain soaked into 
the protein crystals (Ogawa et ah, 2009), whilst the second structure is 
from pig kidney Na+, K+-ATPase incubated with ouabain, pre­
crystallisation (Yatime et al., 2011). The former paper was performed in 
the low affinity E2P.(2K+) conformation and shows ouabain bound at a 
similar site to that previously shown (Middleton et al., 2000) but it is 
intercalated into the transmembrane helices perpendicular to the membrane 
surface. The more recent paper in the high affinity ouabain binding state is 
in a similar conformation but is shifted laterally by about 2 A towards the 
oMl—2 transmembrane helices. It is unclear if this change is due to the 
difference in affinity states of Na+, K+ -ATPase, the method of applying 
ouabain to the Na+, K+-ATPase, or the organism from which Na+, K+- 
ATPase was extracted.
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1.4. Aims of this work
The aims of this project focus on gaining further understanding of the 
structural and functional interaction of FXYD proteins and cardiac 
glycosides with the Na+, K '-ATPase. The initial hypothesis of this study is 
that the cytoplasmic region of PLM interacts with one or more specific 
sites on the surface of the Na+, K+-ATPase which alters ATPase activity. 
This interaction is likely regulated by phosphorylation of Ser 68 and/or Ser 
63 both located in the cytoplasmic region of PLM. Short form Mat-8 and 
CHIP should not share this feature as they do not have similar 
phosphorylation sites. It is unclear if long form Mat-8 would also not share 
this feature as it has only recently been discovered and it is not known if it 
contains phosphorylation sites within its cytoplasmic region like PLM. 
Any interaction of the cytoplasmic region of PLM and the Na+, K+-ATPase 
would have to compliment the affinity the cytoplasmic region of PLM has 
for negatively charged lipid bilayers. It is therefore hypothesised the 
interaction of the cytoplasmic region of PLM and the Na+, K+-ATPase is in 
close proximity of the cell membrane surface to allow this to happen.
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The work performed to test this hypothesis and gain further understanding 
of cardiac glycosides four main headings:
1.4.1. The association of the cytoplasmic region of FXYD proteins with 
phospholipid bilayers
The cytoplasmic region of PLM is known to interact with negatively 
charged phospholipid bilayers (Clayton et aL, 2005). In this project the 
cytoplasmic regions of other FXYD proteins including both isoforms of 
Mat-8 and CHIP will be tested to see if they too interact with negatively 
charged membranes in a similar fashion. The interaction of the PLM 
cytoplasmic domain with phospholipid bilayers will be investigated further 
by developing a system for determining peptide/lipid interactions in the 
presence of the Na+, K+-ATPase. This will help determine if the observed 
interaction of the cytoplasmic region of PLM with negatively charged 
phospholipid bilayers is physiologically relevant.
1.4.2. The function of the cytoplasmic region of FXYD proteins
This section of the work involved testing the effect of the cytoplasmic
regions of PLM, both isoforms of Mat-8 and CHIP on Na+, K+-ATPase 
activity. The effect of PLM phosphorylation on the potency of its 
functional effects on the Na+, K+-ATPase was also investigated. The final 
aim of this section was to further analyse the interaction between the 
cytoplasmic region of PLM and the Na+, K+-ATPase using bioinformatics
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techniques. The interaction could be modelled and provide insight as to 
how this could affect ion affinity of the Na+, K ' -ATPasc.
1.4.3. The development of an expression system for FXYD proteins
Work was undertaken to develop a system in the pMAL vector for the
expression and purification of FXYD proteins as an alternative to a current 
protocol (Thai et a!., 2005) which could not be reliably replicated. With the 
new expression system in place, further refinements had to be carried out 
to allow the expression and purification of fully labelled fusion proteins in 
quantities suitable for NMR.
1.4.4. The development of a new method to determine the orientation 
of cardiac glycosides in the Na+, K+-ATPase
The final section of work aimed to develop a novel method for probing the 
depths that ligands penetrate the transmembrane region of a protein, which 
would allow the orientation of ouabain within the Na+, K+-ATPase to be 
determined. The initial aim of this section was to produce a ouabain 
derivative containing !3C acetonide bridges. This would produce a 
signature peak when analysed by solid-state NMR. The second aim using 
solid-state NMR was to obseive the ouabain derivative whilst bound to the 
Na+, K+-ATPase. By using cross-polarisation techniques the natural 
abundance 13C peaks in Na+, K+-ATPase can be observed. The final aim
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was to observe the effect of the paramagnetic broadening agent manganese 
on both the natural abundance 13C and the ouabain derivative signature 
peak to probe the depth of ouabain penetration within the Na"1', K+-ATPase.
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Chapter 2
2.1. Nuclear Magnetic Resonance
Nuclear magnetic resonance (NMR) spectroscopy, particularly in the solid 
state, is the principal technique used in this project. The theory of NMR is 
described in detail in several textbooks (Evans, 1995; Duer, 2004) and 
websites (Reusch, 2000; Hornack, 2011). This chapter briefly describes the 
main theoretical aspects that are relevant to the work presented in this 
thesis.
2.2. Nuclear Spin and the Larnior Frequency
For nuclei to be NMR active they must have the quantum mechanical 
property known as spin given the symbol I to represent total angular 
momentum. Nuclei with an odd atomic mass number have fractional spins 
(e.g. ^ I3C, 31P have a spin of 1/2, nB has a spin of 3/2 and 170 has a 
spin of 5/2). Even mass nuclei with odd atomic numbers have integral 
spins (e.g. 2H, 14N have a spin of 1). Both of these nuclei types are 
therefore suitable for NMR as they have at least one unpaired proton. Even 
mass nuclei with even atomic numbers have a spin of 0 making them NMR 
silent (e.g. 12C and 160). The movement of the unpaired positively charged 
protons in nuclei with spin produces a magnetic field with nuclear 
magnetic moment, which is defined by the following equation:
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(2.1)
Where y is the gyromagnetic ratio (the proportionality constant) and h is 
Planck’s constant (6.26 x 10'34 J s'1).
When an external magnetic field (B0) is applied to a sample, each nuclear 
magnetic moment will either align with the magnetic field (a spin) or 
against it ((3 spin) (Figure 2.1).
Magnetic 
Field of 
strength B0
Figure 2.1. Effect of external magnetic field on the orientation of the magnetic 
moments of nuclei with spin properties.
When 7^0 a nucleus cannot align exactly with or against the applied 
magnetic field. The nucleus will in fact precess at an angle around the 
applied magnetic field at an angular frequency specific to each nucleus 
known as the Larmor frequency (v) (Figure 2.2). Larmor frequency is 
defined by the following equation:
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(2.2.)V _ YBq2n
Bo
Figure 2.2. Representation of the spin and precession of a nucleus within an applied 
magnetic field.
Larmor frequency is also related to angular velocity oo (rad s'1) and is given 
by the following equation:
(a) = 27TV (2.3.)
The number of possible orientations a nuclei has with respect to the 
magnetic field is 2/ + 1 so for common NMR experiments on biomolecules 
observing l3C, 'H or 15N which all have spin values of Vi there are two 
possible orientations. These two orientations either align against the field 
(antiparallel) and arc said to be in a high-energy state whereas the ones that 
align with it are in a low energy state (parallel). This splitting of energy
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levels is known as the Zeeman effect. The population of each state is 
determined by the difference in energy (AE) between these two states in an 
applied magnetic field, according to the Boltzmann equation:
% = e-AB/kBT ,2 . ,
Pre-Magnetic
field
Magnetic 
field applied
Antiparallel -'A
Parallel ♦K
Figure 2.3. Effect of external magnetic field on energy levels. As magnetic moments 
are usually distributed randomly there is no net energy in the absence of an external 
magnetic field. In this sample on nuclei where / — ‘A all nuclei either adopt a +!4 (low) or a 
-‘A (high) energy state in the presence of an external magnetic field.
The change in energy is proportional to gyromagnetic ratio and B0 due to 
Planck’s law according to the following equation:
AE = ^ = hv
2n (2.5.)
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2.3. Radio Frequency Pulses
The Boltzmann equation indicates that at equilibrium the high energy and 
low energy states of nuclei are nearly equally populated, but there is a 
slight excess of low energy state nuclei giving a bulk magnetisation (Mo) 
parallel the z axis of B0. In magnetic fields of up to 21 Tesla the Larmor 
frequency falls within the MHz range, i.e. radio frequency (RF). When 
electromagnetic radiation at the Larmor (radio) frequency is applied to the 
nuclei along an axis perpendicular to the z axis of the magnetic field B0 the 
nuclear spins begin to precess about the oscillating magnetic field. This 
effect is known as nuclear magnetic resonance. The net effect of this 
process is to cause Mo to flip from alignment with Bo to alignment with the 
direction of the 90° pulse.
Figure 2.4. Diagram showing the flipping of magnetisation due to the effects of a 90° 
RF pulse.
After the RF pulse is complete the sample magnetisation is able to undergo 
free precession around the xy plane generating a current in the surrounding
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coil of the NMR spectrophotometer which is processed as a sinusoidal 
signal comprising all the Larmor frequencies of all the nuclear spins in the 
sample. The signal is detected by the spectrometer as a dampened wave or 
free induction delay (FID) (Figure 2.5.). In a typical experiment many 
FIDs are added together because the signal detected is often very weak and 
noisy. By adding together scans the signal accumulates and the signal to 
noise ratio improves. Finally the FID is treated with a mathematical 
function known as a Fourier transformation (FT) which converts it into a 
frequency domain spectrum in which the individual nuclear frequencies are 
represented by peaks (Figure 2.5.).
Figure 2.5. Fourier Transformation (FT) of a Free Induction Decay into a Frequency 
Domain Spectrum.
2.4. Relaxation
When the nuclear spins are perturbed from their equilibrium state, they 
become subject to processes known as relaxation, which affect the 
appearance of the NMR spectrum and must be taken into account when
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setting up an NMR experiment. After the RF pulse is switched off the 
alignment of Mo reverts from the xy axis back to Bo by a process known as 
spin-lattice (or longitudinal) relaxation (Figure 2.4.). This process 
determines the rate at which the spin states re-establish their Boltzmann 
populations. The time constant for this process is called Tl. Spin-lattice 
relaxation takes a relatively long amount of time (sometimes minutes) 
particularly compared to other spectroscopic techniques. T2 occurs 
simultaneously to Tl and it is driven by interactions of the nuclear spins 
and by inhomogeneities in Bq. When the RF pulse is switched off the 
individual nuclei experience slightly different local magnetic fields and 
have their own Larmor frequencies. This causes processing spins to lose 
phase coherence (i.e. they diphase) with time and the result is seen in the 
exponential dampening of the NMR signal. The NMR signal often decays 
to zero long before the nuclear spins re-establish their equilibrium state.
2.5. Chemical Shift
The NMR frequency of a nuclear spin is dependent on the strength of the 
applied magnetic field, as shown above, and also on the very small 
magnetic fields generated by the circulating electron cloud around the 
nucleus. Hence the NMR spectrum is sensitive to the chemical shielding of 
the nuclei. The movement of electric charges of the electron cloud around a 
nucleus induce a local magnetic field that opposes (and sometimes
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enhances) the applied field Bo. The effective magnetic field (BCff) 
experienced by the nucleus is therefore defined by the following equation:
Beff ~ Bq(1 — cr) (2.6.)
where a in equation 2.6. is the chemical shielding tensor. The actual 
resonance fiequency ©o of a nucleus is therefore given by:
OIq Bq(1 OV-gyO (2.7.)
The chemical shift tensor defines the extent a nucleus is “shielded”. This 
becomes important in solid state NMR and is described later (2.6.1.1.). o1Cf 
refers to the reference material which in solid state NMR is usually 
adamantane. All chemical shifts in an NMR spectrum are defined as 
differences in chemical shift from this reference. In practice, the 
frequencies © are expressed as chemical shifts relative to the frequency ©o 
of a reference molecule. Chemical shift (8) is defined by the following 
equation and it is in parts per million (ppm):
$ _ fU^xio6 (2.8.)
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2.6. Solid State NMR
2.6.1. Anisotropic Spin Interactions
Many of the internal magnetic interactions which affect processional 
frequency of a nuclear spin are anisotropic; in other words, the magnitude 
of the interaction depends on the orientation of the nucleus within the 
applied magnetic field. In a liquid sample rapid molecular tumbling 
averages out the effects of these anisotropic interactions and narrow peaks 
are generally observed in the NMR spectrum at each resonance frequency. 
In a solid sample molecules are static and the nuclei have all possible 
orientations within the applied magnetic field, each associated with an 
orientationally-dependent resonance frequency. As a consequence the 
NMR peaks for a solid sample are veiy much broader than for a liquid 
sample unless special measures are taken. The broad spectra are called 
powder patterns in recognition of the orientational distribution of a powder 
sample.
The next sections describe the three principal anisotropic interactions that 
are relevant to this thesis.
2.6.1.1. Chemical Shielding Anisotropy
The chemical shielding tensor can be described by a second rank tensor a 
with principal elements on, 022 and 033 reflecting the anisotropy of the
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interaction. The isotropic value of the shielding tensor seen in isotropic 
liquids is an average of the principle elements:
Of. — V3 (an + °22 + ^ss) (2.9.)
The chemical shielding tensor, which is related to the electron distribution 
surrounding the nucleus, can be represented by an ellipsoid drawn in a 
reference frame in which on, 022 and 033 are aligned along the principle 
axes x’, y’ and z’ (Figme 2.6.)
50
Figure 2.6. The Chemical Shielding Ellipsoid. This indicates the different orientations of 
the magnetic field relative to B0 resulting in different resonance positions for the same 
chemical species.
In a solid sample the lack of tumbling removes the averaging effects seen 
in a solution sample, which means every slight deviation in orientation has 
its own chemical shift, causing broadening of peaks belonging to one 
chemical species. This is represented in Figure 2.7.
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s 11 = S 22
chemical shift (ppm) chemical shift (ppm)
Asymmetrical shift anisotropy Axially symmetric shift anisotropy
Figure 2.7. Theoretical powder line shapes for the chemical shift tensor in 
asymmetrical and axially symmetric nuclei.
The chemical shielding o for a given nucleus is determined by:
G - °iso + V2 A(3cos20 - 1) (2.9.)
Where 0 is the angle between the z axis of the principal axis system and the 
magnetic field Bo and A is the span of the chemical shielding anisotropy, 
defined as:
An = <733 - 1/2 (tJn + n22) (2.10)
In a powder the shape and width of the spectrum is determined by the 
principle elements and by the statistical distribution of orientations (Figure 
2.7).
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2.6.I.2. Dipole-Dipole Coupling
As shown in equation 2.1., nuclei possess a magnetic dipole moment p. 
Dipole-dipole coupling is the interaction through space of two or more 
magnetic moments and is analogous to the interaction of a pair of bar 
magnets. In essence, a single spin acts like a bar magnet with its own 
magnetic field and another spin in close proximity to it interacts with this 
magnetic field. This much like chemical shift anisotropy is averaged out in 
a solution sample and needs no consideration. In a solid state NMR 
homonuclear and heteronuclear dipolar coupling cause broadening of 
spectral peaks. For a pair of dipolar coupled nuclear spins /I and i2 the 
NMR lines are split into a doublet separated by frequency Av according to
Av = D(3cos26 — 1) (2.11.)
Where D is the dipolar coupling constant given by:
rj _ YiiYiih 
2nr3
(2.12.)
Here r is the linear distance separating the spins, 0 is the angle of the 
dipolar vector relative to Bo and yn and yn are the gyromagnetic ratios of 
the two spins used in this equation (Figure 2.8.).
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Figure 2.8. Representation of dipolar coupling between tw o nuclear spins 71 and 72.
A spectrum of a powder sample is a superimposition of doublets split by 
frequencies dependent on the statistical distribution of dipolar vector 
orientations. In organic and biomolecular materials the strongest dipolar 
couplings occur between proton spins (because of their high gyromagnetic 
ratio and abundance), which give rise to extremely broad and 
uninformative spectra. For this reason, protons are not routinely observed 
directly in solid-state NMR at the time of writing, although methods are 
being developed to improve the resolution of proton spectra.
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2.6.I.3. Quadrupole Interactions
Nuclei of spin > V2 possess a quadrupolar moment Q, which interacts with 
the electric field gradient generated by the circulating electrons and causes 
rapid spin-lattice relaxation. A nucleus of spin 1 such as 2H possess 3 spin 
states; +1,0 and -1 which occupy 3 energy levels in an applied magnetic 
field. In an isotropic liquid the quadrupolar interaction is averaged to zero 
and the energy levels are equally spaced with transition frequency due to 
the Zeeman effect. In the solid-state the quadropolar interactions are non­
zero and consequently the energy levels become shifted positively or 
negatively so that the transition frequencies, the frequencies of transitions 
from +1 to 0 and 0 to -1, Va and Vb, become inequivalent. (Figure 2.9.)
ZEEMAN
A
VB
----------------
QUADRUPOLAR
Figure 2.9. The effect on transitional frequencies due to quadropolar interactions in 
nuclei with a spin of 1.
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The quadropular interaction is also orientation dependent as represented in 
the following equation:
(2.13)
Where e2qQ is the quadmpole coupling constant.
2.6.2. Solid-State NMR methods 
2.6.2.I. Wide Line NMR
The shape of anisotropically broadened solid-state NMR lines can be 
analysed to give information on dynamics and interactions. This is 
particularly useful when the observed line arises from a unique nuclear site 
in a molecule, but line shape analysis becomes more difficult when the 
NMR spectram is a superimposition of signals from many chemically 
inequivalent nuclei. The spin 1 nucleus 2H is attractive for this purpose 
because it can be incorporated into molecules such as phospholipids at 
specific sites, so that the spectram can be assigned immediately and 
unambiguously. The anisotropy of the quadrapolar interaction gives rise to 
a characteristic spectrum called Pake patterns (Figure 2.10.). The horns of 
the Pake patterns are split by Avq (which is related to the quadrapolar 
coupling constant shown in equation 2.13.) which is sensitive to molecular 
motions and to the orientation of functional groups relative to an axis of
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rotation. It will be shown in Chapter 3 how this phenomenon can be 
exploited to probe the interactions of peptides with headgroup-deuterated 
phospholipid membranes.
%X
Figure 2.10. The Pake pattern formed in a deuterium spectra due to there being two 
allowed spin transitions.
2.6.2.2. Solid-State NMR methods for high resolution spectra
The majority of solid-state NMR experiments use techniques to overcome
the effects of anisotropic spin to produce high-resolution spectra in which 
peaks from individual nuclear sites can be obseived at different chemical 
shifts. The principal line-narrowing technique in solid-state is magic angle 
spimiing but can also be combined with cross polarisation.
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2.6.3.1 Magic Angle Spinning
The magnitude of the line broadening interactions have a 3cos20-l 
dependency on the magnetic field (recall that 0 is the angle between the 
magnetic field and the axis of the co-ordinate system expressing the 
anisotropic interaction). When 0 equals 54.7°, the chemical shielding, 
dipolar coupling and quadmpolar interactions become zero because 
3cos2(0) -1=0. The angle of 54.7° is therefore known as the magic angle. 
If a powder sample is rotated mechanically in the applied magnetic field 
about an axis inclined at the magic angle, all anisohopic interactions are 
averaged to zero over one cycle of rotation. If the spinning frequency 
approaches or exceeds the frequency range of the anisotropic interaction, 
then the effects of the anisotropy are eliminated from the spectrum and 
narrow lines are observed.
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Bo
Figure 2.11. Diagram representing a sample spinning at 54.7° or the magic angle 
relative to the applied field Bq. A method to reduce line broadening in solid state 
NMR.
For a nucleus such as 13C, the chemical shielding anisotropy can be 15- 
20 kHz and so the sample must be spun at this frequency to completely 
remove the effects. At slower spinning rates the MAS spectrum will 
consist of a series of “spinning sidebands”. These are sharp lines that 
radiate from the central chemical shift peak set apart at a frequency equal 
to the spinning speed (Figure 2.12.). The spinning sidebands will 
effectively take signal away from the central peak reducing signal intensity 
i.e. the faster a sample is spun, the fewer sidebands are observed resulting 
in better signal to noise. If spinning sidebands appear in a region of interest 
in a sample, an alternative spin speed must be selected and in some cases
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experiments will have to be run at different spin speeds to get a full picture. 
Figure 2.12. shows the creations of spinning sidebands at different spin 
speeds.
chemical shift (ppm) chemical shift (ppm) chemical shift (ppm)
Figure 2.12. Representation of the effect of increased spin rate in solid-state NMR 
MAS experiments.
Dipolar couplings involving the network of protons in organic materials 
are normally very strong and the effects of these couplings cannot be 
completely eliminated from the spectrum with MAS rates that are achieved 
with current technology. Consequently, proton MAS spectra are rather 
broad even at MAS rates of 50 kHz. When less abundant nuclei such as 13C 
or 1|P are observed, as in Chapter 3 and Chapter 6 of this thesis, strong 
heteronuclear couplings with protons must be removed by combining MAS 
with high-power proton decoupling, in which proton spins are irradiated 
with a strong radiofrequency field during sampling of the FID.
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2.6.3.2 Hartniann-Halm Cross Polarisation
Observing dilute spins like 13C presents two major problems. Firstly the 
low abundance of nuclei means the signal to noise ratio is inevitably poor. 
Secondly, the spin-lattice relaxation times of dilute spins (Tl) are veiy long 
due to the absence of strong homonuclear dipolar interactions. This means 
that large delays must be left between accumulation of successive scans 
and consequently experiment times to achieve a suitable signal to noise 
ratio can be veiy long. Hartmami-Hahn cross polarisation (CP) is a signal 
enhancement technique used in solid-state NMR to counteract these 
problems. CP works by transferring the magnetisation from an abundant 
and sensitive spin (usually 1H) to a dilute spin with lower sensitivity (e.g.
C). A pulse scheme for a typical cross polarisation experiment is shown 
hi Figure 2.13.
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90° pulse
jSI Contact
1H 1 Pulse Decoupling
13C
Figure 2.13. A typical cross polarisation pulse sequence. Following the 90° pulse 
magnetisation is transferred from 'H to l3C by cross polarisation. 13C is then observed 
whilst 'H is decoupled from l3C.
The initial 'H 90° pulse creates 'H magnetisation along -y. The 'H contact 
pulse is then applied on resonance which is continuous and maintains the 
magnetisation along -y in the absence of a 90° pulse. This is known as the 
spin-lock field (Bi('H)). The l3C contact pulse is applied simultaneously to 
the ’H contact pulse. This must be set to move 13C into the same axis as 'H 
at the same Larmor frequency to allow cross-polarisation to occur. This is 
known as the Hartman-Hahn matching condition, which is given by the 
following equation:
YhB1CH) = YxB^X) (2.14.)
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CP has been used on cell membranes to allow the observation of natural
abundance 13C peaks in both frozen and in a “fluid,, state (Spooner et al, 
1994). Early CP NMR on lipid membranes was performed on frozen 
membranes, which allows efficient CP to occur. However, this is an 
inaccurate picture of real cell membranes which are in a “fluid” state. The 
two different states have different dynamic properties which are detectable 
by NMR. In either case CP can be used to detect natural abundance 13C of 
membrane proteins and the membrane it is embedded in. A sample spectra 
studying GalP in native membranes is shown in Figure 2.14, showing how 
CP solid state NMR can detect the effects of I3C labelled ligand (in this 
case glucose) binding to membrane embedded protein. This is possible 
since the nuclear spins of the ligand become restrained upon binding 
allowing cross-polarisation to occur. Free ligand is not restrained and will 
therefore not be detectable by solid-state NMR as cross-polarisation will be 
ineffective. This means solid-state NMR can be used to provide evidence 
of ligands binding to proteins.
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Figure 2.14. The effect of glucose on GalP in native cell membranes. All samples 
contain GalP in native membranes. Two full spectra containing 0.5 pmol GalP (A) then 
titrated D-[l-°C]glucose (B) are shown. Expanded spectra (90-100 ppm) containing the 
minimum detectable 250 nmol of D-[l-13C]glucose (C) and maximum detectable D-[l- 
IJIC]glucose (D) are also shown. Figure taken from Spooner et.al, 1994.
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Chapter 3
3.1. Study of interactions of the cytoplasmic region of FXYD Proteins 
with membranes and the Na+, K+-ATPase
All seven FXYD proteins interact with the Na+, K+-ATPase (Beguin et al, 
1997; Pu et ah, 2001; Beguin et al, 2002; Crambert et al, 2002; Garty et 
al, 2002; Crambert et al, 2005; Arimochi et al., 2007). As FXYD proteins 
are tissue-specifically expressed it is thought they alter activity of the 
Na+, K+-ATPase to suit the needs of the tissue (Crambert and Geering, 
2003). This hypothesis has been supported by evidence showing that 
different FXYD proteins cause ion affinities in the Na+, K+-ATPase to 
change in different ways. For example the FXYD protein RIC (related to 
ion channel) increases affinity for Na+ and/or K+ ions in an alp 1 complex 
but in the same complex FXYD6 slightly decreases apparent K+ affinity 
and significantly decreases the apparent Na+ affinity of the 
Na+, Kl-ATPase (Lubarski et al, 2005). The 35 amino acid signature 
sequence (Figure 1.5) of FXYD proteins incorporates the entire 
transmembrane region and a large part of the extracellular region. It is 
therefore unlikely the tissue specific features of FXYD proteins are found 
in this region. Therefore this chapter aims to look into the interaction of the 
Na+, Kh-ATPase with the cytoplasmic region of FXYD proteins where 
there is the most variation in amino acid sequence in order to understand 
how FXYD proteins alter the ion affinity of the Na+, K+ -ATPase to suit the
needs of the tissue in which it is located. Two FXYD proteins were
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selected for study. The first is phospholemman (PLM); its cytoplasmic 
region has been shown to interact with negatively charged membrane 
surfaces (Clayton et al7 2005) and is subject to phosphorylation (discussed 
later) which may be crucial to the function of the cytoplasmic region. 
Mat-8 was also selected as it has a cytoplasmic region of a similar size but 
a very different sequence to PLM.
PLM has an arginine-rich cytoplasmic region giving it a net positive 
charge. A full length PLM structure has been solved by solution NMR in 
SDS micelles (Teriete et aL, 2007). This is shown in Figure 3.1. A micellar 
environment is not at all indicative of a biomembrane environment so the 
cytoplasmic region in this structure may not be an accurate representation 
of the cytoplasmic region in its natural phospholipid bilayer environment. 
Nevertheless, the structure shows the cytoplasmic region to consist of the 
continuation of the transmembrane helix connected to another helix (h4) 
via a relatively long linker region which would allow flexibility of h4.
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Figure 3.1. Structure of PLM solved in SDS micelles with predicted bilayer location.
The structure of PLM was solved in SDS micelles (Teriete et al., 2007) by solution NMR. 
The above structure (PDB1D:2J01) has the following colour scheme: cytoplasmic region 
(blue), transmembrane region (green) and extracellular region (red). The predicted 
membrane locations are indicated (downloaded from Orientations of Proteins in 
Membranes database (OPM).
The cytoplasmic region of PLM has been shown to be phosphorylated at 
four residues. These residues are highlighted in Figure 3.2. Protein kinase 
A (PKA) phosphorylates at Ser 68 whereas protein kinase C (PKC) 
phosphorylates at both Ser 63 and Ser 68 (Palmer et al, 1991; Walaas et 
al, 1994).
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Figure 3.2. Sequence of the cytoplasmic region of Phospholemman. One letter amino 
acid codes of the cytoplasmic region of PLM are shown. Phosphorylation sites are 
highlighted in red. Both PKA and PKC phosphorylated Ser 68 (double underlined) 
whereas Ser 63 is only phosphorylated by PKC (single underlined). Location of the 
cytoplasmic region relative to the extracellar region (containing FXYD motif) and the 
transmembrane (TM) domain is indicated. Sequence is from human PLM.
PLM reduces Vmax of the ATPase activity of the Na1, K' -ATPase, however 
this effect is reduced upon phosphorylation of PLM (Fuller et al., 2009) by 
PKA. Voltage clamp experiments have revealed that phosphorylation of 
Ser 68 alone induces an increase of 31% in Na+, K4-ATPase current 
(Silverman et al., 2005). Experiments on PLM knock out and wild type 
mice confirm this observation (Pavlovic et al., 2007). Introduction of 
synthetic peptide representing the 19 C-terminal residues of PLM to these 
murine cells revealed unphosphorylated peptide reduced Na', K*-ATPase 
activity whereas Ser 68 phosphorylated peptide increased Na+, K1-ATPase 
activity. As both PKA and PKC cause Ser 68 to be phosphorylated, PLM 
could have a role in two separate cell signalling pathways. NMR studies 
have shown that phosphorylation of Ser 68 causes the 'H and 15N chemical 
shifts in the helix of the cytoplasmic region (h4) to change, indicating a 
change in orientation of the cytoplasmic region independent of the rest of
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the protein (Teriete et a!., 2009). With this observation, a model is 
proposed (Figure 3.3.), where the cytoplasmic region of PLM undergoes a 
conformational change upon phosphorylation of Ser 68. The non- 
phosphorylated orientation was modelled by removing the y-subunit from 
the structure of the Na+, K+-ATPase from pig kidney ((Morth et ah, 2007) 
PDBID:3KDP) and replacing its co-ordinates with the structure of PLM 
solved in Na+, K+-ATPase-free SDS micelles (Teriete et ah, 2007). This 
allows the sidechains of h4 to interact with both the Na+, K+-ATPase and 
the cell membrane surface. The alternative conformation induced by Ser 68 
phosphorylation models h4 moving to an alternative site above a 
negatively charged crevice in the transmembrane region which has been 
shown to alter ion affinity of the Na+, Kf-ATPase when a single positive 
charge is added (Reyes and Gadsby, 2006). This could explain the 
mechanism by which phosphorylation modulates the inhibition of the Na+, 
K+ -ATPase by PLM.
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Figure 3.3. Model of PLM within the Na+, K+-ATPase complex showing the change in 
the cytoplasmic region following phosphorylation, (a) The pig kidney Na+, K+-ATPase 
structure with y-subunit removed and replaced with PLM shown at two angles, (b) 
possible alternative orientation of PLM due to Ser 68 phosphorylation. Dotted arrow 
indicates negatively charged crevice of the Na+, K+-ATPase which leads to the ion binding 
pocket in the centre of the a-subunit. Figure taken from (Teriete et ai, 2009).
The cytoplasmic region of PLM not only affects Naf, K4-ATPase function 
but also binds to phospholipid bilayers with a preference for negative 
phospholipids (Clayton et ai, 2005). The same study also analysed 
peptides representing the cytoplasmic region of phospholamban (PLB1.23), 
both in its phosphorylated and unphosphorylated form. Phospholamban 
shares similarities with PLM in that they are both small phosphoproteins 
with a single hydrophobic transmembrane span. Whilst PLM inhibits the 
Na+, K+-ATPase, phospholamban inhibits the related ATPase SERCA and 
this inhibition is relieved upon phosphorylation (Sasaki et ai, 1992). PLM 
phosphorylation may also result in the relief of inhibition of its binding
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partner the Na+, K+-ATPase but this possibility is yet to be investigated. 
Residues 38-72 of PLM which encompass the cytoplasmic domain were 
therefore selected for study to further understand the significance of 
phosphorylation at Ser 68. This will be achieved by using synthetic 
peptides that contain the cytoplasmic sequence (Figure 3.2.) which will be 
referred to as PLM38-72 for the non-phosphorylated form and PPLM38-72 
where Ser 68 is phosphorylated. Phosphorylation of PLM is likely to play a 
role in the tissue specific effects of Na+, K+-ATPase since there is no 
experimental evidence demonstrating phosphorylation of any other 
mammalian FXYD proteins.
Mat-8 is a much less well understood member of the FXYD protein family. 
Although there is no evidence that it is a physiological phosphorylation 
substrate, it does have two isoforms unlike PLM (Bibert et aL, 2006). The 
two isoforms (called long form and short form) have identical extracellular 
and transmembrane regions but the long form contains an additional 26 
amino acids in the cytoplasmic region (Figure 3.4.) The short form of Mat- 
8 decreases the apparent K+ and Na+ ion affinities of the Na+, K ‘ -ATPase 
over a wide range of membrane potentials, whereas long form Mat-8 
decreases the apparent K+ affinity at slightly negative and positive 
membrane potentials and in complete contrast to short form Mat-8 
slightly increases the apparent Na1 affinity of the Na+, K ' -ATPase (Bibert 
et al, 2009). The balance of the two isoforms in the cell appears vital to
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function as in human breast cancer cells the short form Mat-8 is
overexpressed whereas long form Mat-8 levels remain normal 
(Yamamoto et al, 2009).
Short form
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Figure 3.4. Cytoplasmic regions of both Mat-8 isoforms. Long form and short fonn 
Mat-8 have identical extracellular and transmembrane regions but the long form has an 
additional 26 amino acids in the cytoplasmic region (underlined). Location of the 
extracellular region (with FXYD domain), transmembrane region (TM) are shown.
As the cytoplasmic region contains the only difference between the two 
isoforms it seems likely that this region is key to their differential effects 
on the Na+, K+-ATPase. The cytoplasmic region of both isoforms of 
Mat-8 was therefore selected for study as to their effects on the activity of 
the Na+, K^-ATPase in order to further understand the differences 
between the two isofomis further. Like PLM this will be achieved using 
synthetic peptides designed to represent the sequence of the cytoplasmic
•Cytoplasmic-
TM hSA KCKCKFGQKS GHHPGETPPL ITPGSAQS 
40 50 60
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regions of both Mat-8 isoforms (Figure 3.4.) and will be referred to as 
Mat-Ssfss-e? for the short isoform and Mat-SIfss.go for the long isoform.
This chapter will look at how the cytoplasmic regions of PLM and both 
isoforms of Mat-8 interact with the Na+, K+-ATPase and cell membranes. 
There is evidence the cytoplasmic region of PLM regulates the Na+, K+- 
ATPase (Pavlovic et al, 2007) and 2H NMR has shown the cytoplasmic 
region of PLM also interacts with negatively charged phospholipid 
headgroups (Clayton et aL, 2005) but the two interactions are yet to be 
reconciled. To resolve how both of these interactions might occur in vivo 
several methods will be employed.
2H NMR will be utilised to analyse Mat-Ssfas-e? and Mat-81f38-93 
interacting with phospholipid bilayer surfaces. Another peptide CHIF38-69 
will also be studied; this is based on the cytoplasmic region of the FXYD 
protein CHIP. This was selected in order to compare results with the 
short isoform of Mat-8, with which it shares over 60% sequence identity 
(Figure 3.5.). The full structure of CHIP has also been solved in SDS 
micelles (Franzin et al, 2007a). To confirm and quantify these 
interactions, isothermal titration calorimetry (ITC) will be used to 
measure enthalpy changes when phospholipid bilayers are titrated into 
the cytoplasmic peptides; PLM38-72, p PLM38-725 Mat-Ssf^^?, Mat-81f38-93 
and CHIF38-69- In all synthetic phospholipid based experiments in this
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thesis either LMVs (large multilamellar vesicles) or SUVs (small 
unilamellar vesicles) are used. Figure 3.6. compares these two types of 
vesicles to detergent micelles which were used to solubilise PLM and 
CHIF to allow their structural determination by solution-state NMR. 
LMVs and SUVs are both composed of phospholipid bilayers, which 
mimic the phospholipid bilayer of the cell membrane whereas micelles 
are made of a monolayer and are therefore not representative of a cell 
membrane environment.
SG KCKCKSSQKQ-HSPVPEKAIPLITPGSATTC CHIF 
SA KCKCKFGQKSGHHP-GETP-PLITPGSAQS Short form Mat-8
Figure 3.5. Alignment of the cytoplasmic regions of CHIF and short form Mat-8. 
Although the cytoplasmic region contains the most variation between FXYD proteins 
there is high similarity between Mat-8 short form and CHIF. Identical residues are 
highlighted in red.
Following determination of interactions of cytoplasmic peptides with 
membranes, evidence would need to be produced to confirm this 
interaction still occurs in membranes containing the Naf, K+-ATPase. A 
system would therefore need to be developed to remove the Na+, K+- 
ATPase from its native membrane and reconstitute it into synthetic 
membranes similar to ones used in 2H NMR and ITC. With the Na+, K+- 
ATPase reconstituted into these membranes further studies can be
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performed to confirm whether cytoplasmic peptides bind to cell 
membranes in the presence of the Na ', Kf-ATPase.
Micelle L'Pid Bilayer
Figure 3.6. Model systems for cell membranes. When studying membrane proteins 
different systems are used to emulate cell membranes. Detergent micelles are often used as 
they can make proteins soluble however they are a monolayer unlike the phospholipid 
bilayer found in cell membranes. Liposomes are considered more representative of cell 
membranes as they consist of bilayers either single bilayers (small unilamellar vesicles 
(SUVs)) or multiple bilayers (large multilamellar vesicles (LMVs)).
The effect of cytoplasmic peptides on the activity of the Na ' , K'-ATPase 
will also be determined using functional ATPase assays. As the 
cytoplasmic region of FXYD proteins is the most varied region it is 
possible it is responsible for the tissue-specific changes to Na+, K'-ATPase 
function. By establishing this the effect of PLM38-72 on reconstituted Na+,
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K+-ATPase could be analysed and compared to the effects seen in non- 
reconstituted Na+, K+-ATPase in order to explain why, and under what 
circumstances, PLM38-72 interacts with both the Na+, K+-ATPase and cell 
membranes.
3.2. Materials and Methods 
3.2.1. Materials
Phospholipids were purchased from Avanti® Polar Lipids Inc. Peptides 
were purchased from Peptide Protein Research Ltd. and were designed to 
represent the cytoplasmic regions of PLM (Figure 3.1.), short form Mat-8 
(Figure 3.2.) and CHIP (Figure 3.5.). Peptide designed to represent the 
cytoplasmic region of long form Mat-8 (Figure 3.2.) was purchased from 
GenicBio Biotechnology Ltd. Ascorbic acid supplied by J.T. Baker. 
Ammonium heptamolybdate tetrahydrate and trisodium citrate-dihydrate 
supplied by Merck. All other materials were supplied by Sigma.
3.2.2. Na+, K+-ATPase sample preparation
All Na+, K+-ATPase membranes were prepared from either pig kidney or 
spiny dogfish rectal gland by the group of Prof. Mikael Esmami at the 
University of Aarhus using previously described methods (Jorgensen, 
1974; Esmami et al, 1979). Final samples have a protein concentration of 
5-6 mg ml'1 determined by tire Lowry method (Lowry et al, 1951) and a
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protein to phospholipid concentration 100:1 determined by wet ashing 
method (Bartlett, 1959). Sample purity is revealed by SDS-PAGE to be 
approximately 70%.
3.2.3. Functional ATPase assays
ATP hydrolysis rates were measured using the method of Baginski 
(Baginski et al, 1967). Reagent A was prepared on the day of experiment 
by dissolving 3 g of cold ascorbic acid in 100 mL of 0.5 M HC1. Cold 10% 
ammonium heptamolybdate solution (5 mL) was then added to this with 
stining. Various NaCl concentrations were prepared in quadruplet at 10 
fold desired final concentration and 50 pL of each were added to 350 pL of 
test solution (with final concentrations after addition of enzyme and 
peptide of 30 mM Histidine, 3 mM Na-ATP, 20 mM KC1, 4 mM MgCL, 
0.33 mg mL"1 albumin). For each quadruplet, 50 pL of water or peptide 
was added to three samples and 50 pL of 1 mM ouabain was added to the 
fourth as a blank (ouabain completely inhibits Na+, K+-ATPase activity at 
this concentration). Samples were pre-heated at 37°C for 90 seconds and 
each reaction was initiated by addition of 50 pL of Na+, K+-ATPase 
membranes (0.5 pg ml"1 in 20 mM histidine and 25% glycerol. Samples 
were incubated at 370C for precisely 15 minutes. Hydrolysis of ATP was 
halted with addition of 1 mL cold reagent A and left on ice. After at least 6 
minutes 1.5 mL of 1:1 SDS: reagent AC (30 mM sodium-m-arsenite, 140
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mM trisodium citrate-diliyrate, 4% acetic acid) were added and samples 
were returned to 37°C for 10 minutes. The absorbance of samples was read 
at 850 mu using water as a blank.
3.2.4. Preparation of Phospholipid Vesicles
Large multilamellar vesicles (LMVs) of DMPO^/DOPG were prepared 
by first weighing 10 mg of total lipid composed of DMPC-^ and DOPG in 
a 2:1 molar ratio, and dissolving in the minimum volume of chloroform to 
give a clear solution. The chloroform solutions were dried to a film under 
nitrogen and high vacuum overnight. The lipid film was then resuspended 
in 50 pL of sample buffer containing 10 mM Tris and 1 mM EDTA at pH
7.4. The suspension was vortexed and subjected to five freeze-thaw 
cycles. Where appropriate, the peptide was added in 5 pL of sample buffer 
to attain a lipid:peptide molar ratio of 50:1 or 20:1, and the vortex, freeze- 
thaw process repeated.
Small unilamellar vesicles (SUVs) were prepared from 2:1 DMPC:DOPG, 
2:1 DMPC/DOPC and 2:1 DMPC/DOPS (molar ratios). Lipids were 
prepared in chloroform and then dried under nitrogen and high vacuum, 
before resuspension in 10 mM Tris, pLI 7, 1 mM EDTA, pH 7.4. 
Sonication was carried out for 2—3 min on ice, using a Dawe Ultrasonic
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probe sonicator (London) at 50% duty cycle, output control 5, to promote 
formation of SUVs as described previously (Zhu et al., 2003).
3.2.5. Wide 2HNMR
Spectra were recorded on a Broker Avance 400 MHz spectrometer 
operating at a frequency of 61.00 MHz for 2H. Wide line 2H NMR spectra 
of membranes containing DMPOc/4 (1,2-dimyristoyl-sn-gly cero-3 - 
phosphocholine labelled with deuterium) were obtained using a double- 
timed nonspinning probe head with fixed horizontal 5 mm coil. Spectra 
were recorded as a result of accumulating 10000-20000 transients with a 1 
s recycle delay. The quadrupole echo sequence (90.v-x-90y-x-acquisition) 
sequence (Davis et al, 1976), was used with a 90° pulse length of 4 ps and 
delay x of 22 ps. The experimental temperature was 30°C.
3.2.6.31P NMR
Spectra were recorded on a Broker Avance 400 MHz spectrometer 
operating at a frequency of 62.12 MHz for 31P. Magic-angle spinning 
(MAS) 31P NMR spectra were recorded using a double timed MAS probe 
with sample rotation rate of 4 kHz. The samples were contained within a 4 
mm diameter zirconia rotor, and spectra were recorded after applying a 
single 4 ps 90° pulse at the frequency 31P followed by 50 kHz proton 
decoupling during die acquisition period. Experiments were performed at 
maintained temperatures of 4 °C, 9 °C, 14 °C and 19 °C.
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3.2.7. Isothermal Titration Calorimetry
Small unilamellar vesicles (SUVs) were produced as described in 3.2.4 at a 
10 mM concentration. Heat flow resulting from peptide binding to SUVs 
was measured using the ultrasensitive iTC2oo MicroCalorimeter (MicroCal 
LLC, Northampton, MA). Reaction cell volume and total injection volume 
were 200 and 40 pi. Experiments were performed at 25 °C, at a power- 
reference setting of 6 pcal/s with stirring of 1000 rpm. Prior to use all 
solutions were degassed under vacuum. Data analysis was carried out 
using the Origin v.7 software (MicroCal). Experimental conditions were 
designed following established protocols (Oldenburg etal., 1996; Joachim, 
1997; Abraham et al, 2005). The reaction cell contained a 100 pM 
solution of peptide (PLM3S-72, pPLM38-72, Mat-Ssfri-e?, Mat-81f38-93 or 
CHIF3s-69), ha 10 niM Tris; 1 mM EDTA, pH 7.4. Lipid SUVs were 
injected via the syringe. Titrations were carried out at internals up to 
10 min in 0.5-2 pi aliquots following an initial discard aliquot of 0.3 pi. 
Each injection generates a heat of reaction, determined by integration of 
the individual peaks from the heat flow trace.
3.2.8. Reconstitution of the Na+, K+-ATPase in synthetic lipids
Lipid preparations of 100% DMPC, 100% DOPC and 2:1 molar ratio
DMPC:DOPG were dissolved in 333 pL of reconstitution buffer (histidine 
20 mM, 150 mM KC1, 4 mM MgCE, pH 7) and 667 pL C^Eg 150 mg/mL. 
This was sonicated in a water bath sonicator for 1.5 hours at 4°C. 3.6 mL
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spiny dogfish enzyme (5.6 mg mL"1) was added to 450 pL KC1 1.5 
M/MgCf 40 mM and 450 pL C^Eg 70 mg/mL. This mixture was 
centrifuged at 50000 rpm for 1 hour- at 10 °C. 1.05 mL of the supernatant 
(solubilised enzyme/native membranes) was added to 0.630 mL histidine 
20 mM/ KC1150 mM/MgCf 4 mM, pH 7 and 0.84 mL of sonicated lipid.
1106 mg of BioBeads were added to give a 12:1 ratio by weight of 
biobeads to CiaEg. This mixture was incubated overnight in a cold room on 
a shaker. Membranes were removed from BioBeads with a pastern pipette. 
Excess BioBeads were removed by passing the sample through an 8pm 
filter. Samples were put into ultracentrifuge bottles and topped up to 10 mL 
with histidine 20 mM/ KC1 150 mM/MgCL 4mM, pH 7. The samples 
were centrifuged at 60,000 rpm for 1 hour at 10°C. The resulting pellets 
were homogenized in 0.84 mL histidine sucrose EDTA (HSE). This was 
performed in two 0.42 mL volumes die second being used as a rinse to 
minimise loss. The ATPase activity of the reconstituted Na+, K+-ATPase 
was tested with the Baginski method.
Control samples of Na+, K! -ATPase reconstituted into native membranes 
were produced by not adding any sonicated lipid after solubilising 
enzyme/native membranes with C^Eg. The Na+, K+-ATPase was 
reconstituted back into the native membranes by using BioBeads as 
described for reconstitutions into synthetic membranes.
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3.3. Results
3.3.1. The interaction of FXYD protein cytoplasmic domains with 
phospholipid bilayers.
3.3.1.1. Wide-Line 2H NMR
The initial focus of this chapter is the interaction of the FXYD protein 
cytoplasmic domains with the Na+, K+-ATPase. The cytoplasmic regions 
of FXYD proteins are both water-soluble and in close proximity to 
phospholipid headgroups. Specific phospholipid headgroups may therefore 
influence the conformation of these cytoplasmic domains. Solid-state 
NMR is increasingly being utilised to understand the interactions of 
proteins with phospholipid headgroups (Franzin and Macdonald, 2001; 
Clayton et ah, 2005). Two principal methods for this are 2H NMR and 31P 
NMR. Wide-line 2H NMR is a static technique which means magic angle 
spinning is not utilised and the anisotropic quadrupolar interactions that 
give rise to wide peaks are observed in the spectrum (Seelig and 
Macdonald, 1987). Lipid vesicles can be prepared using synthetic lipids 
into which 2H is incorporated into sites on phospholipid headgroups. 
Phospholipids are carefully selected to produce an environment emulating 
cell membranes. This means having an overall slightly negative charge 
which would be contributed by negatively charged phospholipids like 
DOPG. Native membranes are also in a fluid state at body temperature; 
therefore synthetic membranes must consist of enough unsaturated 
phospholipids like DOPG (l,2-dioleoyl-57?-glycero-3-[phospho-rac-(l-
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glycerol)), DOPC (l,2-dioleoyl-sn-glycero-3-pliosphocholine) and DOPS 
(dioleoyl-sn~glycero-3-phospho-L-serine) so the bilayer is in a fluid state at 
experimental temperatures. DMPC (l,2~dimyristoyl-sn-glycero-3- 
phosphocholine) is zwitterionic and often mixed with negatively charged 
phospholipids to produce bilayers with similar features to native cell 
membranes. DMPC can also be labelled with deuterium at its phospholipid 
headgroup to produce DMPC-cW, which is frequently used in solid state 
NMR. The structure of these phospholipids and the locations of the 2H 
labels are shown in Figure 3.7.
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method has revealed that PLM38-72 associates with negatively charged 
phospholipid bilayers (Clayton et al, 2005). These 2H NMR experiments 
were repeated using peptides that represent the cytoplasmic regions of both 
Mat-8 isoforms; Mat-Ssfss-e? and and Mat-81f38-93. pPLM38-72 was also 
tested to see the effect of Ser 68 phosphorylation on membrane affinity as 
well as CHIF38-69 as a comparison to the homologous Mat-8sf38-67 (Figure 
3.5.)
The 2H NMR spectra of 2:1 DMPC-<#:DOPG LMVs in the presence of 
PLM38-72 (Clayton et al, 2005) and pPLM38-72 (provided by personal 
communication with Dr. Eleri Hughes), are shown in Figure 3.8 with a 
and (3 splittings indicated. The LMVs contain a 33% negative charge 
which is about three times higher than those of cell membranes in nature 
(Akio, 1971). If the negative charge was as low as obseived in vivo the 
small interaction would become undetectable. By using a higher 
concentration of negatively charged phospholipid the interaction can be 
measured. Although this is clearly not ideal, the phospholipid interaction 
of a cytoplasmic peptide is weaker in isolation and veiy different to a 
typical protein/protein interaction. Such interaction is made more likely 
due to the constant close proximity of the cytoplasmic regions and 
membrane surfaces in vivo, this helps validate the results since these 
residues are tethered in place by the transmembrane domain. When 
phospholipid headgroups are perturbed the a and (3 splittings will change.
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Table 3.1. shows the changes in splitting values due to increased 
concentration of cytoplasmic peptides. Both PLM38-72 and PPLM38.72 
peptides appear to induce a change in splittings. There is approximately a 
1 kHz decrease in a-splittings at a 50:1 ratio with a subsequent additional 
0.5 kHz decrease at a 20:1 ratio. The P-splittings increase by 
approximately 1 kHz increase at a 50:1 ratio of lipid to PLM peptide with 
a further increase in p-splittings of approximately 200 Hz at 20:1 lipid to 
PLM peptide ratio.
PLM38.72 PPLM38-72
pure lipid 
(PC/PG)
pure lipid 
(PC/PG)
2H (kHz) 2H (kHz)
Figure 3.8. 2H NMR showing the effect of PLIV^^z and pPLIV^g^ on phospholipid 
bilayers. Wide line 'H NMR spectra of membranes containing DMPC-r/4 and DOPG in a 
2:1 molar ratio (5 mg total lipid) alone and in the presence of PLM38.72 and pPLM38.72 in a 
lipid to peptide molar ratio of 20:1. The quadrupole splittings for the deuterons at the a- 
and P-choline positions of DMPC-r/4 are denoted by the separation between the pairs of 
dotted lines. The spectra were obtained at 30 °C and are the result of accumulating 8000 
scans. Figure taken from Clayton et al, 2005.
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Further 2H NMR experiments were performed on DMPC-^:DOPG 
LMVs in the presence of Mat-Ssfss-ey, Mat-Slfsg.gs or CHIF38-69 (Figui'e 
3.9.). Mat-8sf38-6? has a smaller effect than the PLM peptides with an 
approximate 1 kHz decrease in a-splittings and approximately 300 Hz 
increase in P-splittings at the 20:1 lipid to peptide ratio. At a 50:1 lipid to 
Mat-8sf38-67 ratio there is a very small change in splittings suggesting a 
much larger quantity of Mat-Ssfsg-e? is required to make any appreciable 
change to the splittings in 2H NMR spectra than the PLM peptides. Both 
Mat-81f38-93 and CHIF38-69 have only small changes in a and p splittings 
of approximately 100-500 Hz at the 20:1 lipid to peptide ratio. The 
Mat-81f3s-93 spectra required double the number of scans to achieve the 
signal to noise seen in Figure 3.9. which is not as good as the spectra for 
other peptides. Ideally this would be repeated but as the process requires 
several milligrams of expensive peptide it was not possible.
In 2H NMR a change in splittings indicates an interaction of peptide with 
the phospholipid surface by perturbation of the orientation of the choline 
headgroup. These data suggest that PLM38-72 and PPLM38-72 have the 
strongest interaction with negatively charged phospholipid bilayers whilst 
Mat-8sf38-67 also interacts with phospholipid bilayers albeit to a smaller 
extent. CHIF38-69 seems to have little effect on negatively charged 
phospholipid bilayers. The quality of data for Mat-SIfjs-gs is not good 
enough to draw any definite conclusions. These spectra may only detect
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variations in the structures or orientations of the peptides at the 
membrane surface, which perturb the phospholipid headgroup in some 
way. This means NMR alone cannot quantify interactions between 
peptides and phospholipid membrane surfaces.
Mat-Ssfj|_$7 Mat-81f?s.9j CHIF}g_j9
pure lipid 
(PCPG)
pure lipid 
(PCPG)
pure lipid 
(PCPG)
*H (kHz) *H (kHz) *H (kHz)
Figure 3.9. 2H NMR showing the effect of Mat-Ssf^y, Mat-Slfjg.^ and CHIF38^9 on 
phospholipid bilayers. Wide line 2H NMR spectra of membranes containing DMPC-rfi 
and DOPG in a 2:1 molar ratio (5 mg total lipid) alone and in the presence of Mat-Ssfjg^y, 
Mat-81f38-93 and CHIF38.69 in a lipid to peptide molar ratio of 20:1. The spectra were 
obtained at 30 °C and are the result of accumulating 8000-16000 scans.
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Table 3.1. a and p splittings in 2H NMR spectra of 2:1 DMPC-rW:DOPG at various 
lipid:cytoplasmic peptide concentrations. All values given in Hz.
Peptide
AvQa(Hz)
Lipid only 50:1 20:1
AveP(Hz)
Lipid only 50:1 20:1
PLM38.72 8559 7608 6951 2002 3179 3377
PPLM3S.72 8667 7674 6958 2009 2674 3073
Mclt“8sf38.67 8661 8639 7862 2121 2236 2499
Mclt-81f38-93 9165 9000 8859 2478 2500 2536
CHIF38.69 8690 8962 8793 2108 2178 1864
3.3.1.2. Isothermal Titration Calorimetry
As 2H NMR is only indicative of an interaction between peptides and 
phospholipid headgroups, ITC was performed to quantify any potential 
binding that is occuning. ITC can measure thermodynamic properties of a 
biological interaction such as peptide binding to phospholipid. These 
thermodynamic properties include binding affinity (Ka) and enthalpy 
changes (AH). The liposomes selected were SUVs as they do not sediment 
unlike LMVs. Sedimentation would interfere with the recording of 
enthalpy changes by ITC. 2:1 molar ratio DMPC:DOPG SUVs (overall 
negative charge) were investigated for direct comparison to the 2H NMR 
data. 2:1 molar ratio DMPC:DOPC SUVs (zwitterionic) were also 
investigated as they have identical hydrocarbon chains to 2:1 
DMPC:DOPG but have a different net headgroup charge. At the outset of 
the project, work had already been carried out measuring binding affinities
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of both PLM38-72 and pPLM38-72 for 2:1 DMPC:DOPG and DMPC:DOPC 
SUVs by ITC by Dr. Eleri Hughes (Figure 3.10) who reported effective 
affinity constants (Ka) for PLM38.72 and PPLM38-72 of 3.07 x 10"6 M'1 and 
2.70 x 10"4 M'1 respectively (Table 3.2.), but no appreciable binding in 
DMPCiDOPC. Although the affinity constant is higher in PLM38-72 than 
pPLM38-72 there is a wider spread of points in the former, making it more 
difficult to fit the data. That said the difference is relatively large 
suggesting that Ser 68 phosphorylation reduces the affinity for negatively 
charged membranes by reducing the electrostatic potential of the peptide as 
it introduces a negative charge or by altering the structure of the peptide.
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Figure 3.10. Affinity of PLIV^z (a) and pPLM38.72 (b) for 2:1 DMPC/DOPG 
membranes. ITC binding curve for lipid vesicles (25 to 50 pM lipid per injection) titrated 
into 100 pM PLM38_72. Curves were generated by integrating the raw enthalpic data and 
fitted by the MicroCal ‘one set of sites’ function (black line). Experimental temperature 
25°C. Data provided by personal communication with Dr. Eleri Hughes.
To compare the other peptides to PLM the same SUVs of DMPC:DOPG 
and DMPC:DOPC were titrated into Mat-8sf38-67 (Figure 3.11.), 
Mat-81f38-93 (Figure 3.12.) and CHIF38-69 (Figure 3.13.). The values for Ka 
and AH are shown in Table 3.2. Although none of these peptides had as 
strong binding as PLM38-72 in DMPCiDOPG, Mat-81f38-93 still had an 
effective affinity constant that was considerably higher than the affinity 
constant of Mat-8sf38-67 suggesting the extra 26 amino acids in the long 
isoform of Mat-8 have a role in membrane binding. Although binding
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affinity is veiy small in Mat-Bsfss-e? it is clearly higher than CHIF38-69 
which effectively shows no binding at all with negatively charged 
phospholipids. Interestingly with the exception of an additional single 
histidine residue in Mat-Ssf^-r,? these two peptides share the same charged 
amino acids (Figure 3.5.). This suggests that any lipid/peptide interactions 
involve more than simply electrostatic potential. The observations agree 
with the 2H NMR data for DMPC:DOPG as PLM3S-72 showed the largest 
changes in a and (B splittings as well as the largest affinity constant. Mat- 
Ssfss-e? showed a relatively small change in a and p splittings and relatively 
small binding affinity constant whilst CHIF38-69 had a negligible effect on a 
and p splittings and had no effective affinity constant. Although peptides 
showed varied levels of binding to the negatively charged DMPC:DOPG, 
binding levels were effectively zero in DMPC:DOPC. DMPCrDOPG and 
DMPC:DOPC have identical hydrocarbon chains but has a zwitterionic 
surface. This suggests that electrostatic potential plays the major role in 
phospholipid binding but is not the only factor.
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Figure 3.11. Affinity of Mat-8sf3>M>7 for 2:1 DMPC:DOPG (A) and 2:1 DlYfPC:DOPC 
(B) membranes. ITC binding curve for 100 (dVl Mat-Ssfjs-e? titrated with lipid vesicles 
(25 to 50 pM lipid per injection). Curves were generated by integrating the raw enthalpic 
data and fitted by the MicroCal ‘one set of sites’ function (black line). Experimental 
temperature 25°C.
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Figure 3.12. Affinity of for 2:1 DMPC:DOPG (A) and 2:1 DMPC:DOPC
(B) membranes. ITC binding curve for 100 Mat-81f3g_93 titrated with lipid vesicles (25
to 50 pM lipid per injection). Curves were generated by integrating the raw enthalpic data 
and fitted by the MicroCal ‘one set of sites’ function (black line). Experimental 
temperature 25°C.
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Figure 3.13. Affinity of CHIFj^ for 2:1 DMPC:DOPG (A) and 2:1 DMPC:DOPC 
(B) membranes. ITC binding curve for 100 gM CHIFjg.#) titrated with lipid vesicles (25 
to 50 pM lipid per injection). Curves were generated by integrating the raw enthalpic data 
and fitted by the MicroCal ‘one set of sites’ function (black line). Experimental 
temperature 25°C.
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Table 3.2. Thermodynamic data for DMPCiDOPG and DMPC:DOPC titrated into
cytoplasmic peptides. Standard errors are given in brackets. The values for both PLM3S.72 
and pPLM3s_72 were provided by personal communication with Dr. Elen Hughes. The data 
for PLM38.72 and pPLM38_72 in DMPC:DOPC membranes is not shown but showed no 
binding.
Peptide
Ka (M1)
PC:PG PC;PC
AH (cal/mol)
PC:PG PC:PC
PLM38_72 3.07 x 10 "6 -- -211.9(29.05) -
(1.26 x 1 O'5)
pPLJVLjg.?? 2.70 x 1 O'4 -- -232.4 (4.924) -
(3.55x1 O'3)
Mat-8sf38.67 3.07 x 10'3 3.43 x 1 O'3 -243.4(143.5) -107.8 (40.67)
(1.37x1 O'3) 2.22 x 10'3
Mat-81f38.93 3.276 x 1 O'4 0.0357 (4.93) -211.9(29.05) l,771x 10'5
(1.92 x 1 O'4) (7.720x 10'9)
CHIF38-69 0.0147 (39.4) 0.930 -7.292 x IQ-4 -7.811 x IQ-4
(4.53 x I0'3) (1.304 x 10'9) (5.452 x 10'9)
In the ITC experiments presented so far DOPG was used as the negatively 
charged phospholipid. DOPG is a bacterial phospholipid and the peptides 
used are representing mammalian (human) proteins. Further experiments 
were performed using the negatively charged mammalian phospholipid 
DOPS in place of DOPG (i.e. 2:1 molar ratio DMPC:DOPS SUVs) to 
confirm the relatively strong interactions observed in PLM38-72 and 
Mat-81f38-93 with negatively charged phospholipids. Results are indicative
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of an interaction between the cytoplasmic region of PLM and long form 
Mat-8 with cell membranes as shown in Figure 3.14. The binding affinities 
(shown in Table 3.3.) are actually stronger than those observed for both 
peptides in DMPCrDOPG which suggests PLM38-72 and Mat-81f39-93 are 
sensitive to the chemical structure of the phospholipid head-groups and the 
acyl chains as well as surface charge.
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Figure 3.14 Affinity of PLMjs-t: and of Mat-Slf^o for 2:1 DMPC/DOPS membranes. 
ITC binding curves for both 100 j.iM PLMj^ and lOOgM Mat-81f38.93. titrated with lipid 
vesicles (25 to 50 pM lipid per injection). Curves were generated by integrating the raw 
enthalpic data and fitted by the MicroCal ‘one set of sites’ function (black line). 
Experimental temperature 25°C. PLM38.72 data provided by personal communication with 
Dr. Eleri Hughes.
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Table 3.3. Thermodynamic data of DMPCrDOPS titrated into PLM38.72 and 
Mat-81f38.93. Standard errors are given in brackets. The values for PLM38.72 were provided 
by personal communication with Dr. Eleri Hughes.
Peptide
K„ (M‘) AH (cal/mol)
PLM3S-72 3.67 x 10"6 -350.3 (18.25)
(2.13 x 1 O'6)
Mat-81f3s-93 6.62 x 1 O'4 -874.8 (88.98)
2.07 x lO-4
The overall charge in all peptides is actually relatively similar, when taking 
into account positive arginine, histidine and lysine residues compared to 
negatively charged glutamate and aspartate residues. The net charges of 
PLM38-72, Mat-8sf38.67, Mat-81f38-93 and CHIFas-e? are +6, +5, +5 and +4 
respectively. This suggests that charge likely plays a significant role in 
lipid binding but structure is also important. For example PLM3S-72 has an 
arginine rich C-terminus which contains the Ser 68 phosphorylation site. 
This could suggest that this region rather than the rest of the cytoplasmic 
region is crucial for binding negatively charged phospholipids. The 26 
amino acids present in long form Mat-8 but not short form Mat-8 have no 
net change in charge but do contain two arginine residues near the N- 
terminus which would be predicted to be close to the cell membrane. This 
proximity could explain why it has a much higher affinity for cell
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membranes, than the short isoform. It is important to note that although the 
2H NMR has shown different degrees of interactions between cytoplasmic 
FXYD peptides and negatively charged but not zwitterionic phospholipids, 
this is determined in pine lipid, in the absence of the Na+, K+-ATPase. This 
means it is unclear if these peptides are capable of similar phospholipid 
interactions in the presence of their physiological target.
3.3.I.3.31P MAS NMR
To analyse the effects of peptides on phospholipid membranes in the 
presence of the Na+, K+-ATPase, the protein needed to be incorporated into 
well defined phospholipid bilayers. Ideally this would be earned out in the 
same membrane types as the 2H NMR and ITC experiments for direct 
comparison. The Na!, K'-ATPase was reconstituted into 2:1 DMPC 
DOPG at 50:1, 100:1 and 200:1 lipid to protein ratios. 100:1 is the native 
lipid to protein ratio. All three reconstituted samples were analysed by 3IP 
MAS solid-state NMR and titrated with PLM38-72 at 50:1 and 20:1 lipid to 
peptide molar ratios. At a 50:1 lipid to protein ratio a 33:1 lipid to peptide 
ratio titration was also performed. This method was selected in preference 
to 2H NMR as it is more sensitive to PLM38-72 (Clayton et a!., 2005) and 
therefore requires smaller samples. ITC is unsuitable as the Na1, K+- 
ATPase is insoluble. Each experiment was rim at temperatures of 4°C, 9°C, 
14°C and 19°C. By using MAS, the chemical shift of DMPC and DOPG
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can be assigned separately. For each spectra the peaks for DMPC and 
DOPG were analysed using Origin 8.5 using a Lorentzian peak function 
(Figure 3.15.). This allowed the chemical shift change and broadening of 
each peak after addition of peptide to be determined. Figures 3.16-3.18. 
show the change in chemical shift frequency following addition of PLM38- 
72 and the relative peak intensity after each titration of peptide compared to 
lipid alone. All of the data presented are for measurements made at 19°C 
and 4°C but findings at other temperatures are very similar. At 19°C 
DMPC, DOPG and DOPC are all in their liquid phase whereas at 4°C, 
DMPC is in a gel phase and DOPC and DOPG are in a liquid phase. In the 
previous 31P MAS solid state NMR on Na+, IC^-ATPase-free lipid vesicles 
the DOPG peak remains relatively narrow whilst the peak for DMPC 
broadens markedly, which suggests PLM38-72 impairs mobility of DMPC 
(Clayton et al, 2005). If similar results are observed here the mobility of 
DMPC will be impaired by PLM38-72 at 19°C but will have no effect at 4°C 
as it is in its gel phase and already restrained. At all three lipid to protein 
ratios there is no significant change in chemical shift frequency. However 
there is a broadening effect due to peptide obseived on both DMPC and 
DOPG. This is likely due to the different phospholipid environments as the 
nature of the membranes presented here is unclear whereas in the published 
data peptide is titrated into LMVs. LMVs are comprised of multiple 
bilayers which means a high local concentration of peptide could occur in 
the interbilayer space resulting in a larger effect than would be seen on a
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single bilayer. In the 31P data presented here, PLM38-72 impairs the mobility 
of both DMPC and DOPG to a small extent as there is a small non- 
selective peak broadening for both phospholipids suggesting a slight 
interaction with the membrane surface. Importantly, this effect is reduced 
with increased Na+, K+-ATPase levels. This is the first evidence of 
PLM38.72 binding to phospholipid bilayers in the presence of the Na+, K+- 
ATPase.
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Figure 3.15. Example of 31P NMR spectra. DMPC and DOPG give separate chemical 
shifts at approximately 102 and 103 ppm respectively. Data have been analysed using a 
Lorentz function and the calculated overlapping peaks are shown. This example spectrum 
was performed at 19°C in the absence of PLM peptide.
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Figure 3.16. Effect of PLM38.72 on chemical shift and peak width of DMPC and 
DOPG. Chemical shift calculated as a frequency change from the peptide-free chemical 
shift. Peak width relative to peptide-free reconstituted Na+, K -ATPase protein. Lipid to 
protein ratio is 50:1 and experimental temperature is 19°C and 4°C as indicated.
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Figure 3.17. Effect of PLM38-72 on chemical shift and peak width of DMPC and 
DOPG in absence of peptide. Lipid to protein ratio is 100:1 and experimental 
temperature is 19°C and 4°C as indicated. Experimental parameters described in Figure 
3.16.
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Figure 3.18. Effect of PLM^z on chemical shift and peak width of DMPC and 
DOPG in absence of peptide. Lipid to protein ratio is 200:1 and experimental 
temperature is 19°C and 4°C as indicated. Experimental parameters described in Figure 
3.16.
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3.3.I.4. Interaction of FXYD protein cytoplasmic domains with the 
Na+, K+-ATPase.
FXYD proteins have different effects on ion affinities of the Na+, K+- 
ATPase as discussed earlier. It is hypothesised that the specific effect of 
each FXYD protein is largely due to the actions of the cytoplasmic region 
as this is where the FXYD proteins are most sequentially diverse. The 
functional effect of the cytoplasmic peptides; PLM38.72, pPLM38 -72, 
Mat-8sf38-67, Mat-81f38„93 and CHIF3S-69 was determined by following the 
Na+ activation of ATP hydrolysis with and without peptide. This ATPase 
assay was selected as it is a well established system for determining kinetic 
data like Vm£lx and Kq.s for the Na1', K+-ATPase (Esmann, 1988). Figures 
3.19-20. show the Na+ activation curves of pig kidney Na+, K+-ATPase 
with and without 100 pM cytoplasmic peptide. It is important to note that 
the Na+, K+-ATPase samples used were from pig kidney membranes and 
therefore contain the FXYD protein y-subunit in the protein complex. As 
the y-subunit has no predicted cytoplasmic region the peptides representing 
the cytoplasmic domains of other FXYD proteins used in these assays are 
free to interact with the entire cytoplasmic region of the Na+, K+-ATPase.
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Figure 3.19. Na+ activation curve of Na+, K+-ATPase in pig kidney membranes with 
and without PLMj^and pPLM^z. Kidney Na+, K+-ATPase activity was determined at 
the indicated concentrations ofNa' with and without 100 pM PLMjg^ and pPLM38.72 and 
data fit with a Hill function. Experiments performed in triplicate at 37°C. This assay was 
performed by Angelina Damgaard at the University of Aarhus.
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Figure 3.20. Na+ activation curves of Na'1, K+-ATPase with and without Mat-Ssf^?, 
CHIFas.rig and Mat-8Ifj8-93 in pig kidney membranes. Kidney Na+, K+-ATPase activity 
was determined at the indicated concentrations of Na+ with and without 100 |iM Mat-Ssfas* 
67and CHIF38.69 (top graph) and Mat-81f38_93 (bottom graph) and data fit with a Hill 
function. Error bars indicate standard error. Experiments performed in triplicate at 37°C. 
These assays were performed by Angelina Damgaard at the University of Aarhus.
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Table 3.4. shows the apparent Vmax and K0.5 values calculated from these 
activation curves using the following Hill equation:
V " Vmax* (4.1.)
The Mat-Ssfss-e? and CHIF38-69 peptides appear to have no effect on either 
Vmax or K0.5 which suggests that the inhibitory effects of full length short 
form Mat-8 and CHIT are due to the transmembrane region (Garty et al, 
2002; Crambert et al, 2005). PLM38-72 has the largest effect on the 
activity of the Na1, K+-ATPase as it reduces apparent Vmax by 
approximately 40% and increases K0.5 by approximately 15%. This effect 
is reduced by phosphorylation as PPLM38-72 only reduces apparent Vniax 
by 20% and increases K0.5 by the same factor as PLM38-72. This suggests 
phosphorylation of PLM partially relieves the inhibition of the Na+, K+- 
ATPase by the cytoplasmic region of PLM. Mat-81f38-93 has no effect on 
Vmax but causes an approximate 40% increase in K0.5.This highlights a 
significant difference between the Mat-8 isoforms with the long isoform 
of Mat-8 having a larger inhibitory effect on the Na+, K+-ATPase than the 
short form. These data suggest that the functional differences between the 
two isoforms are due specifically to the differences in their cytoplasmic 
domains.
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Table 3.4. Apparent Vmax find Ko,5 values for pig kidney Na+, K+-ATPase with and 
without 100 pM cytoplasmic peptide. Standard errors are indicated in brackets.
Parameter Treatment
Control PLM38_72 pPLM3s_72 Mat-8sf38-G7 Mat-81 f38-93 chif3S.69
V max 30.0(1.8) 17.7 (3.0) 23.7(1.2) 30.2(1.5) 29.3 (1.8) 29.6(1.2)
Ko.5 13.5 (0.41) 15.9 (0.47) 16.0(0.46) 13.3 (0.32) 21.7(3.1) 13.4 (0.36)
As the 31P NMR experiments revealed that the cytoplasmic peptide of 
PLM can bind phospholipids in the presence Na+, K+-ATPase, further 
insight on how this might affect the ATPase activity was investigated by 
performing further ATPase assays in Na+, K+-ATPase reconstituted into 
different phospholipids.
Reconstitution of the Na+, K1 -ATPase into synthetic membranes is well 
known to result in partial loss of function. For example, Na+, K' -ATPase 
reconstituted into DOPC membranes results in just 40-60% of original 
pump activity (Alpes et al, 1988). The best reported recovery of activity is 
80%, achieved in 1:1 molar ratio of dipalmitoylphosphatidylcholine: 
dipalmitoylphosphatidyletlmnolamine (DPPC:DPPE), improved further to 
86% in the presence of 55% cholesterol (Santos et al, 2005). DPPC and 
DPPE are both zwitterionic so despite being the best known system for 
Na+, K+-ATPase activity recovery, no interaction with any of the FXYD 
protein cytoplasmic peptides would be expected. An alternative
composition of reconstitution phospholipids therefore had to be
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determined. Pig kidney Na+, K+-ATPase was reconstituted into DOPC 
alone (as had been performed recently (Hansen et al, 2011)), 2:1 molar 
ratio DMPCiDOPG (for direct comparison to the experiments so far) and 
DMPC alone (as a control as Na+, K+-ATPase should lose activity as it is a 
saturated phospholipid). As a further control, solubilised pig kidney Na+, 
K+-ATPase was reconstituted into the native membrane it was originally 
extracted from (referred to as “native” membranes). This was achieved by 
solubilising the Na+, K+-ATPase in with its native membranes before 
reforming the Na+, K^ATPase membranes using BioBeads. Initially 
ATPase activity was measured by die Baginski method at a Na+ 
concentration of 100 mM. This was to test if any phospholipid systems 
caused a near total loss in activity. Activity remained in all phospholipid 
compositions widi the exception of 100% DMPC. Activity in Na+, K+- 
ATPase reconstituted into 2:1 molar ratio DMPC:DOPG was comparable 
to Na1, K+-ATPase reconstituted into native membranes and was 
approximately 70% of original Na+, K+-ATPase activity. Na+, K+-ATPase 
reconstituted in DOPC alone had approximately 30% of original activity 
and Na+, Kf-ATPase reconstituted in DMPC alone resulted m a virtual 
complete loss of activity. This suggests that the Na+, K1"-ATPase requires 
the presence of negatively charged phospholipids for activity as well as 
compatible phospholipid chain lengths. Full Na+ activation curves were 
therefore produced with Na+, K'-ATPase reconstituted into 2:1 molar ratio 
DMPC:DOPG and DOPC alone (Figure 3.22.). Control Na+ activation
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curves of native pig kidney Na+, K+-ATPase membranes and solubilised 
pig kidney Na+, K+-ATPase reconstituted native membranes (Figure 3.21.) 
were also performed. This reveals that solubilisation of Na+, K'-ATPase 
with C^Eg does not irreversibly kill ATPase activity. Figure 3.23 shows 
Vmax and K0.5 for all reconstitutions.
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Figure 3.21. Na+ activation curve of pig kidney Na+, K+-ATPase before and after 
reconstitution into native membranes. Kidney Na+, K -ATPase activity was determined 
at the indicated concentrations of Na+ and data fit with a Hill function. Experiments 
performed at 37°C. Native membrane assays performed by Angelina Damgaard of the 
University of Aarhus.
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Figure 3.22. Na+ activation curve of pig kidney Na+, K+-ATPase reconstituted into 
DOPC and 2:1 DMPCrDOPG. Kidney Na+, K4-ATPase activity was determined at the 
indicated concentrations of Na+ and data fit with a Hill function. Experiments performed at 
37°C.
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Figure 3.23. Functional analysis of the Na+, K+-ATPase in different phospholipid 
membranes. Pig kidney Na+, K^-ATPase activity was determined at 100 mM Na+ in the 
presence of 20 mM KC1, 3 mM ATP, 4 mM MgCN (pH 7.4 at 37 °C). This was repeated 
after reconstituting in various phospholipid preparations.
As activity remains in DMPC:DOPG and DOPC the activities of Na+, K+- 
ATPase reconstituted in these two systems was measured at 15 mM and 
100 mM Na4 with and without PLM38-72 (Figure 3.24.). Full activation 
curves would have been ideal but the quantity of PLM38.72 peptide was 
limited. In DMPC:DOPG membranes a similar reduction of activity due to 
PLM38-72 at 15 mM Na' is observed to that previously observed in pre­
reconstitution native Na+, K4-ATPase (Figure 3.19.). However the 
reduction of activity due to PLM38-72 at 100 mM in DMPC:DOPG 
membranes is much smaller than in native Na', K'-ATPase. In DOPC 
alone the reduction of activity due to PLM38-72 is smaller at both 100 mM 
Na+ and 15 mM Na4 than in pre-reconstitution native Na4, K -ATPase. 
This suggests that PLM38-72 is not sequestering and immobilising DOPG as
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if this was the case, the concentration of DMPC around the Na+, K+- 
ATPase would increase, which would not support activity (Figure 3.24.). 
These results would suggest that the effect of PLM38-72 on Vmax and K0.5 is 
reduced when the Na+, K+-ATPase is reconstituted into DMPC:DOPG than 
observed in native Na+, K+ -ATPase membranes. This is most likely due to 
a larger proportion of PLM38-72 binding to phospholipids than the Na+, K+- 
ATPase in the reconstituted sample due to the increased negative 
membrane surface charge. This would suggest that in vivo any interaction 
between PLM38.72 and membrane surfaces is not solely driven by 
electrostatic interactions but also indicates weak non-selective interactions. 
This could allow PLM3S-72 to potentially switch more easily between a 
membrane associated and an enzyme bound form. As the reconstituted 
sample has a 33% negative surface charge, which is around three times 
higher than native membranes, it would seem likely that PLM38-72 is 
associating more preferably to the synthetic phospholipids over the Na+, 
K+-ATPase than it would to native cell membranes.
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Figure 3.24. ATPase activities of the Na+, K+-ATPase in different membrane 
environments. Activities measured at 100 and 15 mM Na+ with and without 100 f.iM 
PLM38.72. Control (Native) shows Na+, K+-ATPase activity before reconstitution and 
DMPC:DOPG and DOPC show activities of the Na\ K+-ATPase reconstituted into the 
relevant phospholipid environments.
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3.4. Discussion
The cytoplasmic domain of FXYD proteins is the most varied region 
between members of the family. It would therefore seem likely that the 
specific functions observed for each FXYD protein are a direct result of 
this region. PLM was the first FXYD protein to be discovered (Palmer et 
al., 1991) and as a result is the best understood member of the family. 
Interestingly its cytoplasmic region has been observed to bind to both
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negatively charged phospholipid membranes (Clayton et aL, 2005) and 
inhibit the Na+, K+-ATPase (Pavlovic et aL, 2007). This chapter has shed 
some light into how these two interactions can be reconciled. PLM has two 
physiological phosphorylation sites in the cytoplasmic domain (Palmer et 
aL, 1991; Moimsey et aL, 2000) that appear to alter the effect of the region 
on both cell membranes and the Na+, K+-ATPase. Both 2H NMR and ITC 
have revealed that PLM38-72, a peptide representing the cytoplasmic 
domain of PLM, binds to negatively charged membranes whilst having no 
affinity for zwitterionic membranes (Figure 3.8 and Figure 3.10). This is 
likely because PLM38-72 has a net positive charge. However, it would 
appear that this interaction relies on more than electrostatic potential as 
PLM38-72 also has a preference for eukaryotic phospholipids over 
prokaryotic phospholipids (Figure 3.10 and Figure 3.14). This suggests that 
the affinity of PLM38-72 for phospholipid membranes is detennined by 
specific phospholipid headgroup sidechains. 31P NMR experiments 
revealed that PLM38-72 can bind to phospholipid headgroups in the 
presence of the Na+, K+-ATPase, However, this effect is much smaller than 
that seen previously in the absence of the Na+, K+-ATPase (Clayton et aL, 
2005). This previous study also showed that PLM38-72 had a preference for 
DOPG over DMPC whereas in the data measured here in the presence of 
enzyme it would seem that PLM3S.72 has a similar effect on both 
phospholipid types. This suggests the Na+, K+-ATPase reduces the binding 
of PLM38-72 to the cell membrane. Ser 68 phosphorylation also reduces the
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potency of PLM38-72 as an inhibitor of the Na+; K+-ATPase (Figure 3.19.). 
Phosphoiylation introduces an extra a negative charge to PLM38-72 making 
its net charge less positive, which could explain the reduced affinity for 
both cell membranes and the Na+, K+-ATPase. This supports NMR data 
which reveals a conformational change of the cytoplasmic region after 
phosphoiylation (Teriete et al., 2009), which could be indicative of 
PLM38-72 moving away from the cell membrane whilst either also moving 
away from the Na+, K+-ATPase or re-orientating onto an alternative site on 
the protein surface. Additionally, by reconstituting the Na+, K+-ATPase 
into DMPC:DOPG membranes the effect of PLM38-72 inhibition was 
reduced. DMPC:DOPG is 33% negatively charged which is about three 
times as much as observed in native membranes (Akio, 1971). This means 
the synthetic membranes could exaggerate the PLM/phospholipid 
interaction, so reducing its interaction with enzyme leads to reduced 
ATPase activity inhibition. It does confirm that PLM37.72 appears to 
interact with the membrane surface rather than sequestering and 
immobilising DOPG as observed previously (Clayton et al, 2005). If 
DOPG was indeed immobilised by PLM38-72 a much larger loss of function 
would be expected in reconstituted membranes as by removing DOPG 
from the Na+, K+-ATPase the local concentration of DMPC would 
increase, conditions that do not support ATPase activity (Figure 3.24.). The 
fact that the interaction of PLM38-72 with cell membranes is small suggests 
that the slight difference in phospholipid binding affinities of PLM38-72 and
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PPLM38-72 is insignificant when compared to the effect on the Na+, K+- 
ATPase.
The fact that CHIP and short form Mat-8 have no significant effect on 
negatively charged phospholipid bilayers (Figure 3.9, 3.11 and 3.13) or 
activity of the Na', K+-ATPase (Figure 3.20.) highlights the importance of 
phosphorylation in the regulation of PLM and thus the Na+, K+-ATPase. 
There is no evidence supporting either CHIP or short form Mat-8 as 
phosphorylation targets in vivo and are therefore more likely to be 
functionally inert anchoring domains. Figure 3.25 illustrates a possible 
dynamic equilibrium of multiple conformations of the cytoplasmic region 
of PLM conferred by a flexible linker region present between the 
transmembrane domain and the cytoplasmic helix (Teriete et ah, 2007). 
The precise conformation adopted may be controlled by phosphorylation.
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Figure 3.25. Proposed equilibrium bet>veen two conformations of PLM controlled by 
phosphorylation. The cytoplasmic region of PLM could occupy several orientations in 
dynamic equilibrium, the most extreme of which are shown above. This may be controlled 
by phosphorylation of Ser 63 and Ser 68 located on the cytoplasmic helix. Figure from 
published paper (Hughes ef al., 2011).
The work in this chapter also revealed that the cytoplasmic region of the 
long isoform of Mat-8 can act as an inhibitor of the Na+, K+-ATPase 
(Figure 3.20.). The only difference from the short isoform of Mat-8 is an 
additional 26 amino acids at the start of the cytoplasmic region (Bibert et 
al., 2006). As the short form has no effect on function the 26 amino acids 
are clearly significant. It is unclear if they have a direct role in Na+, K+- 
ATPase binding or if they instead allow the C-terminal residues to occupy
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alternative sites on the Na+, K'-ATPase surface that are out of reach in the 
short Mat-8 isoform. As the long isoform of Mat-8 is a recent discovery 
and is not very well understood it is feasible that it does have physiological 
phosphorylation sites that have not yet been discovered. NetPhos (Blom et 
ai, 1999), was therefore used, which uses neural network predictions for 
serine, threonine and tyrosine phosphorylation sites in eukaryotes. It 
predicts four possible sites (Figure 3.26.), three of which are notably in the 
26 amino acids not present in short form Mat-8. It is therefore possible that 
the inhibition of the Na+, K -ATPase by long form Mat-8 is regulated by 
phosphorylation much like PLM.
NetPhos 2.01 predicted phosphorylation sites in Sequence
Sequence position
SEWRSSGEQAGRGWGSPPLTTQLSPTGAKCKCKFGQKSGHHPGETPPLITPGSAQS 
40 50 60 70 80 90
Figure 3.26. NetPhos prediction of phosphorylation sites in the cytoplasmic region 
of long form Mat-8. The sequence of the cytoplasmic region of long form Mat-8 is 
indicated with the three predicted serine sites shown in blue (with scores of 0.898 0.995 
0.956) and the threonine site shown in green (with a score of 0.710)
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Chapter 4
4.1. Expression and Purification of FXYD Proteins
An initial aim of this project was to develop an expression system for one
or more FXYD proteins to enable structural studies to be performed. The 
procedure had to be reproducible and suitable for producing labelled 
protein samples to be analysed by NMR. All NMR experiments require 
over 99% purity of target protein and proteins must be uniformly labelled 
with NMR suitable isotopes 13C and 15N to achieve the required sensitivity. 
As FXYD proteins are membrane proteins their expression and purification 
can be very difficult largely due to solubility issues. Membrane proteins are 
also difficult to overexpress. This chapter discusses the development of the 
methods to create FXYD protein samples for use in NMR experiments. 
Previously the Marassi group have attempted to express FXYD proteins as 
fusion proteins with a tag that promotes the formation of inclusion bodies. 
The fusion partners attempted include ketosteroid isomerise (KSI) (Thai et 
ah, 2005), a portion of the Tip ALE 1413 polypeptide (TLE) (Crowell et 
al, 2003), and two mutated forms of B-cell lymphoma-extra large (BCL- 
XL) vector (Thai et al, 2005). The first mutated BCL-XL fusion partner is 
BCL173 where the C-tenninal domain (residues 213-233) and the flexible 
loop (residues 44—84) of BCL-XL are removed, and the two methionine 
residues (Metl59 and Metl70) are mutated to leucine to facilitate CNBr 
cleavage of FXYD protein from the fusion partner as CNBr cleaves at
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methionine residues. The second mutated BCL-XL is BCL99, which has 
further deletions based on the structure of the soluble form of BCL-XL 
(Muchmore et al, 1996). In addition to the deletions in BCL173, the 
residues 1-116 (which form a flexible loop) as well as helices 1^4 in the 
structure of the soluble form of BCL-XL are also deleted. The expression 
levels for these systems is compared in the SDS-PAGE gel shown in 
Figure 4.1. where the BCL-XL mutants clearly produce more fusion 
protein than either KSI or TLE fusion partners. This chapter describes the 
efforts to produce FXYD protein using one of these mutated vectors and 
the development of new methods of FXYD protein production in the 
pMAL vector.
BCL173 BCL99KSI TLE 
+ + + +
74 62 25 52
14.4-
6.0-
(vector) 
(IPTG) 
(% Irel)
....... 39.0 kD
29 8 kD 
23.4 kD 
22.1 kD 
21 2 kD
Figure 4.1. Comparison of overexpressed fusion protein levels of PLM with different 
fusion protein tags. Overexpressed protein shown for a BCL173 tag (29.8 kDa), BCL99 
(21.2 kDa), KSI (23.4 kDa) and TLE (22.1 kDa). Pre-induction cells are shown (-IPTG) 
and the intensities (% 1^) of each overexpressed band relative to the band at 39 kDa 
(dashed arrow) are indicated. Figure taken from (Thai et al., 2005).
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All proteins were expressed in Escherichia coli (E.coli) as this is the 
preferred system for protein expression for many reasons. These include 
low cost, fast growth times, fast rate of expression and high plasmid copy 
number. Expression in E. coli is generally easier to perform than other 
systems like yeast. There are many strains widely available with different 
properties and the cells can be stored long term. This method of protein 
expression can be achieved in low cost growth media making it a veiy 
economical way to produce the milligram quantities of proteins required 
for NMR.
As the proteins of interest are membrane proteins they will be particularly 
insoluble in aqueous media. Most purification procedures rely on methods 
that require the production of soluble protein or that targets the protein to 
inclusion bodies. The methods employed in this chapter use constmcts that 
express the protein fused to another protein partner to promote either the 
formation of inclusion bodies or improve solubility. The first method 
generates a fusion protein with a mutated form of B-cell 
leukaemia/lymphoma extra long (mBCL-XL) as the fusion partner 
repeating previous methods (Thai et al, 2005). This protein forms 
inclusion bodies when expressed alone and has been shown to do the same 
in an mBCL-XL/FXYD fusion. These inclusion bodies can be lysed then 
solubilised to give liquid samples suitable for cleavage and purification, hr 
the second method, incorporation of the FXYD gene into the pMAL vector
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expresses a fusion construct with maltose binding protein (MBP). MBP is a 
very soluble protein so theoretically an MBP/FXYD fusion protein would 
express at least partially in a soluble form. A protease site engineered 
between the two proteins would allow the fusion protein to be cleaved 
following purification on an amylose resin columns to which the MBP 
would bind.
4.2. Materials and Methods 
4.2.1. Materials
The primary Mat-8 anti-mouse monoclonal antibody (product name 
FXYD3 (M-20)) was purchased from Santa Cruz Biotechnology. The 
Novex® WesternBreeze™ Chromogenic Immunodetection Kit for dot- 
drop experiments was purchased from Roche. Chloroform and methanol 
were provided by Fisher Chemicals. All other chemicals were supplied by 
Sigma-Aldrich and were of molecular biology grade.
The pBCL99 plasmid was provided by Francesca Marassi of the Burnham 
Institute, California (Figure 4.3.). This plasmid is based on the pET vector 
(Figure 4.2. (Thai et aL, 2005)) and produces a fusion protein of target (e.g. 
phospholemman (PLM)) and modified B-cell lymphoma-extra large (BCL- 
XL) protein that expresses as inclusion bodies.
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Eag I Ava I
BamH I EcoR I Sac I Sa/I Hbid III Not\ Xhol
GGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGt
GlySerGluPheGluLeuArgArgGInAlaCysGlyArgThrArgAl
Figure 4.2. Plasmid map of the pET-21 d(+). The pBCL vector is based on the pET- 
21d(+) vector (shown). The polylinker region contains several restriction sites (shown) and 
is the location into which the desired sequence is cloned. The vector is ampicillin resistant 
(AmpR). Expression is induced by Isopropyl P-D-l-thiogalactopyranoside (IPTG), which 
inactivates the lacl gene which codes for the LacL protein which represses promoter Ptac. 
Origins of plasmid replication (ori) is also shown. Fl ori is for producing single stranded 
plasmids when co infected with M13 helper phage (not used in this project). Figure 
adapted from pET-2 la-d(+) literature on the Novagen website.
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Figure 4.3. Plasmid map of pBCL vector. The sequence (A) contains a His tag and a 
modified Bcl-XL sequence separated by an EcoRI restriction site. Downstream of the 
modified Bcl-XL is an Afil and an Xhol restriction site. Sequence A is subcloned into 
the pET vector at the polylinker region (pLink) and the target protein of interest (e.g. 
PLM) is subcloned into the Afil/Xhol sites in sequence A. Where required the target 
protein has an N-terminal Met added for CNBr cleavage. (B) shows the different BCL 
sequences used by the Marassi group; BCL 173 and BCL99 with the cloned FXYD 
protein sequences shown above. Both vectors lack the hydrophobic C terminus (grey 
box). BCL99 is used in this thesis and is highlighted by the dotted line and therefore 
lacks the first 116 residues of BCL. Figure taken from Marassi group (Thai et ai, 
2005)
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The pMAL-c2X plasmid was purchased from New England Biolabs. The 
plasmid map is shown in Figure 4.4. This system was selected as it 
successfully expressed and purified the small transmembrane proteins 
phospholamban (PLB) and sarcolipin (SEN) (Buck et al, 2003) which are 
regulators of the sarcoplasmic reticulum Ca2+-ATPase (SERCA) with a 
single transmembrane region much like FXYD proteins are in respect to 
the Na+, K+-ATPase. This system expresses a fusion protein of maltose 
binding protein (MBP) and the selected target protein sub-cloned into the 
construct. The Mat-8 DNA sequence was altered to include a Tobacco etch 
virus protease (TEVP) cleavage site preceding the Mat-8 coding sequence. 
The recognition site for TEVP is Glu-Asn-Leu-Tyr-Phe-Gln-Gly (with the 
cleavage occurring between Gin and Gly) (Kapust et al, 2002). Therefore, 
a fusion protein was designed with a TEVP cleaveage site located between 
MBP and Mat-8 sequences. Codons were also optimised for the preference 
of the bacteria. This sequence was engineered into the pMAL-c2X plasmid 
by Yorkshire Bioscience Ltd (York) (Figure 4.4.).
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polylinker
pMAL-c2X, pMAL-p2X Polylinker
Xmn I EcoR I BamH I Xba I
i----------- 1 i------ 1 r
Sail Pali Hind III
nr i r i r
maf.-.ATC GAG GGA AGG ATT TCA GAA TTC GGA TCC TCT AGA GTC GAC CTG CAG GCA AGC TTG.JdcZa
He Glu Gly Arg
t Factor Xa
------------ cleavage site
Figure 4.4. Plasmid map of pIVIal-c2X vector. Polylinker region contains several 
restriction sites (shown) and is the location into which the desired sequence is cloned. 
Upstream of the polylinker is the gene malE which transcribes maltose binding protein 
(MBP) thus the vector produces an MBP fusion protein. The vector is ampicillin resistant 
(Ampr), has a LacZ gene for use as a reporter gene (not required in this project). 
Expression is induced by Isopropyl P-D-l-thiogalactopyranoside (IPTG) which inactivates 
the lacl gene which codes for the LacL protein which represses promoter Ptac. The 
terminator where translation is halted and origins of plasmid replication (ori) are also 
shown. Figure taken from New England BioLabs.
The E.Coli cell lines investigated were: XL 1-Blue for plasmid maintenance 
and BL21 (DE3), Rosetta, Origami DE3 and C41 (DE3) for protein 
expression.
All cells were purchased from Novagen with the exception of C41 (DE3) 
cells which were purchased from Lucigen. Unless otherwise stated all 
methods were taken from Molecular Cloning: A Laboratory Manual 
(Orkin, 1990).
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4.2.2. Preparation of competent E. coli
Different cell lines were made competent for either protein expression or 
plasmid maintenance. Lysogeny Broth (LB) (250 mL) was inoculated with 
1% (v/v) overnight E. coli culture and supplemented with 20 mM MgSCL 
and grown to mid-log phase (ODgoo 0.4-0.6). ODeoo measurements were 
taken using a Cary 300 Bio U.V. visible spectrophotometer. The cell 
suspension was spun down for 5 min. at 10,000 x g at 4 °C. The cells were 
harvested and resuspended in 100 ml TFB1 (30 mM KAc, 10 mM CaCl2, 
50 mM MnCb, 100 mM RbCl, 15% glycerol; pH 5.8) and incubated on ice 
for 5 min. The cell suspension was spun down for 5 min. at 10,000 x g at 4 
°C, resuspended in 10 ml TFB2 (10 mM MOPS, 75 mM CaCl2, 10 mM 
RbCl, 15% glycerol; pH 6.5) and incubated on ice for an horn*. Cells were 
then frozen at -80 °C in 200 pi aliquots.
4.2.3. Transformation of competent E. coli
The appropriate plasmid (2 pi) was added to competent cells (50 pi) and 
the cells were incubated on ice for 30 min. The cells were then heat 
shocked at 42 °C for 90 s, replaced on ice for 2 min. then 800 pi of LB was 
added before incubating with shaking (200 rpm 37 °C) for an horn*. The 
cell suspension was concentrated by centrifugation, removing 800 pi of the 
supernatant and resuspending the pelleted cells in the remaining volume. 
25 pi of the resuspended cells was spread onto an agar plate containing 
ampicillin (50 pg/mL). Both vectors contain ampicillin resistance genes
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permitting growth of transformed cells only. Agar plates were incubated 
overnight at 37 °C. Controls were also set up: a negative without plasmid 
added in the initial step and a positive control where plates contained no 
ampicillin. The plasmid ffee-plate should have no colonies as none of the 
cells are ampicillin resistant and the ampicillin-free, plate should have high 
growth as cells will grow whether or not they have been successfully 
transformed. The transformed plate will have a number of colonies 
dependent on transformation efficiency which would range from one or 
two colonies to a few hundred. Each colony originates from one individual 
transformed bacterial cell. The control plates help confirm whether all 
colonies on the transformed plate have indeed taken up the plasmid and are 
suitable to use for expression.
4.2.4. Preparation of glycerol cell stocks
A transformed colony (produced as described in 4.2.3.) was removed from 
a plate with a sterile pipette tip and placed into LB (50 mL) and ampicillin 
(200 pg/mL) and incubated with shaking overnight at 37°C. The overnight 
culture was aliquoted into 800 pL fractions and 200 pL of sterile glycerol 
was added to each before storage at “80°C.
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4.2.5. Plasmid preparation
To produce additional plasmid when required plasmid preparation from 
E. Colt culture was earned out. Plasmid preparation was performed with a 
QIAGEN® QIAprep spin miniprep kit. This kit contains spin columns to 
purify the DNA and several buffers the contents of which are undisclosed. 
These include resuspension buffer (PI), lysis buffer (P2), wash buffer (PE), 
neutralisation buffer (N3) and elution buffer (EB). LB broth (1 mL) with 
ampicillin (200 pg/mL) was inoculated with a single colony picked from a 
transformed plate using non expressing cells (XL 1-blue) before incubating 
with shaking (200 rpm, 37 °C) overnight. This was pelleted and 
resuspended in Buffer PI (250 pi) before adding Buffer P2 (250 pi) to lyse 
the cells and was immediately mixed by inverting 6 times. Buffer N3 (350 
pi) was added to neutralise and again was inverted 6 times. The mixture 
was spun down for 10 min. at 17,900 x g to remove cell debris and the 
supernatant containing plasmid was added to a spin column. This spin 
column was centrifuged for 1 min. then washed by adding Buffer PE (750 
pi) to remove impurities and centrifuged again for 1 min. Flow through 
was removed and centrifuged again for 1 min to ensure all buffer was spun 
through the column. DNA bound to the column (plasmid) was eluted by 
adding Buffer EB (50 pi), allowing to stand for 1 min. and centrifuging 
into a 1.5 mL microcentrifuge tube for 1 min. Eluted DNA was stored in 
elution buffer at -20°C.
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4.2.6. Expression of PLM in pBCL plasmid
The methods for pBCL expression are based on the work by the Marassi 
group (Thai et al, 2005). LB broth (50 mL) with ampicillin (100 pg/mL) 
was inoculated with a single colony picked from a pBCL99 (containing 
PLM) transformed plate (as described in 4.2.4.) before incubating with 
shaking (200 rpm 37 °C) for 5 hours. 1 mL of this culture was added to 
100 mL of minimal M9 media with ampicillin (100 pg/mL) and grown 
overnight. The cells was spun down and harvested for 10 min. at 8,000 x g 
at 4 °C. The pellet was resuspended in minimal M9 media with ampicillin 
and used to inoculate 1 L of minimal M9 media with ampicillin and 
glucose to an ODeoo of 0.05-0.1 and was allowed to grow to ODgoo of 
0.7-0.9 by incubating with shaking (200 rpm 37°C). Cells were induced 
with 1 mM IPTG for 4 hr after which cells were spun down in a Sorvall 
refrigerated centrifuge for 10 min, at 8000 x g at 4 °C and resuspended in 
30 mL buffer A (50mM Tris-HCl, pH 8.0, 15% glycerol) and frozen 
oveimight at -20°C. Thawed cells were lysed by French press and the 
soluble fraction was removed by centrifugation at 48,000g, 4°C for 30 
minutes. The remaining pellet was washed twice by homogenising with 
fresh buffer A and repeating centrifugation. The final pellet was 
solubilised in 6M guanidium chloride (30 mL) and centrifuged at 
48,000g, 40C for 2 hours.
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4.2.7. CNBr Cleavage
Methodology for this procedure was adapted from (Thai et al, 2005). 
Particular safety care had to be adhered to due to the potential dangers of 
CNBr. Experiments were performed with face mask, lab coat and two pairs 
of nitrile gloves. All experiments were performed in fume hood. 10 mL of 
70 % formic acid (FA) was prepared in a 15 mL falcon tube and added at 
4-fold excess by volume to solubilised inclusion bodies.
5M CNBr in acetonitrile was added slowly to solubilised inclusion bodies 
at various ratios to establish ideal cleavage conditions. Samples were 
wrapped in foil and left overnight at room temperature. Outer gloves, 
pipette tips, eppendorfs were added to 5M KOH before being neutralised 
with bleach and washed into the sink with copious amounts of water. 
Samples were lyophilised three times, with water being added between 
runs. The freeze drier was allowed to defrost before emptying the thawed 
liquid into a beaker of 5M KOH and neutralised with bleach. Contents of 
beaker were washed into the sink with copious amounts of water. The 
freeze dryer condenser was cleaned with 5M KOH followed by bleach.
4.2.8. Expression of PLM in pMAL vector
Attempts were made to express PLM in the pMAL vector in a variety of 
cell strains, including BL21 (DE3), Rosetta, Origami (DE3) and C41. Each 
cell strain was transformed as in 4.2.4. LB (50 mL) with ampicillin (200
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|ig/mL) and glucose (2 mg/mL) was inoculated with a single colony 
containing pMAL (PLM) picked from a transformed plate before 
incubating with shaking (200 rpm 37 °C) overnight. The cells were 
centrifuged and harvested for 10 min. at 8,000 x g at 4 °C. The pellet was 
resuspended in LB with ampicillin and glucose and used to inoculate 50 
mL of LB with ampicillin and glucose to an OD60o of 0.05-0.1 and allowed 
to grow to ODfioo of 0.7-0.9 by incubating with shaking (200 rpm 37°C). 
The culture was induced with 1 mM Isopropyl (3-D-l- 
thiogalactopyranoside (IPTG) and one flask was returned to 37 °C with 
shaking (200 rpm) overnight then centrifuged (8000g, 10 min, 4°C). The 
pelleted cells were resuspended in 3 mL column buffer (20 mM Tris-HCl, 
200 mM NaCl, 1 mM EDTA). These 3 mL samples were lysed using 
pulsed sonication for three 10 s runs with 30 s intervals using a Dawe 
Ultrasonic probe sonicator at 50% duty cycle, output control 7. Lysed cells 
were centrifuged (19, OOOg, 10 min, 4°C) and insoluble protein (pellet) was 
compared with soluble protein (supernatant) by SDS-PAGE.
4.2.9. Expression tests of MBP/Mat-8 fusion protein
Optimal expression conditions for MBP/Mat-8 fusion protein were
determined by expression tests. LB (50 mL) with ampicillin (200 pg/mL) 
and glucose (2 mg/mL) was inoculated with a single colony and grown 
overnight at 37°C. The overnight culture was centrifuged and harvested for
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10 min. at 8,000 x g at 4 DC. The pellet was resuspended in LB containing 
ampicillin and glucose and used to inoculate three flasks with 150 mL of 
LB with ampicillin and glucose to an OD6oo of 0.05-0.1 and allowed to 
grow to ODgoo of 0.7-0.9 by incubating with shaking (200 rpm 37°C). All 
flasks were induced with 1 mM IPTG and one flask was returned to 37 °C 
with shaking (200 rpm) whereas the other two flasks were incubated with 
shaking (200 rpm) at different temperatures (18°C and 25°C). This 
determined an optimal expression temperature. 50 mL samples from each 
flask were taken at 3 hi*, 5 hr and 7 hr intervals and a final sample of the 
remaining 50 mL was taken after incubating overnight, in order to 
determine optimal induction time. All samples were centrifuged (8000g, 10 
min, 4°C) and cells were resuspended in 3 mL column buffer (20 mM Tris- 
HC1, 200 mM NaCl, 1 mM EDTA). These 3 mL samples were lysed using 
pulsed sonication for three 10 s runs with 30 s intervals using a Dawe 
Ultrasonic probe sonicator at 50% duty cycle, output control 7. Lysed cells 
were centrifuged (19, OOOg, 10 min, 4°C) and insoluble protein (pellet) was 
compared with soluble protein (supernatant) by SDS-PAGE. Other 
potential variables such as optimal IPTG concentration and optimal 
detergent (Triton® X-100 for improved solubility) concentration were 
determined in the same way.
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4.2.10. Expression of MBP/Mat-8 fusion protein in LB
LB (50 mL) with ampicillin (200 jiig/mL) and glucose (2 mg/mL) was
inoculated with a single colony picked from a pMal (containing Mat-8) 
transformed plate before incubating with shaking (200 rpm 37 °C) 
overnight. The cells were centrifuged and harvested for 10 min. at 8,000 x 
g at 4 °C. The pellet was resuspended in LB with ampicillin and glucose 
and used to inoculate 1 L of LB with ampicillin and glucose to an ODeoo of 
0.05-0.1 and was allowed to grow to OD6oo of 0.7-0.9 by incubating with 
shaking (200 rpm 37°C). Cells were induced with 0.25 mM (IPTG) for 3 hr 
after which cells were spun down in a Sorvall refrigerated centrifuge for 10 
min. at 8000 x g at 4 °C and resuspended in 30 mL column buffer (20 mM 
Tris-HCl, 200 mM NaCl, 1 mM EDTA, 0.5% Triton® X-100) and frozen 
overnight at -20 °C. The freeze thaw cycle aids cell lysis. The column 
buffer contained Triton® X-100 detergent to aid solubility.
4.2.11. Expression of pMAL/Mat-8 fusion protein in minimal media
Mat-8 was expressed in M9 minimal media made up of 990 mL solution A
(12.5 mg/ml Na2HP04, 7.5 mg/ml KH2PO4) and 10 mL of solution B 
(400 mg/mL glucose, 100 mg/mL NHLCl, 24 mg/mL MgSCLJPLO, 
2 mg/mL CaCb^PLO, 1 mg/mL ampicillin and 1 mg/mL Thiamine HC1). 
This was further supplemented with vitamins and minerals to increase 
expression (Buck et al., 2003) (Minerals: 6 mg/L CaCk, 6 mg/L FeSCL, 
1 mg/L MnCl2, 0.8 mg/L CoCl2, 0.7 mg/L ZnSCL, 0.3 mg/L CuCl2,
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0.02 mg/L H3BO3, 0.25 mg/L (NHLOgMOTC^, and 5 mg/L EDTA; 
Vitamins: 1 mg/L calcium pentothenate, 1 mg/L biotin, and 1 mg/L folic 
acid, 1 mg/L niacinamide, and 1 mg/L pyridoxal phosphate). Minimal 
media usually compromises yield compared to LB but by using 13C 
labelled glucose the expressing cells will use the isotopically labelled 
glucose as its sole carbon source thus producing uniformly I3C labelled 
proteins suitable for study by NMR. 15N labelled NH4CI can be used in a 
similar way separately for 15N NMR or in parallel for multi dimensional 
experiments observing both ,3C and 15N (Lian and Middleton, 2001). Cells 
were grown in LB (to ODeoo of 0.7-0.9) as in 3.2.6. but were resuspended 
in minimal media following centrifugation prior to induction with IPTG.
4.2.12. Purification of pMAL/Mat-8 fusion protein
Phenyhnethanesulphonylfluoride (PMSF) (0.5 mM) and DNase I (25
pg/mL) were added to cells defrosted from the previous step to inhibit 
proteases and break down DNA. The cells were then lysed using the Sim 
Aminco French Pressure Cell at 1000 PSI and the lysate was spun down 
for 30 min. at 19,000 x g at 4 °C. The supernatant was filtered with a 0.2 
pm filter before purification on an amylose resin column.
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4.2.12.1. Amylose resin affinity chromatography
The fusion protein was purified on an amylose resin column. The
protocol was adapted from the pMAL™ Protein System and 
Purification manual from New England BioLabs®. 10 mL of resin was 
added to a 50mL Falcon tube and centrifuged with 50 mL of column 
buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 
0.5% Triton® X-100) x 2 at 6000 x g for 10 min at 4 °C. The 
supernatant was removed and 10 mL of column buffer was added to 
the equilibrated resin before adding the supernatant from the cell lysis 
step (3.2.8.). The lysate/resin mixture was left on a shaker in a cold 
room overnight to allow protein binding before being transferred to the 
column where flow through was collected. 50 mL of column buffer 
was passed through the column three times and retained. This was 
repeated twice with fresh column buffer to wash away impurities that 
do not bind to the column. The amylose resin was transferred to a 
50 mL Falcon tube with elution buffer (30 mL column buffer with 10 
mM maltose) to remove the maltose binding protein (MBP)/Mat-8 
fusion protein from the resin and left shaking overnight at 4°C. The 
amylose resin was then transferred to the column and the eluent was 
collected.
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4.2.12.2. Cleavage of fusion protein
The 30 mL of eluted his ion protein was cleaved by addition of TEYP
(1 mL, 1 mg/mL) and incubated at room temperature overnight. A 
typical preparation produces approximately 20 mg of fusion protein 
(plus impurities) present according to a Bradford assay. TEVP is highly 
specific so should only cleave at the TEVP site Glu-Asn-Leu-Tyr-Phe- 
Gln-(Gly/Ser) engineered into the plasmid in-between MBP and Mat-8. 
The cleaved fusion protein was flash frozen with liquid nitrogen and 
stored at -80DC.
4.2.12.3. Chloroform/Methanol Precipitation of cleaved MBP/Mat-8 
fusion protein
Chloroform/methanol precipitation (Wessel and Fliigge, 1984) was 
used to remove detergent from the samples in order to prevent 
interference with subsequent purification steps. 1 part of TEVP-cleaved 
fusion protein was added to 4 parts methanol and 1 part chloroform, 
vortex mixing in-between each addition. Three parts of MilliQ water 
was then added to this mixture which causes a phase separation in 
which protein is precipitated in the chloroform/methanol/water 
interphase. This mixture was centrifuged at 14,000g for 1 min to 
collect the precipitated protein at the top of the bottom organic layer. 
The top aqueous layer was removed (not disturbing protein between 
layers) and the same volume of methanol originally added was vortex
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mixed with the sample again and the mixture was centrifuged at 
14,000g for a further 2 min to pellet the sample at the base of the tube. 
As much methanol was removed as possible without disturbing the 
pellet and the samples were then dried under a stream of nitrogen and 
then under high vacuum. These solid samples contain MBP, Mat-8, 
TEVP and other impurities.
4.2.12.4. High Performance Liquid Chromatography
The solid samples obtained after chloroform methanol precipitation
that contain Mat-8 and impurities were dissolved in 7M guanidium 
chloride and made up to a final volume of 600 pi. Mat-8 was purified 
by high performance liquid chromatography (HPLC) using a C5 
analytical column (Supelco Discoveiy® Bio Wide Pore) and carried 
out on a Gilson 322 instrument. Columns were equilibrated with 95% 
solvent A (H2O + 0.1% TFA): 5% solvent B (Acetonitrile + 0.1% 
TFA) for 5 minutes. The sample was injected onto the column and the 
gradient was ramped from 5 to 95% Solvent B at a flow rate of 1 
ml/min. Mat-8 was eluted with a linear gradient over 95 minutes and 
1.5 ml samples were collected from 30 minutes until the end. Elution of 
protein is indicated by a large peak and theoretically there should be an 
equal molar concentration of MBP and Mat-8 eluted in different
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fractions as they were co-exprcssed as a fusion protein. Samples were 
then lyophilised for further experiments.
4.2.13. Analysis of protein products 
4.2.13.1. SDS-PAGE
0.75 mm thick gels of either 10% or 15% polyacrylamide were prepared 
using the BIORAD Protean II kit as follows: For 10% polyacrylamide 
resolving gels 3.3 mL 30% acrylamide, 2.5 mL 1.5 M Tris buffer; pH 8.8, 
4.1 mL RO (reverse osmosis) water and 100 pL 10 % SDS and for 15% 
polyacrylamide resolving gels 5 mL 30% acrylamide, 2.5 mL 1.5 M Tris 
buffer; pH 8.8, 2.4 mL RO water and 100 pL 10 % SDS. Stacking gels 
were made up of 1.3 mL 30% acrylamide, 2.5 mL 0.5 M Tris buffer; pH 
6.8, 6.1 mL RO (reverse osmosis) water and 100 pL 10 % SDS. 15% 
polyacrylamide resolving gels have a wider protein size range but poorer 
band separation than 10% polyacrylamide resolving gels. The appropriate 
resolving gel had 75 pL of ammonium persulphate (APS) (100 mg/mL) 
and 7.5 pL of tetramethylethylenediamine (TEMED) added immediately 
before casting and allowing to set, with a thin layer of saturated butanol on 
top to ensure a flat surface. The stacking gel also had 75 pL of APS (100 
mg/mL) and 7.5 pL of TEMED added to it before casting on top of the set 
resolving gel. Well combs were added to the unset stacking gel to make 
wells for protein samples. SDS-PAGE samples were made up as follows:
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10 [i\ protein sample, 10 pi RO water, 20 pi SDS-PAGE sample buffer 
(0.5 M Tris (Melford); pH 6.8, 50% glycerol, 10% (w/v) SDS, 5% (v/v) p- 
mercaptoethanol, 0.1% (w/v) bromophenol blue made up to necessary 
volume with RO water). SDS-PAGE samples were then heated at 100 °C 
for 5 min. and 7.5 pi loaded onto the gel. 5 pi of Sigma markers were also 
loaded onto each gel. Gels were run at 200 V for around 1 hour until the 
dye from the samples had run off the gel. Gels were stained for an hom* in 
Coomassie G250 (0.1% Coomassie G250, 45% methanol, 45% RO water, 
10% acetic acid) with shaking at room temperature. Gels were de-stained 
with water overnight.
4.2.13.2. Western Blot (Dot-Blot)
The protocol from the No vex® WesternBreeze™ kit was followed with 
Polyvinylidene fluoride (PVDF) membranes submerged in methanol for 5 
seconds before equilibration in RO water. These were placed on damp 
filter paper before adding 1 pL of sample and allowing it to absorb before 
incubating with shaking at room temperature in 1 mL of 1% blocking 
solution (diluted in maleic acid solution (100 mM maleic acid, 150 mM 
NaCl; pH 7.5) for 30 min. Blocking solution (prevents non-specific 
binding of antibody to the membrane) was discarded then Mat-8 
monoclonal antibody was diluted 1:5000 in 1% blocking solution and 1 
mL added to the PVDF membrane and incubated with shaking at room
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temperature for 30 min. Antibody was discarded and 4 wash steps of 2 mL 
of TSBT (50 mM Tris, 150 mM NaCl, 0.1% (v/v) Tween 20; pH 7.5) for 
10 min with shaking at room temperature were performed. Anti-mouse 
horseradish peroxidase-conjugated secondary antibody (provided in the 
Novex® WesternBreeze™ kit) was diluted to 800 mU/ml in maleic acid 
solution and 1 mL added to the PVDF membrane and incubated with 
shaking at room temperature for 30 min. A further 4x15 min washes were 
performed then membranes were stained for 30 minutes with ready to use 
stain (5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium 
chloride) which detects the alkaline phosphatase activity of secondaiy 
antibody.
4.3. Results
4.3.1. Expression of PLM in the pBCL plasmid
The pBCL plasmid containing the PLM sequence (Thai et a!., 2005) was 
provided by Francesca Maras si in order to express and purify PLM. This 
expression system involves expressing PLM as a fusion protein with an 
altered B-cell lymphoma protein (BCL) sequence. Small membrane 
proteins are often expressed as fusion proteins as they are difficult to 
overexpress alone. BCL was selected in this case as it expresses as 
inclusion bodies. Inclusion bodies occur when bacteria form aggregates of 
misfolded protein. The proteins are often relatively pure and can be
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refolded using urea. In this expression system the inclusion bodies are 
solubilised using guanidium chloride and followed by CNBr cleavage at 
the Met-X linkage between mBCL-XL and PLM. This method has high 
safety risks that must be taken into account. Transformed cells were grown 
overnight then used to inoculate 1 litre of LB to an ODeoo of 0.05-0.1. This 
was grown to an OD6oo of 0.7-1.0 and induced with 1 mM IPTG. These 
cells were expressed at a variety of temperatures and induction times. 
Inclusion bodies containing insoluble protein were later solubilised and 
Figure 4.5 shows whole cell samples in these various conditions. 
Overexpressed fusion protein is present to varying degrees in all conditions 
although seemingly to a lesser extent than previously (Thai et al, 2005).
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Figure 4.5. Successful PL1M fusion expression in pBCL construct. Lanes show protein 
present in whole cells after induction with 1PTG for various times and temperatures. The 
fusion protein is ~22 kDa and the corresponding band is indicated by the box Low range 
markers (Sigma) are used as shown.
CNBr cleavage was perfonned on samples after solubilising in guanidium 
chloride. As guanidium chloride interferes with the Bradford reagent, 
protein levels could not be accurately determined to calculate CNBr molar 
excesses. Therefore 100 mg of protein was used as a guideline and 
different molar excesses were calculated and used on a small scale. Bovine 
serum albumin (BSA) was also cleaved by CNBr as a positive control to 
confirm the effectiveness of CNBr cleavage. Figure 4.6. shows the results 
of these experiments. In the positive control the starting material (66.8 kDa 
BSA) is partially cleaved giving some remaining starting material and two
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other clear bands. From the methionine residues present in BSA fragments 
of 29.6 kDa, 10.5 kDa, 3.9 kDa and two fragments of 11.4 kDa are 
expected. The 29.6 kDa fragment is clearly apparent. The two 11.4 kDa 
fragments and the 10.4 kDa fragment appear to have travelled the same 
distance along the gel which is entirely possible given their similarity in 
size. The 3.9 kDa fragment is too small to be seen on this gel and has most 
likely run off the end. The markers suggest some deviations in size 
however as this technique separates proteins by shape and there is a lot of 
overlap of bands this is to be expected. It is clear CNBr also has an effect 
on the expressed and solubilised pBCL proteins but it is not clear if PLM is 
present.
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Figure 4.6. CNBr cleavage of BSA and expressed protein from pBCL plasmid. As a
positive control BSA was cleaved with CNBr as shown on the left gel. Fragments are 
expected to be 29.6, 11.4 (x2), 10.5 and 3.9 kDa with BSA starting material expected at 
66.8 kDa. The gel on the right shows the proteins expressed and solubilised from the 
pBCL plasmid (with the BCL/PLM fusion protein indicated by the box) and the results of 
CNBr cleavage at different molar excesses. Low range markers (Sigma) are used as 
shown.
The overexpressed band (indicated by the box in Figure 4.6.) was cut from 
the gel and digested with trypsin. The resulting protein fractions were 
analysed by mass spectrometry. The resulting spectra did not correlate with 
the expected fractions of a trypsin digest of an mBCL/PLM fusion protein. 
This meant there was no way of proving the CNBr cleavage was working. 
Unfortunately the published data for this system did not show any gels of
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either the CNBr cleavage or the purification procedure which meant there 
was no point of reference. Due to the safety implications of CNBr cleavage 
this expression system was not pursued further to allow development of a 
safer method of the expression and purification of FXYD proteins.
4.3.2. Expression of PLM in the pMAL plasmid
The pMAL construct was selected as an alternative system to express and 
purify PLM. This vector has, as a starting point, been used successfully to 
express and purify other similar small transmembrane proteins (Buck et al., 
2003). The target protein is expressed as a fusion protein with maltose 
binding protein (MBP) which aids solubility and allows purification via an 
amylose affinity column. After purification fusion proteins can be cleaved 
with TEVP providing a TEVP site has been engineered in-between the 
MBP and target protein sequences. In pBCL solubility is achieved with 
guanidium chloride and urea which would inhibit proteases like TEVP and 
thus requires the use of highly volatile CNBr as a cleaving agent. pMAL is 
therefore a much safer system than pBCL. PLM was subcloned into the 
pMAL vector with the TEVP site by Yorkshire Bioscience Ltd. This was 
transformed into several cell types; BL21 (DE3), Origami, Rosetta and 
C41 (DE3) and were induced overnight at 37°C. Each cell type was lysed 
by French Press and spun down to give soluble (supernatant) and insoluble 
protein (pellet). Results are shown in in Figure 4.7. PLM is approximately
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8 kDa whilst MBP is approximately 42 kDa making the fusion protein 
around 50 kDa. No overexpressed protein appears at this size in any cell 
type. This is consistent with the difficulties encountered in PLM expression 
described previously (Thai et ai, 2005).
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Figure 4.7. Attempted expression of MBP/PLM fusion protein. Lanes show soluble 
(supernatant) and insoluble (pellet) protein present after inducing with IPTG for 3 hours. 
No cell type yields any significant level of overexpressed protein (expected ~50 kDa). 
Low range markers (Sigma) are used as shown.
4.3.3. Transforming pMal/Mat-8 plasmid into E. Coli
As PLM proved difficult to express, focus was transferred to another
FXYD protein; Mat-8. Although Mat-8 has been expressed by the Marassi
group in the pBCL plasmid (Franzin et al., 2007b) the structural data
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acquired from it is limited. It also required the mutation of two methionine 
residues to leucine residues in the transmembrane region to facilitate CNBr 
cleavage. This is not necessary in the pMAL plasmid when using TEVP 
cleavage at a highly specific site. Mat-8 expression was therefore 
attempted in the pMal plasmid after the difficulties of PLM in the same 
construct.
In standard transformation protocols after transformation occurs there is a 
growth step in which LB is added to the transformed cells before 
incubating for an hour at 37°C. These cells in LB are then plated out and 
grown overnight. After several attempts with this method using the pMal 
plasmid containing Mat-8 and making fresh competent cells no colonies 
formed despite the control plates with no ampicillin showing high growth. 
An extra centrifugation step was thus added after the growth step. The 
pelleted the cells were resuspended in a small volume and plated out, 
effectively increasing the concentration of cells spread onto the agar plate. 
This proved a successfi.il step as suitable colonies formed. These colonies 
were selected for expression. Cell stocks of these colonies were produced. 
However these cell stocks failed to grow when added to fresh LB with 
ampicillin. The difficulty of transformation and the unreliability of cell 
stocks suggest bacterial cells reject the pMal plasmid containing Mat-8. 
Nevertheless by transforming directly prior to each expression, MBP/Mat- 
8 fusion protein can be successfully overexpressed as will be shown later.
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4.3.4. Expression and purification tests of MBP/Mat-8 fusion protein
The ideal expression conditions depend on many factors, one of which is
the sequence of the protein itself. This means that to overexpress a given 
protein, an ideal set of expression conditions will need to be determined 
that will optimise protein expression in the system selected. This is 
achieved by first trying different expression conditions on a small scale, 
determining which conditions are best then scaling up to larger volumes 
capable of producing milligram quantities of protein. The Mat-8/MBP 
fusion protein transformed into BL21 (DE3) cells underwent several of 
these expression tests to optimise yield. Tests were initially performed in 
LB, which is much richer than minimal media and usually yields more 
protein. The first tests covered temperature of expression and time of 
induction. Cells were all grown at 37°C until they reached an OD of 0.7- 
1.0. This is the point at which cells were induced with IPTG. At this point 
cells will have just begun their stationary phase (Figure 4.8.). Inducing 
earlier would have the cells in exponential growth phase so media and 
energy of the cells would be wasted. Inducing cells too late will put them 
in death phase where cell numbers will start to reduce, thus reducing 
potential levels of protein. Upon induction bacterial cells were split into 
three incubators operating at different temperatures; 18°C, 25°C and 37°C. 
The optimal temperature for bacterial growth is 37°C although reducing 
temperature is, in some cases, favourable as this slows down expression
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and increases protein solubility. Samples were taken from the bacterial 
cultures at each temperature at three different time points: 3 hours, 5 horns
Stationary
Exponential 
growth / 
phase /
Death
phase
Figure 4.8. Growth phases of bacteria. In a bacterial culture, cells undergo four phases. 
Initially at the lag phase growth is slow, while cells adjust to the new conditions. This is 
followed by an exponential growth phase where bacteria rapidly multiply. At a saturation 
point cells then enter stationary phase where no growth occurs. When nutrients begin to be 
exhausted cells enter death phase in which cells begin to die allowing their nutrients to be 
used by the remaining living cells.
and overnight. Certain proteins can begin to degrade or become insoluble 
at higher concentrations so allowing expression overnight is not always 
desirable. The cell samples were lysed by sonication and centrifuged to 
separate soluble and insoluble protein. The 15% SDS-PAGE gels of each
153
of the three induction temperatures (18°C, 25°C and 37°C) at the four time 
points (3 hours, 5 hours, 7 hours and overnight) are shown in Figure 4.9. 
At each time point the soluble (supernatant) and insoluble (pellet) protein 
is shown and the intact pre-lysis cells (whole cells) and pre-induction cells 
(uninduced) are included for comparison. A box indicates the location of 
the MBP/Mat-8 fusion protein on the SDS-PAGE gel. This is around 
50 kDa, a combination of MBP (42 kDa) and Mat-8 (8 kDa). Each whole 
cell sample contains overexpressed MBP/Mat-8 fusion protein but when 
cells are lysed the majority of protein is insoluble as it is found in the 
pellet. Cooler temperatures (i.e. 18°C and 25°C) yield less protein as 
expected but the potential gain of improved fusion protein solubility is not 
observed. Therefore, 37°C was selected as the optimal expression 
temperature. At 37°C, longer induction times simply result in increased 
insoluble protein as each soluble sample (supernatant) at this temperature 
looks very similar whilst the insoluble samples (pellet) show increased 
fusion protein over time. A 3-hour induction time was selected as a result.
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Figure 4.9. Expression tests to determine ideal time and temperature conditions for 
expression of Mat-8/IMBP fusion protein. Expression was carried out at 18°, 25° and 
37°C in LB. with samples taken at different induction times. The fusion protein of interest 
is ~50 kDa and is indicated by the boxes. Supernatants contain soluble protein and pellets 
contain insoluble protein. Whole cells are all proteins produced post induction and 
uninduced all proteins pre-induction. Low range markers (Sigma) are used in all gels as 
shown.
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IPTG concentration can also affect the solubility of expressed protein by 
reducing the rate of expression. Therefore further expression tests altering 
IPTG concentration at time of induction were carried out. Four different 
IPTG concentrations were tested (0.25 mM, 0.50 mM, 0.75 mM and 1.0 
mM), inducing at 37°C for 3 hours. The 15% SDS-PAGE gels of each of 
these IPTG concentrations are shown in Figure 4.10. At each concentration 
of IPTG the soluble (supernatant) and insoluble (pellet) protein is shown 
with intact pre-lysis cells (whole cells) and pre-induction cells (uninduced) 
included for comparison. A box indicates the location of the MBP/Mat-8 
fusion protein on the SDS-PAGE gel. Total fusion protein (whole cell) 
increases with higher IPTG concentrations. However when these cells are 
lysed more soluble fusion protein (supernatant) is expressed at lower IPTG 
concentrations. 0.25 mM IPTG was therefore selected for induction.
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Figure 4.10. Expression tests to determine ideal IPTG concentration. IPTG 
concentrations of 0.25, 0.50, 0.75 and 1 mM were tested inducing at 37°C for 3 hours. The 
fusion protein of interest is ~50 kDa and is indicated by the box. Supernatants contain 
soluble protein and pellets contain insoluble protein. Whole cells are all proteins produced 
post induction and uninduced all proteins pre-induction. Low range markers (Sigma) are 
used in all gels as shown.
Although selecting the best induction time, induction temperature and 
IPTG concentration appeared to improve fusion protein solubility, it was 
clear that there was still a lot of protein expressed in an insoluble form. 
Therefore the detergent Triton X-100 ® (TX-100) was incorporated into 
the lysis buffer to see if it could improve fusion protein solubility. 
Purification tests were performed with and without TX-100 (0.5%) in the 
column buffer used to resuspend the cells before lysis and throughout the 
amylose column purification procedure. Fusion protein was expressed at
157
the determined optimal conditions (3 hour expression time 37°C5 0.25 niM 
IPTG) both with and without TX-100 at 0.5% (v/v). The soluble protein 
(supernatant) was added to a small amount of amylose resin, to which the 
MBP fusion protein would be expected to bind, and washed with buffer. 
The washed resin and expression samples were observed on a 15% gel 
(Figure 4.11). There is a more intense fusion protein band (indicated by 
box) present in the supernatant (soluble protein) when TX-100 is used in 
the column buffer in which cells are resuspended which suggests TX-100 
aids solubility. Importantly, when supernatants are added to amylose resin 
there is more fusion protein bound in the presence of TX-100 than in a TX- 
100-free environment (amylose resin lanes) which suggests TX-100 could 
improve yield of purified protein when scaled up to a full amylose column 
as it increases solubility without affecting binding to amylose resin.
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Figure 4.11. Purification tests with and without TX-100. Purification tests with and 
without TX-100 (0.5% v/v) were performed in order to determine if it would aid protein 
solubility. The fusion protein of interest is ~50 kDa and is indicated by the box. These 
expression tests were taken further by adding soluble protein to amylose resin to determine 
whether the fusion protein would bind to the amylose column. Low range markers (Sigma) 
are used as shown.
To determine the optimal TX-100 concentration required to extract soluble 
fusion protein from the cells, further small-scale experiments were 
performed. The optimal conditions were used again and four TX-100 
concentrations were tested: 0.25%, 0.5%, 0.75% and 1% (v/v). Soluble 
protein produced in these conditions was observed on a 15% gel (Figure 
4.12.). The box highlights the position of the fusion protein and this 
indicates 0.5% (v/v) gave improved solubility over 0.25% TX-100 and
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comparable solubility to 0.75% and 1.0% TX-100, therefore 0.5% TX-100 
was selected for full scale expression.
Figure 4.12. Purification tests with various TX-100 concentrations.. The samples 
shown here are soluble protein samples with TX-100 concentrations 0.25%, 0.5%, 0.75% 
and 1.0% (v/v) in the buffer. The fusion protein of interest is ~50 kDa and is indicated by 
the box Low range markers (Sigma) are used as shown.
4.3.5. Full scale expression/purification of MBP/Mat-8 fusion protein 
in LB
With expression conditions determined on a small scale these same 
conditions were scaled up to a full 1-litre preparation. Samples were 
collected at key stages of expression and purification and were analysed in 
a 15% SDS-PAGE gel (Figure 4.13.) The box indicates the location of the 
fusion protein. Good levels of expressed soluble protein are observed as 
indicated by the intense fusion protein band in the supernatant sample. This
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soluble protein was allowed to bind to resin overnight before the eluent 
was collected (flow through). There is a fusion protein band in the eluent 
which suggests not all fusion protein binds to the resin possibly because of 
denaturation by the detergent. Buffer washes contain veiy little fusion 
protein but several other bands indicate the removal of protein impurities. 
After these wash steps, a sample of the amylose resin was taken which 
indicates a large amount of fusion protein has successfully boimd to the 
column. This fusion protein was eluted with elution buffer and can be seen 
in the eluted protein lane. A sample of the resin after elution revealed 
protein was still bound to the amylose column so the elution was repeated 
with fresh elution buffer (as indicated by 2nd eluted protein) and another 
post elution resin sample reveals virtually no protein was left bound to the 
column.
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Fig 4.13. Full scale expression and purification of IMBP/lVfat-8 fusion protein. The
fusion protein was expressed in 1 L of LB and run through an amylose column before 
being eluted with elution buffer. The fusion protein of interest is ~50 kDa and is indicated 
by the boxes. Supernatants contain soluble protein and pellets contain insoluble protein. 
Whole cells are all proteins produced post induction and uninduced all proteins pre­
induction. Samples of flow through and wash steps are shown as well as protein bound to 
the resin before and after adding elution buffer. The elution step was repeated as not all 
fusion protein was eluted (indicated as 2nd eluted protein) Low range markers (Sigma) are 
used in both as shown.
With successful expression and part purification established, Mat-8 needed 
to be cleaved from MBP in the fusion protein. This was done with TEVP 
which recognised the specific sequence in between MBP and Mat-8 in the 
fusion protein. To determine an optimal TEVP concentration for maximal 
fusion protein cleavage, small scale cleavage experiments were performed
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on amylose column purified fusion protein. Figure 4.14 shows a 10% SDS- 
PAGE gel (for improved separation to make the difference between fusion 
protein and MBP clear), of various concentrations of TEVP added to the 
purified fusion protein and incubated overnight at room temperature. At 
this percentage gel Mat-8 is expected to run off the gel. Cleavage appears 
to be successful as the intensity of the fusion protein band reduces whilst 
the intensity of the MBP band (42 kDa) increases with increased TEVP 
concentration. Maximal cleavage is achieved at 250 pg/mL as the ratio of 
the intensity of MBP:fusion protein does not improve beyond this point. 
The extent of cleavage is monitored by the MBP band as the Mat-8 band is 
not clearly visible on the gel as it does not stain particularly well due to its 
small size.
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Fig 4.14. Determination of optimal TEVP concentration for maximal MBP/Mat-8 
fusion protein cleavage. Pilot cleavage tests were performed on the amylose column 
purified fusion protein, varying concentration of TEV protease which can be seen at the 
bottom of the gel. The concentration of TEV is shown above the gel and eluted protein is 
treated with no TEV. Cleavage was carried out overnight at 4 °C. Separation was carried 
out on a 10% acrylamide gel. The fusion protein, MBP and TEVP are indicated by boxes. 
Low range markers (Sigma) are used as shown.
Following cleavage, Mat-8 needed to be purified from MBP, TEVP and 
other impurities. This was first approached by attempting to cleave the 
fusion protein when it was still bound to the amylose column. The 
principle behind this was to omit the elution step following resin binding 
and buffer washes and instead resuspend the amylose resin in column 
buffer containing 250 pg/mL TEV protease and incubate at room
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temperature overnight before returning the resin back to the gravity 
column. Cleaved MBP and other impurities should remain bound to the 
resin whilst TEVP and Mat-8 should now be eluted. The 15% SDS-PAGE 
in Figure 4.15 shows that although the elution appears to contain Mat-8 it 
also contains a large quantity of MBP and fusion protein suggesting at 
some point in this process MBP and fusion protein lost affinity for the 
amylose column and therefore co-eluted with Mat-8. The eluted protein 
was therefore applied to a packed column with fresh amylose resin. Figure 
4.15. also shows the elution from the rebuilt column and shows the process 
reduces the quantity of MBP and fusion protein but only to a small extent.
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Fig 4.15. Cleavage of IVIBP/Mat-8 fusion protein in presence of amylose resin.
Following fusion protein resin binding and buffer washes, amylose was resuspended in 
column buffer containing TEVP to attempt an on column cleavage . A faint band at around 
8 kDa (the size of Mat-8) is visible in the cleaved elution. Also present is MBP and fusion 
protein Low range markers (Sigma) are used as shown.
The second approach to separating MBP and fusion protein after cleavage 
was by using dialysis to remove TX-100. MBP is a water soluble protein 
whilst Mat-8 requires detergent for solubility. By removing the TX-100 by 
dialysis it was hoped that MBP would remain in solution whilst Mat-8 
would precipitate allowing removal by centrifugation. Dialysis tubing with
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a 3 kDa cut off was used in order to retain Mat-8 in the tubing. The 
amylose column purification was performed and the eluted protein was 
cleaved with TEVP then dialysed into column buffer containing no TX- 
100. The buffer was replaced after four hours with fresh buffer twice to 
promote movement of TX-100 out of the dialysis sample. The contents of 
the dialysis tubing were centrifuged (19,000 rpm, 4°C, 30 mins) and the 
supernatant and pellet were run on an SDS-PAGE gel (Figure 4.16). The 
pellet was veiy small and contained Mat-8 and all impurities with most 
protein remaining in the supernatant including Mat-8. This suggests that 
only some TX-100 was removed by dialysis which caused some protein to 
precipitate. Not only is this method inefficient for detergent removal but 
the precipitated protein still contains large quantities of impurities, 
although the purity of Mat-8 is enhanced as seen from the increased 
relative intensity of the Mat-8 band compared to the supernatant after 
dialysis.
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Fig 4.16. Dialysis of cleaved MBP/ Mat-8 fusion protein to remove TX-100. Eluted 
fusion protein contained 0.5% TX-100 in column buffer and was cleaved with TEVP. This 
was dialysed into column buffer with no TX-100. Fusion protein, MBP, TEVP and Mat-8 
are indicated by boxes. The pellet was very small and both supernatant and pellet 
contained Mat-8 and all impurities Low range markers (Sigma) are used as shown.
A third approach for purifying Mat-8 involved an alternative method of 
removing detergent by chloroform/methanol precipitation (CMP). CMP is 
a method for protein precipitation that has proved particularly effective at 
removing TX-100 (Wessel and Fliigge, 1984). Methanol, protein sample 
(30 mL) and chloroform are mixed at a 4:1:1 ratio. At this point the
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solvents, TX-100 and protein can all associate with each other. By addition 
of water, a phase separation is induced as methanol is able to associate with 
water in the aqueous phase whilst the density of chloroform means it forms 
an organic phase below this. TX-100 is particularly soluble in chloroform 
so is pulled down into the organic phase whilst water molecules associated 
with protein are displaced by methanol causing them to precipitate in the 
aqueous phase. Centrifugation causes the precipitated proteins to pellet in 
the interphase between the aqueous phase and organic phase. Small 
membrane proteins are soluble in methanol and not water so it was 
hypothesised that Mat-8 would remain in the aqueous phase whilst 
impurities would precipitate in the interphase. The 15% SDS-PAGE gel 
Figure 4.17. shows both the organic phase and aqueous phase and the 
precipitated protein in the interphase. It appears that all proteins are 
precipitated in the interphase suggesting Mat-8 requires a higher 
percentage of methanol than is present in the aqueous phase for solubility.
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Fig 4.17. Chloroform Methanol Precipitation of TEVP cleaved MBP/Mat-8 fusion 
protein. Eluted fusion protein underwent chloroform methanol precipitation. Virtually all 
protein is present in the interphase. Fusion protein, MPB and Mat-8 are indicated by 
arrows. Low range markers (Sigma) are used as shown.
Although chloroform methanol precipitation did not give the desired result 
it did precipitate all the protein which suggests that the majority of TX-100 
had been removed. The precipitated Mat-8 protein with impurities from 
chloroform-methanol precipitation was dissolved in aqueous 7M 
guanidium chloride and run on reverse-phase HPLC with an acetonitrile 
gradient which separates proteins by hydrophobicity. The HPLC trace can
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be seen in Figure 4.18. which reveals two clear peaks (a and b) after the 
guanidium hydrochloride peak.
(a)(b)
Guanidium
hydrochloride
Figure 4.18. HPLC trace of chloroform/methanol precipitated sample. This trace 
shows different peaks over an acetonitrile gradient (from 5 to 95%). The first peak is 
truncated due to its high intensity and is due to the guanidine present in the buffer. The 
second peak is Mat-8 and the third peak has all other impurities including uncleavcd 
fusion protein, MBP, TEV and other unidentified proteins that coeluted from the amylose 
column with the fusion protein and are found in many fractions. Mat-8 eluted at around 
40% acetonitrile.
Fractions were collected from 23 minutes into the run as this is where 
protein began to be eluted. The first ten fractions were combined and 
lyophilised which incorporate the first peak (a) shown in Figure 4.18. The 
yield of Mat-8 per litre of LB expression was determined to be 2.1 mg
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according to the microbalance. Figure 4.19. shows these combined 
lyophilised fractions and subsequent lyophilised fractions on a 15% SDS- 
PAGE gel. Peak (a) appears to correspond to Mat-8, indicating that the 
protein has been successfully purified.
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Figure 4.19. SDS-PAGE of HPLC fractions to purify Mat-8. This SDS-PAGE shows 
how proteins have separated over the acetonitrile gradient. In this am Mat-8 has separated 
from other impurities. Fraction numbers correspond to the HPLC trace on Figure 4.18. 
Low range markers (Sigma) are used as shown.
To confirm the identity of Mat-8 a dot blot analysis of each of the HPLC 
fractions was performed using a specific Mat-8 antibody and fractions 
from a HPLC run. Figure 4.20 shows the result from fractions 7-13 which 
incorporates the two main peaks. As indicated by the HPLC trace (Figure 
4.19.), fraction 10 gives the most intense dot suggesting this fraction has
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the highest concentration of Mat-8. Fraction 9 and 11 contain a lower 
concentration of Mat-8 indicated by less intense dots. This correlates with 
the HPLC trace as the height of the peak is lower at these fractions. A 
positive control using the synthetic peptide Mat-8sf38-68 which represents 
the cytoplasmic region of Mat-8 and a negative control using the synthetic 
peptide PLM38-72 which represents the cytoplasmic region of PLM confirm 
the antibody is specifically binds to Mat-8.
Positive Negative 
Control Control
o
7 8 9 10 11 12 13
Figure 4.20. Dot Blot of HPLC fractions. Purification was confirmed by performing a 
dot blot using primary Mat-8 antibody. From left to right the squares represent HPLC 
fractions incorporating peak (a). (Figure 4.18.) SDS-PAGE of fractions 10-13 is shown in 
Figure 4.19. The highest concentrations of Mat-8 are in 9th and 10th fraction which 
suggests peak (a) results from Mat-8 according to the HPLC trace. Positive control using 
synthetic cytoplasmic Mat-8 peptide and negative control using synthetic cytoplasmic 
PLM peptide are shown.
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4.3.6. Full scale expression/purification of MBP/Mat-8 fusion protein 
in minimal media
After establishing ideal expression conditions in LB the expression media 
was then changed to minimal media. Minimal media can be prepared with 
[13C] glucose and [15N] ammonium chloride, which will uniformly 
isotopically label proteins suitable for analysis by NMR. The full-scale 1- 
litre expression conditions used were identical to those for growing in LB 
until the point of induction where cells were centrifuged (8,000 g, 10 
minutes, 4°C) and resuspended in the same volume of minimal media. 15% 
SDS-PAGE analysis (Figure 4.21.) indicated that there was seemingly no 
overexpressed protein. A further full-scale experiment was repeated using 
vitamin and mineral supplements (Buck et al, 2003) to create 
supplemented minimal media that has been shown to increase protein yield 
in the same construct with another small transmembrane protein PLB. This 
did successfully produce an overexpressed band on the gel but it was much 
less intense than observed in LB (Figure 4.13.). Finally the cell line was 
changed to C41, which was developed for expressing toxic and membrane 
proteins (Miroux and Walker, 1996). This bacterial strain gave good levels 
of overexpression and so Mat-8 was purified in isotopically labelled 
minimal media using the methods established previously in LB.
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Figure 4.21. Comparison of minimal media expression of MBP/Mat-8 fusion protein 
in different cell lines. Lanes show protein present bound to the amylose column after 
overnight binding. MM is expression in minimal media and SMM is in supplemented 
minimal media. C41 cells are clearly preferable over BL21. Wide range markers (Sigma) 
are used as shown.
In order to analyse Mat-8 by NMR it must be incorporated into a lipid 
bilayer to represent its native environment as a membrane protein. This 
was performed by a process called reconstitution using established 
methods (Li et al., 1999; Smith et at., 2001). Mat-8 and 2:1 DMPCrDOPG 
was dissolved in 50:50 chloroform methanol. The chloroform dissolves the 
lipid whilst the methanol dissolves Mat-8. Whilst the lipid and Mat-8 are in 
solution bilayers containing Mat-8 are formed. After the reconstituted
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samples are dried they can be analysed by NMR. Unfortunately this did not 
produce a signal on NMR suggesting the yield was not substantial enough. 
The methods to express and purify Mat-8 are successfully in place 
however further work needs to be done to improve final yield of fully 
labelled Mat-8.
4.4. Discussion
Expression and purification of membrane proteins is notoriously difficult 
and is highlighted by the difficulties presented in this chapter. FXYD 
proteins have proved particularly difficult to express and purify even in 
comparison to other membrane proteins (Thai et al., 2005). A successful 
method for expression and purification of FXYD proteins for analysis by 
NMR has been established with the pBCL construct (Thai et al, 2005). 
This involves expressing a fusion protein of a modified BCL protein and 
the FXYD protein of interest. The modified BCL causes the fusion protein 
to be expressed as an inclusion body which can be solubilised before 
cleaving the FXYD protein moiety from the modified BCL by CNBr 
cleavage. CNBr cleavage is not a desirable method as it has a high risk and 
a large number of safety precautions must be considered. After attempting 
to recreate the pBCL method (Figure 4.6.), trials were earned out with a 
new expression system which expresses and purifies FXYD proteins in a 
soluble form as a fusion protein with MBP. In this method MBP is cleaved
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from the FXYD protein using TEVP that recognises a specific site 
engineered between the MBP and the FXYD component of the fusion 
protein. This is a much safer method than CNBr cleavage. Unfortunately, it 
was not possible to overexpress PLM in significant quantities (Figure 4.7.) 
despite testing a range of cell strains, including C41 cells which have been 
developed specifically for the expression of toxic proteins. Indeed, PLM 
has been reported to be particularly difficult to express (Thai et aL, 2005) 
with the pKSI and pTLE expression systems having poor levels of 
overexpressed PM fusion proteins. It is possible PLM is too toxic for any 
cell type in this construct. Expression of Mat-8 with this system produced 
results which were much more positive (Figure 4.9.). Mat-8 was expressed 
on a small scale at temperatures of 18, 25 and 37°C and induction times of 
3 horns, 5 hours, 7 horns and overnight. Lower temperature usually yields 
less protein but can often aid solubility. The solubility of Mat-8 is not 
noticeably affected by temperature so was expressed at 37°C which yields 
the most protein. Expression was also stopped after only 3 horns as after 
this time all additional expressed protein was expressed in an insoluble 
form. Reducing IPTG concentration to 0.25 mM resulted in less total 
protein but improved solubility further (Figure 4.10.). This suggests that by 
expressing MBP/Mat-8 fusion protein slowly, the solubility increases. 
Purification of MBP/Mat-8 fusion protein proved far more difficult than 
expression. Whilst the amylose column successfully removed the majority 
of impurities (Figure 4.13.) the problem of separating Mat-8 and MBP
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arose. This was made more complex by the requirement of TX-100 (Figure 
4.12.) to keep the MBP/Mat-8 fusion protein soluble. Protein can either be 
eluted from the column as a fusion protein prior to cleavage or cleavage is 
earned out on the column. An attempt was made to cleave Mat-8 from 
MBP prior to elution. Theoretically Mat-8 should then elute from the 
column whilst MBP remains bound to the amylose. This was not 
successful as MBP apparently co-eluted with Mat-8 (Figure 4.15.). MBP 
appears to lose affinity for amylose post cleavage, possibly due to a 
denaturing effect. This appears to occur after cleavage as the MBP/Mat-8 
fusion protein has a strong affinity for amylose.
Following tlie issues of cleaving the fusion protein on-column, the fusion 
protein was instead eluted with maltose prior to cleavage.Dialysis from 
buffer with TX-100 to TX-100-free buffer was attempted using dialysis 
tubing with a 3 kDa cut off to try and remove enough TX-100 monomers. 
These should pass through the membrane as they have a molecular weight 
of 647 Da, this causes Mat-8 to precipitate. This did yield a veiy small 
pellet with an improved ratio of Mat-8 impurities however Mat-8 still 
remained in solution even after 3 buffer changes (Figure 4.16.). As a TX- 
100 concentration of 0.5% (v/v) was used to solubilise MBP/Mat-8 fusion 
protein, which is above the 0.02% critical micelle concentration (CMC) of 
TX-100 it is no surprise dialysis proved ineffective as the molecular weight 
of the micelles is 90 kDa much higher than the 3 kDa cut off.
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Chloroform methanol precipitation is a method of precipitating proteins 
which is particularly effective with TX-100 and membrane proteins 
(Wessel and Fliigge, 1984). In this method proteins are precipitated in an 
interphase between a lower organic phase (chloroform) and an upper 
aqueous phase (methanol and water). It was hoped that Mat-8 would 
remain in the aqueous phase by being solubilised in methanol. However 
Mat-8 was precipitated at the interphase together with all the impurities 
(Figure 4.17.). This is probably due to the high percentage of water in the 
aqueous phase which results in membrane protein insolubility therefore the 
percentage methanol was not high enough to keep Mat-8 soluble. Despite 
the failure to separate Mat-8 from other protein impurities this method did 
result in the removal of the majority of TX-100 allowing the proteins to 
precipitate. By dissolving the precipitated proteins in guanidium chloride, 
Mat-8 could be successfully purified via reverse phase HPLC (Figure 
4.18.) with a final yield of 2.1 mg per litre of LB expression.
Having established a working method following expression in LB, it was 
necessary to repeat the work in minimal media in order to produce labelled 
protein for NMR. Initially this failed to overexpress the MBP/Mat-8 fusion 
protein. Supplementing the minimal media with vitamins and minerals has 
improved expression of a similar small transmembrane protein PLB 
previously (Buck et al, 2003) but in this case it only generated a small
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quantity of overexpressed protein (Figure 4.21.). By using the C41 cell 
strain, overexpression levels were vastly improved (Figure 4.21.). C41 
cells have been developed specifically for the expression of toxic proteins 
and membrane proteins (Miroux and Walker, 1996). Despite the 
improvement in yield there was still not sufficient protein produced 
following purification to produce an adequate NMR signal for structural 
studies.
Despite the insufficient yield in minimal media for NMR experiments, 
Mat-8 has been successfully expressed and purified in LB. The minimal 
media yield could be improved if time was available. This opens 
possibilities of future experiments on full length Mat-8 for example co­
reconstituting Mat-8 with the Na+, K+-ATPase and observing the effect on 
activity with Na+ activation curves. Truncated forms of Mat-8 could be 
studied where by the cytoplasmic or extracellular regions could be 
removed in order to see the effect on function. Ultimately, improving this 
method to produce sufficient labelled protein would be desirable. Possible 
future experiments could include attempting different cell strains, hying 
different detergents with a lower CMC that will be better suited for 
removal by dialysis or finding alternative chloroform methanol 
precipitation methods without phase separation to purify Mat-8 by 
precipitation (Hu et al., 2007).
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Chapter 5
5.1. Structural and Bioinformatical Studies of FXYD proteins
Chapter 4 highlighted the difficulties of expressing and purifying FXYD
proteins suitable for analysis by solid-state NMR. There are many other 
techniques however, that can provide insights into the structure of proteins. 
In Chapter 3 synthetic peptides were designed with the same amino acid 
composition of the cytoplasmic regions of FXYD proteins and used to 
examine the interactions with lipids and effects on Na+, K+-ATPase 
function. This was possible as the cytoplasmic regions of proteins tend to 
be soluble as they reside in a fluid environment in the cell. This means 
synthetic peptides can be studied using routine structural methods such 
Circular Dichroism spectroscopy (CD) and NMR spectroscopy to give 
information about secondary structure in the cytoplasmic region without 
having to overcome the solubility difficulties of the full length protein.
Currently the only FXYD proteins to be solved in complex with the Na+, 
K+-ATPase are the y-subunit of the Na+, K+-ATPase in pig (Morth et aL, 
2007) and FXYD 10 of spiny dogfish, which has no mammalian equivalent 
(Shinoda et aL, 2009). Unfortunately neither the y-subunit of the Na+, K+- 
ATPase nor FXYD 10 have a cytoplasmic region. This means that there are 
no structural data revealing how the cytoplasmic regions of any FXYD 
proteins interact with the Na+, K+-ATPase. Therefore this chapter will use
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a bioinformatic approach to model how the cytoplasmic region of PLM 
interacts with the Na+, K+-ATPase. PLM was selected for this study as it 
was shown to have the strongest interaction with the Na+, K+-ATPase in 
Chapter 3. This will involve using the structure of the Na+, K+-ATPase and 
using current structural data about PLM solved in the absence of the Na+, 
K+-ATPase which is described below.
The first insight into the structure of the cytoplasmic region of PLM was 
gained by using CD to estimate a-helical content in the cytoplasmic region 
of PLM by inducing a helical stracture in a synthetic peptide representing 
the cytoplasmic region with TFE (Clayton et al, 2005). Trifluoroethanol 
(TFE) is known to induce a-helix in synthetic peptides providing they have 
a natural propensity to do so (Tamburro et al, 1968). This is because TFE 
is much more basic than water so intramolecular hydrogen bonding in the 
peptide is increased due to peptide/solvent hydrogen bonding decreasing 
(Nelson and Kallenbach, 1986). The CD experiments with TFE performed 
here revealed the cytoplasmic region of PLM was estimated to contain 
approximately 15% a-helical content (Figure 5.1.).
Solution NMR of full length FXYD proteins in SDS micelles (Franzin et 
al, 2007a) revealed the secondary structure of full length PLM, CHIF and 
short form Mat-8 to contain a-helical and random coil regions but no (3- 
sheet (Figure 5.1.). The levels of a-helical content present in the
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cytoplasmic region are approximately double that observed in the CD data. 
It is unclear if this is due to a loss of structure caused by studying a peptide 
fragment instead of the full length protein or if the highly negatively 
charged environment of SDS micelles is inducing additional helical content 
not observed in vivo.
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Figure 5.1. a-helical content of FXYD proteins determined by solution state NMR in 
SDS micelles and CD in H20 and 40% TFE. Current published data for secondary 
structure of (a) full-length PLM, Na+, K4-ATPase y-subunit (gamma-b), Mat-8 and CHIP 
solved by solution-state NMR in SDS micelles (Franzin et al., 2007a) where cylinders 
indicate a-helix and lines indicate random coil (b) the cytoplasmic region of PLM in water 
and TFE solved by CD (Clayton et al., 2005).
The 3D structures of human PLM (Teriete et al., 2007) and rat CHIP 
(Franzin et al., 2007d) have solved by NMR with the proteins solubilised
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in SDS micelles in the absence of the Na+, K+-ATPase. Due to the 
homology of the transmembrane region across all FXYD proteins it has 
been possible to model the Na+, K+-ATPase/PLM complex simply by 
replacing the co-ordinates of the y-subunit of the Na"1, K+-ATPase in the 
pig kidney structure with the co-ordinates of the SDS micelle PLM 
structure (Teriete et ah, 2009). Figure 3.3a. shows this model which 
suggests the cytoplasmic region of PLM is located in close proximity to 
both the Na+, K+-ATPase cytoplasmic domain and the membrane surface. 
The same authors paper also showed that phosphorylation of Ser 68 
induces significant ]H and I5N chemical shift changes in helix 4 (Figure 
3.3a.) which is located in the cytoplasmic region of PLM, whilst all other 
chemical shift peaks remain unchanged after phosphorylation. This 
suggests there is a conformational change of helix 4 induced by 
phosphorylation of PLM. Figure 3.3b suggests an alternative orientation 
based on this observation with helix 4 located in close proximity of a 
negatively charged crevice of the Na+, K+-ATPase which leads to the ion 
binding pocket in the centre of the a-subunit. As the cytoplasmic region of 
PLM has a net positive charge it could potentially influence a negatively 
charged crevice which contains conserved acidic residues Asp 813 and Glu 
336 that allow the approach of cations but exclude anions through the 
pump (Reyes and Gadsby, 2006). When just one of these residues has a 
reversal in charge there is a change from cation to anion selectivity in the 
whole Na+, K+-ATPase channel (Reyes and Gadsby, 2006). This is a
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possible explanation for the mechanism of Na+, K^ -ATPase regulation via 
phosphoiylation of PLM.
This chapter aims to further investigate the limited structural information 
about the cytoplasmic region of FXYD proteins. CD will be used to 
determine helical content for the cytoplasmic regions of CHIP and both 
Mat-8 isoforms to see how they compare to the CD data for PLM. If either 
of the Mat-8 isoforms are revealed to contain a-helical content by CD they 
will also be analysed by solution-state NMR in the presence and absence of 
TFE. CD will also be used to see if lipids induce a-helical content in these 
due to the binding observed in Chapter 3.
The structure of the cytoplasmic region of PLM will be investigated 
Luther. CD experiments in the presence of SDS will be used to determine 
if SDS induces a-helix to determine the validity of the current structure of 
PLM (Teriete et al, 2007). Upon this evaluation of the structure of PLM, 
the possibility of its cytoplasmic region interacting with the Na+, K+- 
ATPase will be Luther investigated using bioinformatics techniques to 
identify a putative Na+, Kf-ATPase -binding motif in the cytoplasmic 
PLM sequence. The surface of Na+, K+-ATPase will also be analysed with 
bioinformatics to find a conserved and suitable binding region for this 
motif. These data will be combined to improve the current model of how 
the cytoplasmic region of PLM might dock into the Na+, K+-ATPase in two
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different conformations determined by phosphorylation (Teriete et al., 
2009).
5.2. Materials and Methods
5.2.1. Materials
Phospholipids were purchased from Avanti® Polar Lipids Inc. Peptides 
were purchased from Peptide Protein Research Ltd. and were designed to 
represent the cytoplasmic regions of PLM (Figure 3.1.), short form Mat-8 
(Figure 3.2.) and CHIF (Figure 3.5.). Peptides designed to represent the 
cytoplasmic region of the long form Mat-8 (Figure 3.2.) were purchased 
from GenicBio Biotechnology Ltd. All other materials were supplied by 
Sigma.
5.2.2. Preparation of lipid vesicles
See Chapter 3
5.2.3. Circular Dichroism using TFE
Secondary structural measurements with PLM38.72 Mat-Ssfss-e?, MaL81f3s-93 
or CHIF38-72 peptides and the cytoplasmic region of CHIF were carried out 
by circular dichroism (CD) spectroscopy on a Jasco J-180 
spectropolarimeter at 4 °C. Spectra were recorded from 240 to 190 mn 
using a 0.1 cm cuvette, a scan rate of 20 mn/min, and 4-10 scans per 
sample. Initial measurements were made on solutions of each of the 
peptides (100 pM Mat-8sf38-67, Mat-81f38-93 or CHIF38-72) 10 mM 
phosphate, pH 7 followed by a stepwise tifration with trifluoroethanol
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(TFE) to generate measurements at between 10% and 40% (v/v) TFE. The 
percentage a-helix was calculated using the following equation (Scholtz et 
al, 1991):
% helix = lOOx(0o^s — 0C)/(0H — 0C)
where 6h = ~ 40000 x (1 - x/n) + 100T and 6c = 640 - 457’. The quantities 
Oh and 6C represent the molar ellipticity values for 100% a-helix and 100% 
random coil, respectively, both expressed in deg.cm2/dmol. The quantity 
Bobs is the observed molar ellipticity measured at 222 nm, T is the 
temperature in °C, N is the number of amino acids, and x is a constant set 
at 2.5, which corrects for non-hydrogen bonded carbonyl groups.
5.2.4. Circular Dichroism in the presence of lipids
In separate experiments the aqueous peptide solutions (100 pM Mat-Ssfsg.
67, Mat-81f38-93 or CHIF38-72) were measured before and after tihating in 
SUVs of DMPC and DOPG (in a 2:1 molar ratio) to a final lipid to peptide 
molar ratio of 100:1. Spectra were recorded from 240 to 190 nm using a 
0.1 cm cuvette, a scan rate of 20 nm/min, and 8 scans per sample.
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5.2.5. Solution NMR
Two Mat-8168-72 NMR samples were prepared the first in 5% D2O and the 
second in 40% 2,2,2-Trifluoroethanol-c/j both made to a final volume of 
600 pL volume with distilled water. ID ’hi NMR, double-quantum filtered- 
correlation spectroscopy (DQF-COSY) and nuclear Overhauser effect 
spectroscopy (NOESY) experiments were performed by Dr. Igor 
Barsukov. Spectra collected on a 600MHz Bruker spectrometer equipped 
with TCI ciyo probe™. The number of scans collected for each experiment 
type were 32 (ID lU NMR), 16 (DQR-COSY) and 48 (NOESY). All 
experiments were performed at 20°C and collected with Watergate pulse 
sequence to minimise the intensity of the water peak. The NOESY mixing 
time was 100 ms.
5.2.6. Bioinformatics
5.2.6.I. Bioinformatic analysis of PLM and long form Mat-8
The potential binding motif was discovered using DiLiMOT (Neduva ei
al., 2005) which searches several proteins simultaneously for over­
represented peptide patterns. Secondary structure was predicted by psipred 
(Jones, 1999) which analyses the output of a Position-Specific Iterated 
BLAST (PSIBLAST) (Altschul et al., 1997), with two feed-foiward neural 
networks to predict the secondaiy structure of the given protein. 
Disordered regions of PLM and long form Mat-8 were predicted with meta
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protein disorder prediction System metaPrDOS (Ishida and Kinoshita, 
2008) which uses seven disorder predictors which incorporate several 
methods to predict disorder including physiochemical properties reflecting 
ammo acid composition such as high-net charge, low hydrophobicity, 
and/or low sequence complexity.
S.2.6.2. Bioinformatic analysis of the Na+, K -ATPase to determine 
possible peptide binding sites.
The sequences of the Na+, K+-ATPases known to contain FXYD proteins 
were aligned with MUSCLE (multiple sequence comparison by 
log-expectation (Edgar, 2004)). The MUSCLE alignment file and the spiny 
dogfish rectal gland Na+, K+-ATPase structure (PDBID: 2ZXE (Shinoda et 
aL, 2009)) was analysed with consurf (Glaser et al., 2003; Landau et a!., 
2005; Ashkenazy et al, 2010) to determine conserved patches on the 
surface of the Na+, K+-ATPase. Consurf works by using the MUSCLE 
alignment file to calculate conservation scores and creates a colour coded 
pdb file to highlight the most and least conserved regions of the protein. 
Three methods to determine potential peptide binding sites were utilised. 
The first of these methods is surface triplet propensities (STP) (Mehio et 
al, 2010) which analyses triplets of adjacent surface atomic groups that 
can be touched simultaneously by a probe sphere representing a solvent 
molecule. The second method used was InterProSurf (Negi et al, 2007) 
which analyses the solvent accessible surface area of amino residues of the
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protein of interest (spiny dogfish rectal gland Na+, K+-ATPase was used) 
and uses a propensity scale for interface residues and a clustering algorithm 
to identify surface regions with residues of high interface propensities 
which are therefore likely candidates for peptide binding. The final method 
used was meta-PPSIP (Qin and Zhou, 2007) which combines three 
methods that utilise sequence conservation in different ways to find 
consensus residues that are possible peptide docking sites. These methods 
include solvent accessibilities, secondary structure and sequence 
conservation.
S.2.6.3. Docking the binding motif of PLM and long form Mat-8 to the 
Na+, K+-ATPase.
Two main methods were employed to predict sites for individual amino 
acids in the binding motif of PLM and long form Mat-8 produced by 
DiLiMOT ((Neduva et al, 2005) 5.2.6.1). The first method is Pepsite 
(Petsalaki et al, 2009) which predicts sites on the protein of interest (i.e. 
spiny dogfish rectal gland Na+, K+-ATPase) by capturing the preferred 
environment for each selected amino acid in an inputted motif from a 
database of protein/peptide structure. Pepsite will also try to string together 
the predicted sites of the amino acids in the motif in sequence with 
additional distance constraints. The second method utilised Anchorsmap 
(Ben-Shimon and Eisenstein, 2010) which contains an algorithm which 
predicts the likelihood of a specified amino acid binding to a specific site. 
The algorithm has two stages. The first stage is a geometry based stage, in
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which sub-pockets which could potentially bind single side chains are 
detected and amino acid probes are scattered near them. The second stage 
is an energy based stage in which optimal positions of the probes are 
calculated through repeated energy minimisation and clustering of nearby 
calculated orientations after which their AG are calculated which gives an 
idea of the probability of an identified binding site being real.
5.3. Results
5.3.1. Determination of secondary structure of the cytoplasmic region 
of FXYD proteins.
5.3.1.1. Circular Dichroism
Circular Dichroism (CD) is a technique that detects left and right circular 
polarised light after being applied to an optically active chiral molecule 
such as a protein. At any given wavelength of light the absorption of left 
and right polarised light by the protein will be different. This gives rise to 
molar ellipticity which is detected over a range of wavelengths in the UV 
range. Proteins that are predominantly a-helix (Holzwarth and Doty, 1965), 
P-sheet (Greenfield and Tasman, 1969) or random coil (Venyaminov et al, 
1993) all have unique CD spectral signatures as shown in Figure 5.2. 
Spectra of proteins with unknown secondary structure can be compared to 
these spectral signatures to understand the structural content present.
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Figure 5.2. Far-UV CD spectral signatures of different secondary structure types.
Figure adapted from (Greenfield, 2007). Note the characteristic differences between 
different states. Random coil exhibits negative CD at -195 nm, P-sheet exhibits negative 
CD at 215 nm and a-helix shows a double dip at 205 and 220 nm.
Peptide representing the cytoplasmic region of PLM (PLMsg^) has 15% 
a-helical content in 40% TFE (Figure 5.1b.) as revealed in CD experiments 
(Clayton et al, 2005). The secondary structure of the cytoplasmic peptides 
Mat-8sf38-67 (Figure 5.3.), Mat-81f38-93 (Figure 5.4.) and CHIF38-90 (Figure 
5.5.) were analysed here using CD and the calculated percentage helical 
content of each at different TFE v/v concentrations of 0%, 10%, 20%, 30% 
and 40% are shown in Table 5.1. The spectra suggest that the cytoplasmic 
region of Mat-8sf is disordered in both 0% and 40% TFE whereas the
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cytoplasmic region of CHIP has around 7% a-helix induced by 40% TFE 
which is much lower than reported when full length PLM was solubilised 
in SDS micelles (Franzin et ah, 2007a) in which it has around 50% a- 
helical content. Although the spectra for Mat-81f38-93 suggests that it 
undergoes a much larger structural change than CHIF38-69 upon addition of 
40% TFE this actually only equates to around 8% a-helical content when 
the number of amino acids are taken into account. For Mat-81f38-93, a 55 
amino acid peptide, this equates to approximately 4 amino acids forming 
an a-helix. It is possible therefore, that the extra amino acids in the 
cytoplasmic region of long form Mat-8 contain a small helix which could 
be responsible for the lipid binding and Na+, K+-ATPase regulating 
features of long form Mat-8 presented in Chapter 3 that are not observed in 
short form Mat-8.
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Figure 5.3. Far UV CD measurements of Mat-Ssfjg.oy over a range of TFE 
concentrations. Spectra are shown for 50 pM Mat-8sf3Mi7 over a 195-240 nm range of 
wavelengths at 4°C. Data smoothed with adjacent averaging (20 pts).
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Figure 5.4. Far UV CD measurements of Mat-Slfj^ over a range of TFE 
concentrations. Spectra are shown for 50 pM Mat-81f38_93 over a 195-240 nm range of 
wavelengths at 4°C.
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Figure 5.5. Far UV CD measurements of CHIFsg.^ over a range of TFE 
concentrations. Spectra are shown for 50 pM CHIFjg^g over a 195-240 nm range of 
wavelengths at 4°C. Data smoothed with adjacent averaging (20 pts).
Table 5.1. Calculated percentage o-helical content in different cytoplasmic peptides
at various TFE concentrations.
% TFE Mat-Ssfsg-e?
Peptide
Mat-SIfas-go CHIF38-69
0 2.2 3.0 4.3
10 2.4 3.6 4.2
20 3.5 4.6 4.7
30 3.6 6.5 6.1
40 0.2 7.7 7.3
5.3.1.2. Solution NMR of Mat-81f38.93
The NMR spectra of PLM38-72 in solution has been determined (Hughes et. 
al, unpublished data). A similar strategy was employed to attempt to gain
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further insight into the structure of the cytoplasmic region of the long form 
Mat-8 given its observed cx-helical content in 40% TFE. Initially ID ’H 
NMR was performed in both 5% 2H20 and 40% 2,2,2-trifluoroethanol-Jj. 
to reduce the intensity of solvent signals. Figure 5.6 shows the results of 
the ID ’H NMR and an example spectra indicating where each chemical 
shift type is expected for a protein exhibiting elements of both p-shcet and 
a-helix secondary structure. In random coil protein spectra the chemical 
shift dispersion is somewhat reduced by the near-equivalent environments 
of the various nuclei. Many additional peaks and greater peak dispersion 
are observed upon addition of TFE from 9-5 ppm where backbone HN 
chemical shifts are observed suggesting an induction of secondary structure 
upon addition of TFE.
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Figure 5.6. Comparison of ID ’H solution NMR of Mat-81f38.93 with 5% 2H2Q and 
40% TFE. Example spectra (a) shown to indicate locations of different ’H chemical 
shifts. (Cavanagh et al, 2007). (b) 5% 2H20 (black) shown below 40% TFE spectra (blue). 
Spectra are the result of accumulating 32 scans at 20°C.
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The ID NMR spectrum is too complex to assign due to the number of 'H 
signals observed leading to high levels of overlap between signals. 
Therefore the two dimensional homonuclear method was attempted 
(Wuthrich, 1986). ]H ’H COSY NMR is a homonuclear 2D NMR 
experiment which allows identification of two nuclear spins that are 
coupled to each other by 3 bonds. There are two types of peak in a COSY 
spectra. Peaks appearing along the diagonal of the plot and correspond to 
the peaks on a ID NMR experiment. Cross peaks off the diagonal result 
from magnetisation transfer between two coupled nuclei and give rise to 
two symmetrical peaks above and below the diagonal each of which has 
two chemical shift components from the two coupled nuclei. The 
experiments presented here use a DQF which reduces the single quantum 
transitions and hence width of the diagonal enabling greater resolution. 
Characteristic of this spectrum is the presence of harlequin shape of the 
peak comprising two positive and two negative sign contributions. Figure 
5.8 shows the results of the DQF-COSY and an example SQF-COSY 
spectra indicating where each chemical shift type is expected is shown in 
Figure 5.7. Figure 5.9 shows the NH-aH region where backbone H signals 
are expected. For a 55 amino acid peptide all non-proline amino acids 
should give rise to a NH-Ha, unfortunately in the spectra shown this is 
clearly not the case. Therefore there is potential line broadening of signal 
due to chemical exchange of labile NH which prevents a foil assignment 
being made.
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Figure 5.7. Example COSY spectra of neuropeptide Y to indicate locations of 
different ’H chemical shifts. Figure taken from (Bader et al., 2008). The boxes indicate 
the following signals:
(a) all non-labile, non-aromatic sidechain protons except those from pH -yCH3 of Thr, 8H- 
5H of Pro and PH-pH of Ser.
(b) aH-pCH3 of Ala and pH-y CH3of Thr.
(c) aH-pH of Val, He, Leu, Glu, Gin, Met, Pro, Arg, and Lys.
(d) aH-PH of Cys, Asp, Asn, Phe, Tyr, His and Trp.
(e) ctH-aH of Gly,aH-pH of Thr,8H-5H of Pro,aH-pH and pH-pH of Ser.
(f) aromatic ring protons, including 2H-4H of His, as well as sidechain protons from Asn 
and Gin.
(g) backbone NH-aH.
(h) 5 CH2-eNH of Arg
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Figure 5.8. Comparison of 2D DQF-COSY solution NMR of Mat-SIf,^ with 5% 
2H20 and 40% TFE. 5% 2H20 (black) shown above 40% TFE spectra (blue). Spectra are 
the result of an accumulation of 16 scans at 20°C. ID projections of 2D spectra are shown 
top and left.
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Figure 5.9. Comparison of 2D DQF-COSY of NH-Ha correlation of Mat-Slfj^ with 
5% 2H20 and 40% TFE. 5% 2H20 (black) shown alongside 40% TFE spectra (blue). ID 
projections of 2D spectra are shown top and left.
Where COSY helps identify chemically bonded nuclei up to 3 bonds, 
NOESY instead connects nuclear spins that are spatially close in proximity 
regardless of the number of bonds separating them. Spectra appear similar 
with diagonal peaks and cross peaks and the technique of sequential
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walking combines COSY and NOESY to assign peaks based on their 
through-bond coupled partner nuclei and spatially coupled partner nuclei 
respectively. Figure 5.11 shows the ‘H ’ll NOESY of Mat-81f38-93 and an 
example spectra indicates (Figure 5.10) where each chemical shift type is 
expected. This reveals how even with a Watergate pulse sequence the aH 
region is masked by the signal from water preventing Mat-81f38-93 peaks 
being observed in this region. Figure 5.12. shows the NH-CH3 region and 
although assignment is not possible there is a clear broadening of peaks in 
this region upon addition of TFE and the quantity of observed NOEs 
increases. This together with the increased signal dispersion suggests a 
small but substantial induction of structure.
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Figure 5.10. Example NOESY spectra of protein D (phage envelope protein) to 
indicate locations of different ’H chemical shifts. Figure taken from (Bader et al, 2008). 
The boxes indicate the following signals:
(a) NH; aromatic - NH; aromatic-aromatic.
(b) NH; aromatic - aH; 8H of Pro; pH of Ser and Thr.
(c) NH; aromatic - aliphatic sidechains.
(d) aH; 5H of Pro; pH of Ser and Thr - aH; 8H of Pro; pH of Ser and Thr.
(e) aH; 8H of Pro; PH of Ser and Thr - aliphatic sidechains.
(f) Aliphatic sidechains - aliphatic sidechains.
(b) 5% 2H20 (black) shown below 40% TFE spectra (blue). Spectra collected on 600MHz
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Figure 5.11. Comparison of 2D 'll 'h NOESY solution NMR of Mat-Slfa^ with 5% 
2H20 and 40% TFE Spectra are the result of an accumulation of 48 scans at 20°C, ID 
projections of 2D spectra are shown top and left.
205
2H20 and 40% TFE. 5% 2H20 (black) shown alongside 40% TFE spectra (blue). Number 
and dispersion of peaks increases when TFE has been added. Cross peaks between NH
region 7-8.2 ppm and CH3 region 0.8-2.6 ppm. ID projections of 2D spectra are shown top 
and left.
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5.2.2. The effect of SDS on the structure of the cytoplasmic region of 
PLM
The CD data and solution NMR data suggest that the cytoplasmic region 
long isoform of Mat-8 contains a small quantity of a-helical content not 
present in the short isoform. This a-helix could be responsible for the 
inhibition of the Na+, K+-ATPase reported in Chapter 3. As PLM and the 
long form of Mat-8 are the only FXYD proteins known to have a 
cytoplasmic region that inhibits the Na+, K+-ATPase it is possible they 
share a small a-helical motif that is responsible for this inhibition. As there 
is no solved structure for long form Mat-8 any modelling studies to 
investigate this possibility would have to be performed using the structure 
of PLM (Teriete et a!., 2007). The full length structure is limited as it was 
solved in highly negatively charged SDS micelles which are not indicative 
of the slightly negatively charged phospholipid bilayer of cell membranes. 
This highly negatively charged environment may induce additional 
secondary structure over what is observed in vivo. From CD data the 
percentage of a-helix in the cytoplasmic region of PLM has been 
calculated as 15% (Clayton et al., 2005) which is double that what is 
observed in the SDS structure. With this contradiction in mind experiments 
were undertaken to asses to validity of the PLM structure for use in 
bioinformatics studies.
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To investigate the possibility of SDS inducing a-helical content further CD 
experiments were performed on PLMag^. Two sets of experiments were 
performed. The first was PLM38-72 in water with and without SDS at 
500 mM; the same concentration used in the full length solved structure 
(Figure 5.13.). The second was in the presence of 40% TFE again with and 
without 500 mM SDS (Figure 5.14.). The percentage a-helical content 
calculated is shown in Table 5.2 calculated by the equation discussed in the 
methods (5.2.3.). Without SDS, the calculated a-helical content agrees with 
the published data (Clayton et al, 2005) as there is effectively no a-helix 
before addition of 40% TFE after which 15% helix is observed. 
Interestingly, SDS appears to induce around 9% a-helix to a PLM38-72 
sample in H20. When SDS is added to PLM38.72 with 40% TFE there is a 
combined effect as an additional 6% helical content is observed in 40% 
TFE with SDS over 40% TFE alone. This strongly suggests that the highly 
negative charge of SDS induces a-helical content that may not be 
indicative of full length PLM in a cell membrane.
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Figure 5.13. Far UV CD measurements of PLMs^ in water with and without SDS.
Spectra are shown for 50 pM PLM38_72 over a 195-240 nm range of wavelengths at 4°C 
with and without 500 mM SDS.
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Figure 5.14. Far UV CD measurements of PLIVU^ in 40 % TFE with and without 
SDS. Spectra are shown for 50 pM PLM3g_72 over a 195-240 nm range of wavelengths at 
4°C with and without 500 mM SDS.
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Table 5.2. Calculated percentage of a-helical content in PLM38.72 at 0 and 40% TFE 
concentrations with and without SDS.
% TFE PLM38-72 PLM38-72 + SDS
0 3^4 93
40 14.8 20.5
The structural data shown so far in this chapter reveal that all of the 
cytoplasmic FXYD peptides tested, PLM38-72 has the largest amount of a- 
helical content, which is interesting since it also had the greatest effect on 
Na+, K+-ATPase activity (Chapter 3). The current knowledge for the full 
structure of PLM is limited as it has only been solved in SDS micelles 
(Teriete et al., 2007). Additionally the CD data shown here reveals that 
there is an additional 5% a-helix present in PLM38-72 that is induced by 
SDS. However, recent data reveal that a-helical structure can also be 
induced in PLM38-72 by negatively charged phospholipid bilayers (Hughes 
et al, 2011). This means that the true a-helical content of PLM38-72 is most 
likely higher than observed in CD in the absence of phospholipids but 
lower than that observed in SDS micelles due to the presence of high 
negative charge. The differences are relatively small however, therefore the 
current structure of PLM in SDS micelles is probably similar to its actual 
structure in cell membranes. This makes it suitable for use in bioinformatic 
modelling provided the possibility of lower a-helical content is taken into 
account when interpreting results. Mat-81f38-93 was the only other 
cytoplasmic FXYD peptide studied that also had an effect on the activity of
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the Na+, K+-ATPase (Chapter 3). In this chapter CD and solution NMR 
revealed Mat-81f38.93 contains a small amount of a-helical content that is 
not present in Mat-Ssfss-e?. This could mean that the additional 26 amino 
acids of Mat-81f38.93 contribute to the increase in a-helix and that this is 
responsible for the inhibition of the Na+, K+-ATPase. As the cytoplasmic 
regions of both PLM and the long isoforms of Mat-8 are found in similar 
locations relative to the Na+, K+-ATPase it is possible that they bind to the 
same site on the protein surface. PLM and long form Mat-8 were therefore 
further analysed by bioinformatics to test this possibility.
5.3.3. Bioinformatics
5.3.3.1. Determination of possible Na+, K+-ATPase binding motif in 
PLM and long form Mat-8.
In order to determine how the cytoplasmic region of PLM and long form 
Mat-8 may interact with the Na+, K+-ATPase several bioinformatical 
strategies were employed. Firstly DiLiMOT (Neduva et al., 2005) was 
used to search for a possible linear binding motif. PLM and long form 
Mat-8 (Figure 5.15.), were searched for a possible convergently evolved 
motif that interact with the Na+, K+-ATPase with other proteins known to 
interact with the Na+, K+-ATPase which included adducin (Ferrandi et al, 
1999), sarcoma (SRC (Tian et al., 2006)), Phosphoinositide-3 kinase (PI3K 
(Yudowski et al, 2000)) and ankyrin (Ank (Devarajan et al, 1994)).
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Phospholemman
MASLGHILV FCVGLLTMAK AESPKEHDPF TYDYQSLQIG GLVIAGILFI 
10 20 30 40
LGILIVLSRR CRCKFNQQQR TGEPDEEEGT FRSSIRRLST RRR 
50 60 70 80 90
Long form Mat-8
MQKVTLGLL VFLAGFPVLD ANDLEDKNSP FYYDWHSLQV GGLICAGVLC 
10 20 30 40
AMGIIIVMSE WRSSGEQAGR GWGSPPLTTQ LSPTGAKCKC KFGQKSGHHP
50 60 70 80 90
GETPPLITPG SAQS
100 110
Figure 5.15. Sequences of PLM and long form Mat-8 used in bioinformatics 
studies. Colour scheme as follows: signal peptide (red), extracellular domain (green), 
transmembrane domain (blue) and cytoplasmic domain (purple).
This discovered the motif SxxRxS found in PLM (residues 63-68 SIRRLS) 
and long form Mat-8 (residues 38-43 SEWRSS) as well as adducin, SRC, 
P13K but not Ank (Appendix B). The instances of the motif in these 
proteins can be seen in the alignment below (Figure 5.16.)
PI3K
SRC
Long form Mat-8 
PLM
Adducin
VYE
KD.
I Vi
FRS
GTC
SGPRKS
QRRRS
EWRSS
SIRRLS
SPLRHS
VIP
LEP
GEQ
TRR
FQK
Figure 5.16. Instances of the SxxRxS motif in proteins studied. Alignment of the
amino acids in and around the predicted Na+, K+-ATPase motif in the proteins studied
by DiLiMOT. Box indicates location of SxxRxS motif.
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DiLiMOT calculated an SCons value (which is the product of all binomial 
probabilities from the genomes considered) of 5.94e'08 and a P value of 
1.03e06. The P value is much below 0.001 suggesting the occurrence of the 
motif is statistically significant. However the Scons value is above the 
7.0x1 O'38 cut off value quoted by DiLiMOT for humans. This is due to the 
limited number of proteins used in the experiment but it can still be 
considered a hypothetical motif. For all the proteins used in this instance 
there is experimental evidence confirming that they interact with the Na+, 
K+-ATPase.
Interestingly, the SxxRxS motif this incorporates Ser 68 of PLM which, as 
discussed in Chapter 3 is a phosphorylation site which reduces the 
inhibitory effect on the Na+, K+-ATPase when phosphorylated. Chapter 3 
also discussed how the corresponding serine in long form Mat-8 could 
possibly be phosphorylated. Long form Mat-8 has so far only been 
discovered in humans however PLM has been characterised in cow, dog, 
human, mouse, rat, western clawed frog and African clawed frog 
(Crambert et al., 2002). The instance of the motif SIRRLS is identical in 
all these species with the exception of the western clawed frog which has 
the leucine substituted for a methionine. Crucially the SxxRxS is conserved 
through all species as conservation is described as a key feature of short 
linear motifs (Davey et al., 2012).
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Secondary structure data are available for PLM (Teriete et al, 2007) as it 
has had its full structure solved in SDS micelles. No residue-specific 
secondary structure information is available for long form Mat-8. 
Therefore secondary structure was predicted for both PLM (Figure 5.17. to 
use in parallel with the experimental data) and long form Mat-8 (Figure 
5.18.) using psipred (Jones, 1999). In both cases the SxxRxS motif is 
predicted to occur at the end of an a-helix. The a-helical content of the 
cytoplasmic region of PLM is predicted to be approximately 30% which 
would agree with the SDS micelle structure of PLM (Teriete et al, 2007). 
The disorder predictor metaPrDOS predicts that the instance of the 
SxxRxS motif in PLM is disordered (Figure 5.19.) whilst it is predicted to 
be ordered in long form Mat-8 (Figure 5.20.). This may suggest that in 
solution the motif in PLM is disordered but in the native environment of 
the membrane surface and the Na+, K+-ATPase could form ordered 
secondary structure.
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Figure 5.17. Predicted secondary structure of PLM. Figure produced using psipred. 
Location of SxxRxS motif is underlined in red.
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Figure 5.18. Predicted secondary structure of long form Mat-8. Figure produced using 
psipred. Location of SxxRxS motif is underlined in red.
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Figure 5.19. metaPrDOS prediction of disorder in PLM. metaPrDOS predicts disorder 
by detennining the mean values of disorder tendency predicted by several methods. It 
predicts SxxRxS to be disordered. Location of motif indicated by arrow.
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Figure 5.20. metaPrDOS prediction of disorder in long form Mat-8. metaPrDOS
predicts disorder by detennining the mean values of disorder tendency predicted by 
several methods. It predicts SxxRxS to be ordered. Location of motif indicated by arrow.
5.3.3.2. Determination of possible peptide binding sites on the surface 
of the Na+, K+-ATPase
After identifying a possible Na+, K+-ATPase binding motif in PLM and 
long form Mat-8, the Na+, K+-ATPase structure was analysed to try and
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find potential binding sites for the motif. When considering these methods 
it is important to consider the position of the membrane in respect to the 
Na+, K+-ATPase as the cytoplasmic region of both PLM and long form 
Mat-8 can only viably interact with the cytoplasmic region of the Na+, K+- 
ATPase. Figure 5.21. shows the position of the cell membrane as predicted 
by the orientations of proteins in membranes (OPM) database (Lomize et 
al, 2006) which has been verified with experimental data with several 
membrane proteins. This and all subsequent data in this chapter is 
produced using spiny dogfish rectal gland Na+, K+-ATPase ((Shinoda et 
al, 2009) PDBID:2ZXE).
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Figure 5.21. Membrane location relative to the Na+, K+-ATPase. The location of the 
membrane relative to the Na+, K+-ATPase as calculated by OPM is shown above in two 
different views where the orientation on the right is rotated 180° about the y axis from the 
structure on the left. The cytoplasmic membrane surface is in blue whilst the extracellular 
membrane surface is in red.
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Initially, the Na+, K+-ATPase was analysed for sequence conservation. The 
likelihood of a potential binding site being real is increased when it is 
conserved through many species. The a-subunit sequence of spiny dogfish 
rectal gland Na+, K+-ATPase was aligned using MUSCLE to all other 
instances of the Na+, K+-ATPase that were from species which are known 
to express FXYD proteins. ConSurf was used to calculate a conservation 
measure which it mapped to the structure of the Na+, K+-as shown in 
Figure 5.22. Due to the relatively small number of species that are known 
to express FXYD proteins high conservation is observed in the majority of 
the Na+, K+-ATPase which means it is not particularly useful for finding 
peptide binding sites.
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Figure 5.22. Conservation analysis of the Na+, K+-ATPase using Consurf. All
instances of the Na+, K+-ATPase in species which are known to express FXYD proteins 
were aligned and analysed using Consurf. The Consurf colour scheme is shown with a 
score of 1 being least conserved and a score of 9 being most conserved. The cytoplasmic 
membrane surface is indicated by a dotted blue line whilst the extracellular membrane 
surface is indicated by a dotted red line.
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Three servers were used to try and determine possible binding sites for 
peptides on the surface of the Na+, K+-ATPase. Prosurf (Figure 5.23.) only 
identified sites within the transmembrane region of the Na+, K+-ATPase 
which is inaccessible to the motif which lies in the cytoplasmic region of 
PLM and long form Mat-8. It appears the majority of sites identified are in 
the regions where the a-subunit of the Na+, K+-ATPase is in close 
proximity of FXYD 10 and the [3-subunit of the Na+, K+-ATPase 
suggesting their interactions are preventing other potential sites being 
discovered by this method. PPISP (Figure 5.24.) has predicted the majority 
of its sites in the negatively charged cavity (Reyes and Gadsby, 2006) 
located within the transmembrane domain. There are some predicted sites 
above this cavity which lie above the membrane surface. Finally STP 
(Figure 5.25.) was also used and predicts the majority of sites throughout 
the transmembrane region most likely due to its hydrophobicity. It does 
predict certain sites in the cytoplasmic region of the Na+, K+-ATPase to be 
more likely binding sites for peptides than others which may become 
significant when combined with other methodologies.
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Figure 5.23. Analysis of the Na+, K+-ATPase for potential non-specific peptide 
binding sites by Prosurf. The residues determined by Prosurf to be potential peptide 
binding sites are coloured in red. The a-subunit of the Na+, K+-ATPase is in green, the 0- 
subunit is in cyan and FXYD10 is in magenta. The cytoplasmic membrane surface is 
indicated by a dotted blue line whilst the extracellular membrane surface is indicated by a 
dotted red line.
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Figure 5.24. Analysis of the Na+, K+-ATPase for potential non-specific peptide 
binding sites by metaPPISP. The residues determined by metaPPISP to be potential 
peptide binding sites are coloured in red. The a-subunit of the Na+, K+-ATPase is in green, 
the P-subunit is in cyan and FXYD10 is in magenta. The cytoplasmic membrane surface is 
indicated by a dotted blue line whilst the extracellular membrane surface is indicated by a 
dotted red line.
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Figure 5.25. Analysis of the Na+, K+-ATPase for potential non-specificpeptide 
binding sites by STP. STP was used to analyse the surface of the Na+, K+-ATPase for 
potential binding sites. The colour scheme is indicated on a scale of 0-100 where 100 is the 
most likely. Surface is shown semi transparent to show locations of all subunits of the Na+, 
K+-ATPase. The cytoplasmic membrane surface is indicated by a dotted blue line whilst 
the extracellular membrane surface is indicated by a dotted red line.
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S.3.3.3. Determination of specific motif binding locations in the Na+, 
ICV&TPase.
Two methods were employed to try to find more specific binding locations 
for the SxxRxS motif on the Na* K+-ATPase. As these methods are more 
specific the size of the input file is limited. For this reason, and to reduce 
the number of false positives the PDB structure of the Na+, K+-ATPase had 
portions of amino acids removed from the structure. These included the 
entire FXYD10 and (3-subimit of the Na+, K+-ATPase and regions of the a- 
subunit of the Na+, K+-ATPase inaccessible to the cytoplasmic region of 
PLM which included the extracellular region, part of the transmembrane 
region towards the extracellular side of the membrane and parts of the 
cytoplasmic region furthest from the cell membrane. The first software 
utilised on this new structure was PepSite. This software finds binding 
pockets and attempts to string together a given sequence of amino acids in 
the binding pocket ensuring each amino acid lies in a suitable environment 
and the sites lie spaced with separations compatible with the inputted motif 
sequence. However, it can often lead to unrealistic results. For example it 
can string together two sites that are close in space but are located at 
opposite sides of the protein. PepSite often erroneously uses the same 
potential amino acid binding site twice when there are two instances of the 
same amino acid in an inputted motif. Figure 5.26 reveals all the potential 
ammo acid binding sites uncovered on the Na+, K+-ATPase for the SxxRxS 
motif in PLM and long form Mat-8. For PLM all potential amino acid
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binding sites were in the transmembrane region, therefore inaccessible to 
the cytoplasmic region of PLM. In long form Mat-8 all but one sites 
calculated are also in the transmembrane region. The one site that is in the 
cytoplasmic region is for an arginine residue and is located above the 
negative cavity suggested as a possible alternative orientation (Teriete et 
ah, 2009). Many of the sites in both cases are at the base of the structure 
where regions of the original structure have been removed. This suggests 
that by using a structure altered in this way creates false binding sites.
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PLM potential binding sites Long form Mat-8 potential binding sites
Figure 5.26. PepSite results for altered Na+, K+-ATPase structure. PepSite was used to 
find binding sites for the amino acid residues in the motifs discovered in PLM (S1RRLS) 
and long form Mat-8 (SEWRSS). The region of the protein analysed is indicated by the 
blue mesh. All predicted binding sites are indicated by red spheres. The cytoplasmic 
membrane surface is indicated by a dotted blue line whilst the extracellular membrane 
surface is indicated by a dotted red line. This means only one site (indicated by arrow) is 
above the membrane surface.
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Anchorsmap was used on the same edited Na+, K+-ATPase structure. 
Ancliorsmap finds smface only sites for given amino acids. Unfortunately 
serine is not compatible with this method due to its small sidechain. 
Isoleucine also did not work with Anchorsmap due to technical problems 
with the presently distributed version of the software. Therefore arginine 
(present in both SIRRLS of PLM and SEWRSS of long form Mat-8), 
leucine (present in SIRRLS of PLM) and glutamate and tryptophan (both 
in SEWRSS of long form Mat-8) were inputted into Anchorsmap. Figure 
5.27. and 5.28 show the top 200 sites calculated by this method. As serine 
could not be used with this method the arginine data is most important, as 
it is the only residue present in all instances of the SxxRxS motif that can 
be detected by Anchorsmap. PLM also has an additional arginine site in the 
motif over long form Mat-8 which could explain its increased effect on 
Na+, K+-ATPase activity due to a higher charge affinity. Interestingly there 
are two major clusters of arginine sites that are circled in all figures. With 
the exception of glutamate in one of these sites there are possible sites for 
all other amino acids in these clusters. They are two possible candidates of 
docking locations that agree with the current model (Teriete et al., 2009).
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Leucine
Arginine
Figure 5.27. Predicted sites for leucine and arginine determined by Anchorsmap. In
both cases the top 200 predicted sites are shown with a spectral colour scheme indicating 
probability with blue being the most likely and red being the least likely. Blue dotted lines 
indicate the cytoplasmic membrane surface.
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Glutamate
Figure 5.28. Predicted sites for glutamate and tryptophan determined by 
Anchorsmap. In both cases the top 200 predicted sites are shown with a spectral colour 
scheme indicating probability with blue being the most likely and red being the least 
likely. Blue dotted lines indicate the cytoplasmic membrane surface.
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S.3.3.4. Determining possible orientations of the motif within the Na+, 
K+-ATPase.
Not only are the two clusters of arginine sites in close proximity of other 
amino acid sites in the Mat-8 and PLM motif but they are also conserved 
(Figure 5.22.). One cluster is also in close proximity of the arginine site in 
the cytoplasmic region of the Na+, K+-ATPase determined by PepSite 
(Figure 5.26.) and several cytoplasmic sites determined by metaPPISP 
(Figure 5.24.). Using these data the helix solved in the cytoplasmic region 
of PLM by NMR in SDS micelles (Teriete et ah, 2007) and the 
unstructured amino acids at the C-terminus was successfully docked into 
one of these sites using PyMol (Figure 5.29). This reveals potential 
interactions of the positive sidechains of arginine residues in PLM with 
negative sidechains of glutamate and aspartate residues located at the N- 
terminus of helix M5 of the Na+, K+-ATPase. The sidechains of the 
arginines required no manipulation for this interaction with the exception 
of Arg 66 for which a veiy small adjustment of one of the most common 
arginine sidechain rotamers from the backbone-dependent rotamer library 
in PyMol. These interactions could feasibly be weakened upon 
phosphorylation of Ser 63 and/or Ser 68 due to the removal of positive 
charges. It also reveals the surfaces of both PLM and the Na+, K+-ATPase 
are sterically compatible at this site. Finally the positively charged 
sidechains of the unstructured arginine residues can also simultaneously 
interact with negatively charged cell membranes in this conformation.
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Figure 5.29. Proposed orientation of the a-helix in the cytoplasmic region of PLM
The helix of PLM is shown in blue with its arginine residues highlighted in red. 
Negatively charged residues in the Na+, K+-ATPase are shown in purple with side chains 
represented by sticks. Blue dots indicate membrane surface. 3D image shown in cross­
eyed stereo.
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The surface of the other possible site is shown in Figure 5.30. The arginine 
binding site is located in a very small pocket which is therefore 
incompatible with an a-helix. This is also true in the recently solved 
structure in a different conformation also shown on this figure (Yatime et 
gL) 2011) where the pocket is even smaller. It therefore seems unlikely that 
the alternative orientation due to Ser 68 phosphorylation of PLM 
corresponds to what is proposed in the model.
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Figure 5.30. Predicted arginine binding sites on the surface of the Na+, K+-ATPase 
Although several sites are predicted in a pocket which lies above the membrane surface in 
a location similar to the proposed alternative orientation after phosphorylation of Ser 68 
(top image) this pocket is sterically incompatible with an a-helix. An alternative Na+, K+- 
ATPase conformation (Yatime et al., 2011) has an even smaller pocket (bottom image) 
making the interaction less likely. Cytoplasmic membrane surface indicated by dotted blue 
line.
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5.4. Discussion
In this chapter several practical and bioinformatics methods have been 
employed to gain further insights of structural details of the cytoplasmic 
region FXYD proteins in the absence of any solved stractmes in either 
lipid bilayers or native cell membranes.
Currently, the y-subunit of the Na+, K+-ATPase in pig (Morth et al., 2007) 
and FXYD 10 in shark (Shinoda et al, 2009) are the only FXYD proteins 
to have a frill structure solved in native membranes whilst in complex with 
the Na+, K ' -ATPasc. As both of these FXYD proteins have no cytoplasmic 
region it is difficult to determine how the cytoplasmic regions of other 
FXYD proteins may function in the absence of a structure of the Na+, K+- 
ATPase in complex with a FXYD protein such as PLM which does have a 
cytoplasmic region. PLM (Teriete et al., 2007) and CHIF (Franzin et al, 
2007d) do have full structures solved and short form Mat-8 has secondary 
structure solved (Franzin et al, 2007a) in SDS micelles in tire absence of 
the Na+, K+-ATPase. SDS micelles are not representative of a cell 
membrane as they form a monolayer rather than a bilayer. This chapter 
also reveals that SDS micelles induce additional a-helical content in the 
cytoplasmic region of FXYD proteins (Figure 5.11. and Figure 5.12.). This 
is likely due to the highly negative charge present in SDS. As phospholipid 
membranes with a 33% negative charge have been revealed to induce a- 
helix in PLM38-72 (Hughes et a/., 2011) it is feasible that native membranes
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that have around an overall 12.5% negative charge (Akio, 1971) will also 
induce a-helical content in PLM38-72. This suggests the true helical content 
is only probably slightly lower than observed in the foil length PLM NMR- 
structure solved in the presence of SDS micelles. This means the structural 
data are suitable for modelling discussed later.
TFE induces helical content in synthetic peptides only when they have the 
natural propensity to do so (Tamburro et al., 1968). This was observed to 
be approximately 15% in PLM38-72 (Clayton et al, 2005), 0% in short form 
Mat-838-67, 8% in Mat-81$8-93 and 8% in CHIF38-69 (Table 5.1.). This 
suggests that the binding to negatively charged lipids and inhibition of the 
Na+, K!-ATPase by cytoplasmic peptides observed in Chapter 3 is 
dependent on structure, as PLM38-72 binds more strongly to negatively 
charged membranes and inhibits the Na+, K+-ATPase more than any of the 
other peptides tested and has the highest helical content. Mat-81f38-93 also 
binds to negatively charged membranes and inhibits the Na1, K+-ATPase 
but to a lesser extent than PLM38-72 and has lower helical content. 
Mat-Ssfss-e?, which has no helical content, exhibits only very weak binding 
to negatively charged membranes and also has no effect on Na+, K+- 
ATPase activity. As Mat-8sf3s-67 and Mat-81f3 8-93 are identical apart from 
the insertion of an additional 26 amino acids in Mat-81f38-93 it can be 
hypothesised that the helical content in Mat-81f38-93 lies somewhere within 
this 26 amino acid insert. Mat-81f38-93 has also been analysed by solution
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NMR experiments to try and assign the apparent helical content and 
confirm this hypothesis (Figure 5.7.-Figure 5.10.). However, the number of 
peaks observed is clearly below the number of amino acids present in the 
peptide. The spectra do reveal an increased dispersion of signal upon 
addition of TFE and an increase of quantity of NOEs. Although this does 
not help determine which amino acids form the helical content it does 
support the CD data that measured a small amount of secondary structure 
content in Mat-81f3s-93. It is possible that the structure is unstable in 
solution and the cytoplasmic region of long form Mat-8 needs to be in a 
native environment in close proximity of lipid headgroups and the 
cytoplasmic region of the Na+, K+-ATPase.
Although the structure of PLM can be used to model the interaction of the 
cytoplasmic region of PLM with the Na+, K+-ATPase by replacing the co­
ordinates of a FXYD protein in a Na1, K+-ATPase solved structure like has 
been done with y-subunit of tire Nah, K+-ATPase in pig kidney (Teriete et 
al., 2009), this assumes the stracture of PLM will not be at all affected by 
the Na+, KH-ATPase. It is even more difficult to determine how the 
cytoplasmic region for long form Mat-8 as the only structural data 
available for it are the limited data presented in this chapter. Therefore a 
bioinformatic approach was taken to try to understand how the cytoplasmic 
region of both PLM and long form Mat-8 might interact with the Na+, K+- 
ATPase. As they are both FXYD proteins and have homologous
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transmembrane domains (Geering, 2006) it can be assumed they occupy 
the same relative location whilst in complex with the Na+, K+-ATPase as 
FXYD10 in spiny dogfish rectal gland Na+, K'-ATPase (Shinoda et aL, 
2009). This also increases the chance that the cytoplasmic region of both 
PLM and long form Mat-8 bind to the Na+, K+-ATPase at a similar site. 
With this hypothesis, DiLiMOT was used to discover a potential motif 
present in the cytoplasmic region of PLM, long form Mat-8 and several 
other proteins known to interact with the Na+, K+-ATPase. The sequence of 
this motif is SxxRxS and its occurrence are the residues SIRRLS in PLM 
and SEWRSS in long form Mat-8. In PLM the motif is predicted to be at 
the end of a helix as predicted by psipred (Figure 5.17.) and solved by 
solution NMR in SDS micelles (Teriete et ah, 2007). It is also predicted to 
be disordered by metaPrDOS (Figure 5.19.) but this could suggest it forms 
a stable helix upon binding cell membranes and/or the Na+, K+-ATPase. 
Indeed the frequency of short linear' motifs in predicted disorder regions is 
reported to be over 70% and it appears they have a propensity to form 
secondary structure upon interaction with an ordered protein (Fuxreiter et 
at, 2007). The motif in long form Mat-8 is also predicted to be at the end 
of a helix (Figure 5.18.) but is predicted to be ordered (Figure 5.20.). Due 
to the potential functionality of this motif it is possible these residues are 
responsible for the helical content of long form Mat-8.
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Several methods were employed to find potential binding sites for the 
motif on the surface of the Na+, K+-ATPase. Consurf revealed that the 
majority of the Na+, K+-ATPase is conserved in species which are known 
to express FXYD proteins. Although this is expected as relatively few 
species are known to express FXYD proteins it does limit the studies as 
finding conserved patches on protein surfaces is extremely helpful when 
finding binding sites (Figure 5.22.). Other methods to find potential peptide 
binding sites appeared to be limited due to the hydrophobic content of the 
transmembrane region skewing the data in the case of PPISP (Figure 5.24.) 
and STP (Figure 5.25.) whereas Prosurf (Figure 5.26.) only calculates sites 
that are involved in the interaction of the a-subunit of the Na+, K' -ATPase 
with the P-subimit and FXYD 10. Prosurf did reveal certain sites close to 
the membrane surface in the cytoplasm.
The specific amino acids found in the instances of the motif in PLM and 
long form Mat-8 were run locally on PepSite using a structure of the Na+, 
K+-ATPase with large regions removed as they are inaccessible to the 
cytoplasmic region of the Na+, K+-ATPase (Figure 5.26.). Unfortunately 
these data were again skewed by the transmembrane region. The Na+, K+ - 
ATPase structure inputted into PepSite had portions removed from the 
filed deemed inaccessible to the cytoplasmic region of PLM. This meant 
many potential binding sites were found in one region of the structure 
where part of the protein had been removed. This suggests these are false
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positives as PepSite treated it as the surface of the protein when in reality it 
is not. PepSite did reveal one potential arginine binding site near the 
membrane surface in the cytoplasm in a similar location to the sites 
determined by Prosurf. The altered Na1, K+-ATPase was also used with 
Anchorsmap with amino acids in the instances of the motif of SIRRLS in 
PLM and SEWRSS in long form Mat-8 (Figure 5.27-Figure 5.28.), with 
the exception of serine and isoleucine are incompatible with Anchorsmap. 
This revealed two potential locations for the docking of the motif to 
SIRRLS in PLM and SEWRSS in long form Mat-8. One orientation 
(Figure 5.29) puts the cytoplasmic helix in a site both sterically and 
electrostatically compatible with the Na+, K'!-ATPase and would only 
require a small change in orientation of the cytoplasmic region compared 
to the SDS micelle solved structure (Teriete et al, 2007). NMR studies 
revealed that Ser 68 phosphorylation of PLM causes a conformational 
change in the cytoplasmic helix (Teriete et al, 2009). It was proposed that 
the cytoplasmic region either adapts a conformation identical to the 
structure in SDS micelles or an alternative conformation where it binds to 
an alternative site on the Nah, K+-ATPase in close proximity of the 
negatively charged crevice located in the transmembrane region (Figure 
3.3.). It is unlikely that PLM adopts a conformation identical to the SDS 
micelle structure as it is solved in both a lipid-free, and a Na+, K+-ATPase- 
free environment. The surface of the Na+, K+- proposed alternative PLM 
conformation induced by Ser 68 phosphorylation also seems unlikely as
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despite there being potential arginine sites found by Anchorsmap in this 
region, the surface in is not compatible with an a-helix in either the 
E2P.(2K+) or the E2P conformations (Figure 5.30). The true change in the 
cytoplasmic region of PLM due to phosphorylation could be far more 
simple with the proposed interaction (Figure 5.29.) being weakened and 
thus causing movement of the helix due to the negative charge added by 
the phosphate group. This would explain the smaller effect on Na+, K+- 
ATPase function observed in phosphorylated PLM38.72 over 
unphosphorylated PLM38-72.
As the proposed interaction occurs at the N-terminus of helix M5 of the 
Na+, K+-ATPase it could feasibly cause the whole helix to move towards 
the cytoplasmic region for PLM. As described in the introduction (Chapter 
1.1.3.), the third NaH binding site is located at the C-tenninus of helix M5, 
M6 and M9 (Morth et al.t 2007) so a movement of helix M5 is likely to 
have an effect on the affinity for Na+ of the third binding site which could 
explain the reduction of ATPase activity caused by the cytoplasmic region 
of PLM.
The true nature of the interaction of the cytoplasmic region of PLM and 
long form Mat-8 with the Na+, K+-ATPase will only be definitively 
understood if a structure for both in complex with the Na+, K+-ATPase is 
solved. However this provides some possibilities of how the interactions
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may occur. Further bioinformatics could also be used to model foil length 
FXYD proteins with the Na+, K+-ATPase to see how the entire cytoplasmic 
region of PLM and long form Mat-8 could orientate whilst in the proposed 
conformations.
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Chapter 6
6.1. NMR studies of ouabain analogues
The previous three chapters concentrated on structural and biophysical 
studies of FXYD proteins, physiological regulators of the Na+, K ' -ATPase. 
This chapter concentrates on structural studies of cardiac glycosides which 
are pharmacological regulators of the Na+, K+-ATPase and possibly have 
an additional physiological role. The cardiac glycosides such as ouabain 
have been used as drugs for cardiac arrhythmia and congestive heart failure 
over 200 years (Withering, 1785). The cardiac glycosides are potent and 
very specific inhibitors of the Na+, K+-ATPase (Hansen, 1984). As the 
cardiac glycosides inhibit the Na+, K+-ATPase there is an increase of Na+ 
ions in the cytoplasm with a loss of intracellular K+ to the extracellular 
space. The increased Na+ concentration inside the cell lowers the activity 
of the Na+/Ca2+ exchanger that usually exchanges extracellular Na+ for 
intracellular Ca2H (Tanaka et al, 2007). With the Na+/Ca2+ exchanger not 
functioning intracellular Ca2+ concentration also increases. Cardiac 
glycosides are described as positive inotropic agents as by increasing 
intracellular Na+ and Ca2+ ion concentration they increase the strength of 
heart muscle contraction.
There are still uncertainties about the recognition site for cardiac 
glycosides and the structure and orientation of drugs within the site of
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action. Ouabain binds to die K+ sensitive Na+, K+-ATPase in the E2 
conformation (Yoda and Yoda, 1982). Before K+ binds the Na1, K+- 
ATPase is in a high affinity ouabain binding state (E2P) and after K+ binds 
it is in a low affinity ouabain binding state (E2P(2K+)). Before the Na1', K+- 
ATPase had been successfidly crystallized and subsequently analysed by 
X-ray crystallography in 2007 (Morth et al, 2007) there were few 
structural insights into how the Na1, K+-ATPase/ouabain reaction might 
occur. In the absence of a ciystal structure, solid-state NMR provided 
initial indicators of the structure of cardiac glycosides in the site of action. 
(Middleton et al, 2000). To achieve this ouabain was modified with 
acetonide bridges at two locations to allow isotope labels to be 
incorporated for NMR studies. Figure 6.1 shows the chemical structures of 
ouabain and the derivatives used. Diacetylated ouabain (ODA Figure 6.1.) 
was produced with [2H6]acetone which gave deuterated methyl groups. 
This made it suitable for analysis by 2H NMR to probe the local dynamics 
of the interaction between ouabain and the Na+, K+-ATPase. All modified 
ouabain derivatives were inhibitors albeit with a lower potency than 
ouabain.
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Ouabain Monoacetonide (OMA)
Diacetonide (ODA) steroid-Flurodiacetonidc (OFDA)
Figure 6.1. Ouabain and acetonide derivatives. The chemical structures of ouabain and 
the chemical derivatives are shown. OMA has one acetyl bridge at the steroid group 
whereas ODA has an acetyl bridge at both the steroid and rhamnose group. OFDA is 
produced by monoacetylating ouabain with fluroacetone then transferring to acetone or 13C 
acetone to form the rhamnose acetyl bridge. ODA can be produced with [2H6]acetone 
which gives deuterated acetyl groups i.e. CH3 groups would instead be CD3 groups. 
OFDA can also be produced with a CH2F group in place of CF3 (Middleton et ai, 2000).
2“H NMR revealed the rhamnose was only loosely associated with the 
binding site on the Na+, K -ATPase whereas the steroid group was more 
constrained. CP-MAS l 3C-NMR on ODA revealed the acetyl bridge of the 
rhamnose group had a chemical shift change upon binding to the Na+, K+- 
ATPase, which is possibly due to the rhamnose being situated close to 
aromatic side groups. OFDA was used in double resonance experiments
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(19F, 13C) to determine the structure of OFDA whilst bound to the Na+, K+- 
ATPase. These data was used to model the interaction of ODA within the 
Na+, K+-ATPase binding site, using the recently determined ciystal 
structure of the homologous protein SERCA (Toyoshima et al, 2000). The 
model showed just one possibility of the interaction with ODA bound to 
the Na+, K+-ATPase whilst lying across the membrane surface obeying all 
the constraints determined by NMR. The absolute orientation of the 
ouabain ligand within the Na+, K+-ATPase could not be determined.
More recently crystal structures of the Na1, K!-ATPase including a 
structure from spiny dogfish with bound ouabain (Ogawa et al, 2009) have 
shed more light on the digitalis site. This Na+, K+-ATPase was stabilised in 
a form analogous to the E2P (2K+) conformation by using MgF42' before 
crystallising. This is the low ouabain affinity conformation. Ouabain was 
soaked into the ciystal and then the structure of the complex was solved by 
x-ray crystallography. Ouabain was found to be intercalated into the 
membrane and agrees with the constraints revealed in the NMR studies 
(Middleton et al., 2000). Figure 6.2. compares the possible model from the 
NMR studies and the ciystal structure of the Na+, K+-ATPase with bound 
ouabain.
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ATP
Figure 6.2. Possible models of Na+, K+-ATPase/ouabain interaction. Following 
dynamics and solid state NMR studies model I was created as a possible interaction that 
obeyed the constraints determined. Model II which also obeys these constraints comes 
from a structure of Na+, K+-ATPase in a low ouabain affinity conformation that had 
ouabain soaked into the crystal.
Questions still remain on the orientation of ouabain in membrane 
embedded Naf, K'-ATPase, largely because the crystal structure was 
limited in that it was solved in a low ouabain affinity conformation of Na1, 
K+-ATPase. This may not even be observed in nature as the high affinity 
form of Na+, K+-ATPase preceded the low affinity form in the cycle so 
upon binding ouabain it stops the cycle from continuing. The Na4, K4- 
ATPase was also crystallised before ouabain was added which means 
ouabain was binding to an inactive protein, which may affect the 
interaction.
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This chapter aims to characterise the Na+, K+-ATPase/cardiac glycoside 
interaction in a non-crystalline, membrane environment using in silico and 
solid-state NMR methods. The aims of this work provided an opportunity 
to evaluate a new solid-state NMR approach for studying ligand binding 
using paramagnetic broadening relaxation agents.
6.2. Materials and Methods
6.2.1. Materials
Preparative and analytical thin-layer chromatography (TLC) plates, 
ouabain octahydrate and fluoroacetone provided by Sigma-Aldrich. 
Acetone was purchased from Fisher Scientific. I3C acetone was purchased 
from Goss Scientific. Na', K+-ATPase was prepared as described in 
chapter 3.2.2.
6.2.2.1. Na+, K+-ATPase/ouabam docking (GOLD)
Bioinformatics studies were performed with Genetic Optimisation for
Ligand Docking (GOLD) (Jason et a!., 2005). Experimental parameters
were given to Dr. Jaclyn Bibby who ran the experiments. This software
relies on a genetic algorithm (GA) that incorporates many features. The
GA allows for frill ligand flexibility or fixed ligand and partial selected
active site flexibility (Jones et al, 1997). Crucially the GA ensures each
docking would cause loosely bound water to displace on binding which is
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fundamental to any ligand/protein binding. Experimentally determined 
interactions deposited on the Protein Data Bank have been compared to 
interactions determined by GOLD and have 71% agreement (Jones et al, 
1997). Various Na+, K+-ATPase structures from the PDB (PDBID: 3KDP 
(Morth et at., 2007), PDBID: 2ZXE (Shinoda et al, 2009) and PDBID: 
3A3Y (Ogawa et al, 2009)) were selected as protein files. A SERCA 
structure also from the PDB was selected due to its homology with the a- 
subunit of the Na+, K+-ATPase as a negative control (PDBID: 1SU4 
(Toyoshima et al, 2000)). The ouabain ligand was extracted from the Na+, 
K+-ATPase PDB file with bound ouabain (3A3Y). OMA and ODA ligands 
were made using the chemid database. The search point centres were 
selected based on the cluster of amino acids showed to be involved in 
ouabain binding in mutagenesis studies (Price and Lingrel, 1988; Price et 
al, 1989; Lingrel et al, 1991; Canessa et al, 1992; Burns and Price, 1993; 
Canessa et al, 1993; Schultheis and Lingrel, 1993; Schultheis et al, 1993; 
Palasis et al., 1996; Croyle et al, 1997b). The top 100 ranked orientations 
were selected with ChemScore (Baxter et al, 1998) The positions and 
angles defining the orientation of ouabain in the output files were 
calculated using a C program developed by Dr. David Middleton and 
visualised using Origin.
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6.2.2.2. Modeller
Sali Lab Modeller 9v8 (Sail and Blundell, 1993) was used to produce a 
homology model of the high-ouabain affinity E2P conformation of the Na+, 
K+ -ATPase using the E2P conformation of SERCA deposited in the PDB 
(PDBID:3B9B) as a template (Toyoshima et ai, 2000). Methods follow 
the basic modelling tutorial on the Sali Lab website 
(http://salilab.org/modeller/tutorial). The spiny dogfish rectal gland was 
selected and its sequence was aligned using the align2d() command in 
modeller which takes into account structural information of the template as 
well as sequence. After the models were built the best model was selected 
with the lowest discrete optimized protein energy (DOPE) assessment 
score which is a statistical potential which assesses homology models 
based on the finite size compared to the template structure.
6.2.3. Synthesis of ouabain derivatives
Ouabain monoacetonide (OMA) and ouabain diacetonide (ODA) were 
prepared following a procedure described earlier (Middleton et al.t 2000). 
Ouabain octahydrate (50 mg) was dissolved in acetone (1 g). Copper 
sulphate (200 mg) was added and mixture was stirred at room temperature 
in darkness for 48 hr. The product solution was separated from insoluble 
copper sulfate by vacuum filtration. The remaining product was analysed 
by analytical TLC to confirm that the reaction had occurred to produce 
OMA and ODA (Figure 6.1). To prepare 13C-labelled OMA and ODA [2- 
13 C] acetone was used as the solvent.
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6.2.4. OMA and ODA purification
6.2.4.1 Analytical thin layer chromatography
After ouabain was incubated in acetone for 2 days the product solution was 
spotted onto analytical TLC plates and placed in a mobile phase of 3:1 
ethyl acetate: methanol and the solvent front allowed to nm —10 cm before 
being dried and sprayed with 50% H2SO4. Plates were placed on a heat 
block until development.
6.2.4.2 Silica chromatography
Silica slurry was produced by mixing silica with 3:1 ethyl acetate: 
methanol. The shiny was then poured into the gravity column and packed 
under vacuum. The column was then closed before slowly adding the 
sample to the silica and loading onto the column with additional solvent. 
ImL samples were taken as solvent was continuously added to the top. 
Samples checked via analytical TLC to find which fractions contained 
ouabain derivatives.
6.2.4.3. Preparative Thin Layer Chromatography
Samples were streaked onto the base of preparative TLC plates with a glass
pastern- pipette and placed in solvent (3:1 ethyl acetate: methanol) and the 
solvent line was allowed to run close to the edge of the plate before being 
dried and sprayed with 50% H2SO4. A narrow preparative TLC plate was 
run alongside this before being dried and sprayed with 50% H2SO4. This 
plate was developed on a heat block and used as a guide for the other plate
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to determine where to scrape off silica that contains OMA or ODA. Silica 
was collected in test tubes and OMA or ODA was eluted by adding 
methanol and vortexing. Samples were then filtered to remove silica, dried 
to a film under nitrogen and fully dried on the vac pump overnight.
6.2.5. Testing inhibitory potencies of ouabain derivatives
The inhibitory potencies of ouabain, OMA and ODA and were calculated
as the IC50 (the inhibitor concentration causing 50% enzyme inactivation) 
for ATP hydrolysis using the Baginski method as has been shown 
previously (Middleton et at, 2000).
Na+, K+-ATPase 0.5 mg protein ml'1) was preincubated in incubation 
medium (3 mM MgCl2, 3 mM Pi, 40 mM Tris, pH 7.3) and 0-100 niM of 
ouabain, OMA or ODA. This was incubated at 20°C for 60 min, an 
aliquot was subsequently transferred to hydrolytic assay medium (30 mM 
Histidine, 3 mM Na-ATP, 20 mM KC1, 4 mM MgCl2, 0.33 mg ml/1 
albumin), whereby the enzyme and glycoside was diluted 40-fold and 
incubated for a further 10 min before determining the liberated Pi by a 
colorimetric assay. The selectivity and binding affinity of the ouabain 
derivatives were determined from competition experiments using 
[3H]ouabain. Na+, K+-ATPase membranes (0.25 mg protein ml'1) were 
added to incubation medium containing 5-280 nM ouabain with 3,000 B
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ml'1 [3H]ouabain and either OMA or ODA to a final concentration of 0-5 
niM. The mixture was incubated at 37°C for 3 h and filtered to determine 
the amount of free ouabain left in the solution. The amount of bound 
ouabain was calculated as the difference between the radioactivity of the 
initial incubation medium and the filtrate. Displacement of [3H]ouabain 
by OMA and ODA was followed by incubating Na+, K+-ATPase (0.23 
mg protein mf1) in incubation medium containing 30 nM [3H] ouabain for 
60 min at 37°C. Ouabain, OMA, or ODA was added to a final 
concentration of 50 mM, and the release of bound [3H]ouabain was 
followed for up to 25 hr by filtration as described above (Middleton et 
al, 2000).
6.2.6.13C NMR of ouabain derivatives
Samples were transferred to a 4 mm diameter magic-angle spinning rotor. 
The rotor held 100 pL of membrane sample containing Na+, K+-ATPase 
(13 nmoles) complexed with ouabain or derivatives (16 pmoles) and 
concentrations of Mn2+ of 0-5 mM. Experiments are based on previous 
solid-state NMR studies of the Na+, K+-ATPase (Middleton et al, 2011). 
Spectra were obtained by using a Bruker Avance 400 instrument operating 
at a frequency of 100.13 MHz for 13C. Membrane samples were spun at a 
MAS rate of 5.0-8.0 kHz for one-dimensional (ID) experiments. ID 
spectra were obtained by averaging no more than 170000 transients. 
Conditions common to all experiments were a 4.0 ps !H excitation pulse,
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two-pulse phase modulated (TPPM) proton decoupling at a field of 85 kHz 
during signal acquisition and a 1 s recycle delay pulse. For CP-MAS 
experiments cross-polarisation was achieved with a 2 ms contact time at a 
proton field of 65 kHz. Each spectrum was the result of accumulating 
102,400 transients in 5 blocks of 20,480 transients at temperatures of - 
25°C, -10°C and 4°C.
6.3. Results
6.3.1. Investigation of the Na+, K' -ATPase/ouabain interaction using 
GOLD
In order to gain further insight into the interaction of cardiac glycosides 
with the Na+, K+-ATPase after the low ouabain affinity Na+, K+-ATPase 
structure was published (Ogawa et al, 2009) GOLD was selected as a 
software package to dock the ouabain ligand into the Na+, K'-ATPase 
structures deposited into the PDB (PDBIDs: 3KDP, 2ZXE, 3A3Y). GOLD 
requires a central residue to be selected and calculates docking sites within 
a 20 A from this residue. The central residue was selected by highlighting 
residues on the Na+, K+-ATPase shown to effect ouabain binding (Figure 
1.9 and Table 6.1.) and picking a central point in the main cluster of 
residues (central start point). After experimental parameters were defined, 
all GOLD experiments were run by Dr. Jacyln Bibby.
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Table 6.1. Amino acids shown to affect ouabain sensitivity of the Na+, K+-ATPase in 
site directed mutagenesis experiments. The decrease in apparent Ko5 is given to allow 
comparison between different species and different studies of the Na+} K+-ATPase. The 
fold increase is therefore relative to the wild type Na+, K+-ATPase used in the cited 
studies.
Original
Amino Acid
Decrease
in apparent
K().5 (-fold)
Reference
C104F 23 (Canessa et al., 1992)
Y108A 9.1 (Canessa ei al., 1992)
Q111R 12.5 (Price and Lingrel, 1988)
D121N 65 (Price et al., 1989)
N122D 3.9 (Lingrel etal., 1991)
P118K 3.9 (Schultheis and Lingrel, 1993)
Y308C 2.7 (Canessa et al., 1993)
L330Q 7.9 (Croyle et al, 1997b)
A331G 3.1 (Croyle et al., 1997b)
T338N 3.3 (Croyle et al, 1997b)
F786N 19 (Palasis etal, 1996)
L793P 24 (Palasis et al., 1996)
T797N 80 (Burns and Price, 1993)
F863L 5.7 (Palasis etal, 1996)
R880P 7.9 (Schultheis et al, 1993)
F982S 6.3 (Croyle etal, 1997b)
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6.3.1.1. Validation of GOLD
Although GOLD has successfully produced publishable protein/ligand data 
in other membrane proteins (Horsefield et ah, 2006; Klepsch et al., 2011) 
experiments needed to be performed to ensure the suitability of GOLD to 
docking ouabain into the Na+, K' -ATPase. The low ouabain affinity Na+, 
K' -ATPase (PDBID:3KDP) structure was used to test the reliability of the 
GOLD prediction algorithm. The ouabain ligand was removed from 3KDP 
in PyMol then redocked back into it using GOLD (Figure 6.3.). The active 
site centre was selected in the middle of the main cluster of amino acids 
that affect ouabain binding (Table 6.1.) and ouabain was docked within a 
20 A range of this active site centre. The top 100 ranked orientations all 
only deviate slightly from the x-ray crystallography structure (Figure 6.3.) 
To test the GOLD software further a new start point was selected away 
from the main cluster of residues at the protein surface (Leu 791) in close 
proximity of the previous active site centre. This results in a more varied 
distribution of orientations (Figure 6.4.) and it does not pick up the actual 
ouabain bound in the original structure. This shows the software is most 
accurate when a specific active site location is selected.
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Figure 6.3. Evaluating the reliability of GOLD for prediction of Na+, K+- 
ATPase/ouabain interactions. The Na+, K+-ATPase structure with bound ouabain 
(PDB1D:3A3Y) had its ligand removed and then redocked using ouabain. The active site 
centre was picked in the middle of the main cluster of amino acids that affect ouabain 
binding (Table 6.1.) and ouabain was docked within a 20 A radius of this. The ouabain 
bound in the original structure is shown in navy blue.
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Figure 6.4. Evaluating the reliability of GOLD for prediction of Na+, K+- 
ATPase/ouabain interactions. The Na+, K+-ATPasc structure with bound ouabain 
(PDBID:3A3Y) had its ligand removed and then redocked using ouabain. The active site 
centre was picked at the surface of the protein in close proximity of the previous centre 
used (Figure 6.4.). Ouabain was docked within a 20 A radius of this active site centre. The 
ouabain bound in the original structure is shown in navy blue.
The reliability of using GOLD to predict Na+, K'-ATPase/ouabain 
interactions was tested by using SERCA as a negative control. SERCA is 
homologous to the a-subunit of the Na+, K+-ATPase which ouabain binds 
to. Despite this homology, ouabain does not bind to SERCA so GOLD 
should give a relatively random distribution of orientations of docked 
ouabain. A non-occluded E2 conformation structure of SERCA was used
with PDBID: 3B9B (Toyoshima et al., 2000) as the corresponding E2
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conformation in the Naf, K-ATPase is the high ouabain affinity state. The 
active site centre selected corresponds to the location of the active site 
centre used in the Na+, K'-ATPase in the middle of the main cluster of 
amino acids that affect ouabain binding. Figure 6.5. shows there are two 
major clusters of dockings that are both very broad in distribution and 
orientation.
Figure 6.5. Evaluating the reliability' of GOLD for prediction of Na+, K+- 
ATPase/ouabain interactions using SERCA as a negative control. The E2 SERCA 
structure (PDBID: 3B9B) is homologous to the a-subunit of the Na+, K+-ATPase but does 
not bind ouabain. The active site centre was picked in the middle of the main cluster of 
amino acids that affect ouabain binding (Table 6.1.) and ouabain was docked within a 
20 A radius of this.
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6.3.1.2. Application of GOLD to the ouabain free structures of the Na+, 
K^-ATPase
Ouabain was next docked using GOLD on the two originally deposited 
ouabain-free structures of the Na+, K -ATPase (Morth et aL, 2007; 
Shinoda et aL, 2009) that are from pig kidney (PDBID:3KDP) and spiny 
dogfish rectal gland (PDBID:2ZXE). This was designed to determine if 
there were any potential differences in the interaction of the Na+, K+- 
ATPase and ouabain between species. Both pig kidney (Figure 6.6.) and 
spiny dogfish rectal gland (Figure 6.7.) appear similar with two major 
clusters of dockings.
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Figure 6.6. GOLD docking distribution of ouabain into Na+, K+-ATPase in pig 
kidney. GOLD was used to dock ouabain into the Na\ K+-ATPase from pig kidney 
(PDBID: 3KDP) in the E2P (2K+) conformation. The active site centre was picked in the 
middle of the main cluster of amino acids that affect ouabain binding (Table 6.1.) and 
ouabain was docked within a 20 A radius of this.
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Figure 6.7. GOLD docking distribution of ouabain into Na+, K+-ATPase in spiny 
dogfish rectal gland. GOLD was used to dock ouabain into the Na+, K -ATPase spiny 
dogfish rectal gland (PDBID: 2ZXE) in the E2P (2K+) conformation. The active site centre 
was picked in the middle of the main cluster of amino acids that affect ouabain binding 
(Table 6.1.) and ouabain was docked within a 20 A radius of this.
6.3.1.3. Statistical analysis of GOLD results
Although the orientations of ouabain docked in the Na \ K -ATPase appear 
similar in both species as would be expected, there arc noticeable 
differences between them. To visualise this data statistically a C program 
was written and run by Dr. David Middleton to determine three variables. 
The first is the distance (r) from the centre of mass of each docked ouabain 
ligand to the centre of mass of the Na+, K'-ATPase. The two other 
variables are a pair of angles (0 and i|/). These angles are calculated relative
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to the principal axes of inertia of the Na+, K+-ATPase (Figure 6.8a.). A 
straight line is drawn between two points on ouabain (Figure 6.8b.). These 
sites were selected as they are at opposite ends of the most rigid part of the 
ouabain structure. The angles produced with this line in the principal axes 
of inertia of the Na+, K-ATPase are calculated on both the xy and yz 
planes (Figure 6.8c.). These angles define the orientation of the inhibitor in 
within the Na+, K+-ATPase.
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Figure 6.8. Definition of the angles defining the orientation of ouabain docked into 
Na+, K+-ATPase. Angles of docked ouabain ligands relative to the Na+, K-ATPase were 
calculated to represent orientations. This was performed by first rotating the Na+, K+- 
ATPase into its principal axes of inertia (A) and selecting two sites on the ouabain ligand 
in a rigid part of the molecule labelled in red and blue (B). With this data the angles 0 and 
v|/ were calculated (B)
The distance (r) was calculated for both pig kidney and spiny dogfish rectal 
gland (Figure 6.9.) In pig kidney the majority of r values are 46-48 A 
whereas in spiny dogfish rectal gland the majority of r values are 50-52 A. 
A small change like this could be explained by the small differences in 
structure between the two species.
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Figure 6.9. Histograms representing the distribution of distances from the centre of 
mass of the Na+, K+-ATPase to the centre of mass of the top 100 ranked ouabain 
dockings in pig kidney and spiny dogfish rectal gland. The distances from each of the 
top 100 ranked ouabain dockings obtained from GOLD in pig kidney (PDB1D: 3KDP) and 
spiny dogfish rectal gland (PDBID: 2ZXE) were calculated and are presented here as 
histograms
The angles 0 and V}/ that define the orientation of a docked ouabain ligand 
in the Na+, K'-ATPase site are plotted as a scattergram for both pig kidney
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and spiny dogfish rectal gland (Figure 6.10.). These reveal the majority of 
orientations have a similar \|/ angle of approximately -45°. There is a 
greater spread of distributions of angle 0 in both species. Also there are two 
separate clusters between species of angle 0 at around 50° for spiny dogfish 
rectal gland and 135° for pig kidney which again is likely due to the 
differences in structure and sequence between the Na+, K+-ATPase in pig 
kidney and spiny dogfish rectal gland. Crucially there are no dockings at 
90°, i.e. parallel to the membrane surface which was arbitrarily defined in 
the earlier solid-state NMR study (Middleton et al, 2000) which suggests 
the x-ray crystallography data showing ouabain parallel with the 
transmembrane helices of the Na+, K+-ATPase (Shinoda et al., 2009) is a 
more accurate representation of the interaction.
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Figure 6.10. Scattergram representing spread of orientations of the top 100 ranked 
ouabain dockings in the principal axes of inertia of the Na+, K+-ATPase from pig 
kidney and spiny dogfish rectal gland. The angles T and 0 were calculated (explained in 
Figure 6.9.) for the top 100 ranked ouabain dockings and plotted against each other in a 
scattergram to give an idea of the spread and of orientations obtained from GOLD 
experiments.
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The structure of the Naf, K'-ATPase in the ouabain-sensitive E2P 
conformation is not known. A homology model of the NaH, K -ATPase in 
the E2P conformation was therefore produced using modeller by taking the 
spiny dogfish rectal gland sequence and modelling it to the E2P structure of 
SERCA (Toyoshima et al, 2000). SERCA is homologous to the a-subunit 
of the Na+, K'-ATPase and no E2P structure of the Na4, K+-ATPase had 
been published at the time of writing. The E2P conformation is the high
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ouabain affinity conformation so is more ideal for these studies. Figure 
6.11. shows that in this model there is a far less random distribution of 
orientations. This suggests the high ouabain affinity Na+, K4-ATPase may 
bind ouabain in a very different way to the low ouabain affinity Na+, K - 
ATPase.
Figure 6.11. GOLD analysis of ouabain docking to the EjP model of the Na+, K+- 
ATPase. The E2P conformation of the Na+, K+-ATPase is the high ouabain affinity 
conformation whereas the two structures studied so far are the low ouabain affinity E2P 
(2K+) confonnation. An E2P structure was produced in Modeller (modelled to the E2P 
SERCA structure) and the GOLD experiments were run as before.
6.3.2. NMR Analysis
Based on GOLD, ouabain is predicted to have a higher propensity to dock 
into the protein roughly parallel with the long axis rather than sitting on the
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membrane surface. The E2P model however revealed there are potential 
differences between how ouabain binds to the low-ouabain affinity and 
high-ouabain affinity conformations of the Na+, K+-ATPase. Therefore, a 
novel approach using solid-state NMR combined with paramagnetic 
broadening was used to analyse the orientation of ouabain in the high- 
affinity Na1’, K+-ATPase state. For NMR analysis 13C must be incorporated 
into ouabain without losing affinity for the digitalis site. This was achieved 
previously by forming the acetonides (OMA and ODA) with I3C labels at 
the quaternary carbon sites (Middleton et al,, 2000). The solid-state NMR 
13C spectrum of ODA bound to the Na+, K+-ATPase has two signature 
peaks at ~100 ppm and ~110 ppm from the steroid and rhamnose 
acetonides respectively (Middleton et al, 2000). The identity of 13C 
labelled OMA and ODA was confirmed by mass spectrometry (Figure 
6.12.) with masses of 650.6 and 690.6 expected respectively (this includes 
sodium adducts).
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Figure 6.12 Mass Spectrometry of OMA and ODA with nC acetonide bridges.
6.3.2.I. Testing suitability of OMA and ODA using GOLD
To ensure OMA and ODA would bind to the Na4, K-ATPase in a similar
way to ouabain GOLD was used to dock the OMA (Figure 6.14.) and
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ODA (Figure 6.14.) ligands to spiny dog rectal gland as had been done 
previously with ouabain (Figure 6.7). Statistical analysis shows a very 
similar distribution of distances from the centre of mass of the Na+, K+- 
ATPase to the centre of mass of ligand (ouabain/OMA) as shown in Figure 
6.15. The distribution of orientations of ligand is also similar as shown in 
Figure 6.16 although the main cluster of orientations has become more 
widespread.
Figure 6.13. GOLD docking distribution of OMA into Na+, K+-ATPase in spiny 
dogfish rectal gland. GOLD was used to dock OMA into the Na+, K+-ATPase spiny 
dogfish rectal gland (PDB1D: 2ZXE) in the E?P (2K+) conformation. The active site centre 
was picked in the middle of the main cluster of amino acids that affect ouabain binding 
(Table 6.1.) and ouabain was docked within a 20 A radius of this.
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Figure 6.14. GOLD docking distribution of ODA into Na+, K+-ATPase in spiny 
dogfish rectal gland GOLD was used to dock ODA into the Na+, K+-ATPase spiny 
dogfish rectal gland (PDBID: 2ZXE) in the E2P (2K+) conformation. The active site centre 
was picked in the middle of the main cluster of amino acids that affect ouabain binding 
(Table 6.1.) and ouabain was docked within a 20 A radius of this.
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Figure 6.15. Histogram representing the comparison of distribution of distances from 
the centre of mass of the Na+, K+-ATPase to the centre of mass of the top 100 ranked 
dockings in spiny dogfish rectal gland between ouabain and OMA. The distances from 
each of the top 100 ranked ouabain and OMA dockings obtained from GOLD in spiny 
dogfish rectal gland (PDB1D: 2ZXE) were calculated and are presented here as a 
histogram
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Figure 6.16. Scattergram representing the comparison of the spread of orientations 
of the top 100 ranked dockings between ouabain and OMA in the principal axes of 
inertia of the Na+, K+-ATPase from spiny dogfish rectal gland. The angles T and 0 
were calculated (explained in Figure 6.9.) for the top 100 ranked ouabain and OMA 
dockings and plotted against each other in a scattergram to give an idea of the spread and 
of orientations obtained from GOLD studies.
6.3.2.2. Testing the potencies of OMA and ODA compared to ouabain.
To ensure the ouabain derivatives produced had similar inhibitory effects
on the Na\ K'-ATPase to what had been observed previously (Middleton 
et al., 2000), the effects of the synthesised ODA on the Naf, K'-ATPase 
was analysed by ATPase assays. A K0.5 of around 6 pM for ODA 
compared to around 0.5 pM for ouabain was observed (Figure 6.18.) which 
makes ODA much less potent than ouabain (as had been observed
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previously where OMA and ODA exhibited IC50 values of between 5 and 
15 pM compared to <0.08pM for ouabain). The published data also show 
how ODA displaces [3H]ouabain in a similar manner to unlabelled ouabain 
suggesting ODA binds at the same site albeit with lower potency.
— ODA1 
—o—ODA2 
—A— Ouabain
ba-Q=Q—o—=1
0.00.3
Concentration of ligand (pM)
Figure 6.17. Inhibition curves of ouabain and ODA. In two ODA samples tested the 
potency of ODA was much lower than that of ouabain.
6.3.2.3. CP-MAS 13C NMR
NMR samples of the Na+, K'-ATPase were prepared by Prof. Mikael 
Esmann of the University of Aarhus. These all contained spiny dogfish 
Na\ K4-ATPase and included samples with OMA or ODA and a range of 
manganese concentrations. Magic angle spinning was combined with 
cross-polarisation to allow the transfer of magnetisation from 'H to l 3C and
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improve signal to noise (this is described in more detail in Chapter 2). 
Cross polarisation is only effective when 13C nuclei are in a restrained 
state. Whilst in solution, molecules undergo isotropic tumbling preventing 
cross-polarisation occurring. Ligands can be restrained and allow cross­
polarisation to occur by being frozen or binding to a restrained molecule 
such as a membrane protein embedded in a membrane. Although cross­
polarisation will occur on 13C nuclei in a ligand bound to a membrane 
protein at non-freezing temperatures, the molecular motions will scale 
down non-polar interactions reducing cross-polarisation efficiency. In a 
frozen membrane these dynamics are reduced which improves cross­
polarisation efficiency giving better signal. This does mean that both free 
and bound ligand will produce signal due to the freezing temperatures so 
when selecting experimental temperatures there is a trade off between 
having a high enough temperature so free ligand is undetected and a low 
enough temperature for efficient cross-polarisation (Spooner et al, 1994). 
This work studies ouabain derivatives both at frozen and unfrozen states.
Samples were also treated with various concenfrations of manganese. 
Manganese is a paramagnetic broadening agent which means it shortens 
the T2 time (relaxation time). With a shorter relaxation time the sensitivity 
reduces causing peaks to broaden. Previous paramagnetic broadening 
studies have probed the depths of peptides (Grobner et al, 1999; Buffy et 
al, 2003) and drugs (Boland and Middleton, 2008) in lipid bilayers, by
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comparing the broadening of peaks from the lipids which locations are 
known to peaks of the ligand which locations are unknown. The effect of 
manganese is proportional to distance so if a low concentration of 
manganese was added to a sample of the Na+, K'-ATPase in a cell 
membrane the manganese would bind to the membrane surface and the 
most accessible parts of the protein surface. Experiments run at higher 
manganese concentration would have manganese bind to less accessible 
regions of the protein surface causing peaks on the spectra to broaden 
further and would also bring manganese into closer proximity of the less 
accessible nuclei and will also broaden their chemical shift peaks. By using 
ODA and analysing the broadening of both chemical shift peaks separately 
their individual accessibility can be determined and will help understand 
the orientation of ouabain in the Na+, K+-ATPase further. A typical 13C CP- 
MAS NMR spectra of the Na1, K'-ATPase is shown in Figure 6.18 with 
added OMA at 4°C. The OMA peak can be seen at 100 ppm and is 
displaced by ouabain showing it binds to the same site. The signal can be 
assigned exclusively to OMA in the high affinity site.
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Figure 6.18. Example of a l3C spectrum of Na+, K+-ATPase with OMA at 4°C. The 
signal of OMA is found around 100 ppm and is shown enlarged. This also shows a sample 
to which ouabain was added before OMA and displaces it from the binding site of the Na\ 
K+-ATPase causing a signal loss at 100 ppm. There are many other peaks between 0 and 
200 ppm that are caused by natural abundance l 3C nuclei each of which is labelled with its 
source.
Initial experiments were performed on Na+, K'-ATPase with OMA as it 
could be produced in a higher yield compared to ODA and could be used 
to determine starting conditions for ODA experiments. Two temperatures 
were attempted (4°C and -25°C) and were both performed at 4000 Hz
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spinning rate. The natural abundance 13C were observed as follows; lipid 
chain and protein side groups at 50-0 ppm (Figure 6.19), Ca and lipid 
headgroups at 80-50 ppm (Figure 6.20), OC at 140-115 (Figure 6.21) and 
CO at 185-160 ppm (Figure 6.22.). Spectra are shown at -25°C with similar 
results at 4°C. Spectra are normalised to the lipid methyl peak as it should 
not be significantly affected by manganese due to its inaccessibility caused 
by its location at the centre of the phospholipid bilayer. These are all 
affected to different degrees by manganese which is due to their 
accessibility. Lipid headgroups are affected the most by manganese as they 
are particularly accessible.
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Figure 6.19 l3C Spectra of Na+, K+-ATPase samples with OMA at various manganese 
concentrations at -25°C and 4°C in the 50-0 ppm range where lipid chain and protein 
side groups occur. Spectra are the result of accumulating 102,400 transients in 5 blocks of 
20,480 transients with a spinning rate of 4000 Hz. Spectra are normalised to the lipid 
methyl peak.
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Figure 6.20 UC Spectra of Na+, K+-ATPase samples with OMA at various manganese 
concentrations at -25°C and 4°C in the 80-50 ppm range where protein Cct and lipid 
headgroups occur. Spectra are the result of accumulating 102,400 transients in 5 blocks 
of 20,480 transients with a spinning rate of 4000 Hz. Spectra are normalised to the lipid 
methyl peak.
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Figure 6.21 l3C Spectra of Na+, K+-ATPase samples with OMA at various manganese 
concentrations at -25°C and 4°C in the 140-115 ppm range where C=C occur. Spectra 
are the result of accumulating 102,400 transients in 5 blocks of 20,480 transients with a 
spinning rate of 4000 Hz. Spectra are normalised to the lipid methyl peak.
283
-25°C
-------OMA
------- 2 mM Mn
5 mM Mn
185 180 175 T iTo T 165 160
13C chemical shift (ppm)
-------OMA
-------2 mM Mn
5 mM Mn
13C chemical shift (ppm)
Figure 6.22 UC Spectra of Na+, K+-ATPase samples with OMA at various manganese 
concentrations at -25°C and 4°C in the 185-160 ppm range where CO occur. Spectra 
are the result of accumulating 102,400 transients in 5 blocks of 20,480 transients with a 
spinning rate of 4000 Hz. Spectra are normalised to the lipid methyl peak.
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A Na4, K+-ATPase spectrum without OMA (labelled background) is 
shown with a Na', K+-ATPase spectrum with OMA (labelled OMA) to 
highlight the peak derived from OMA at both -25°C (Figure 6.23.) and 4°C 
(Figure 6.24.).
Background
OMA
115 110 105 100 95
13C chemical shift (ppm)
Figure 6.23. I3C Spectra of Na+, K+-ATPase samples with OMA at 118-95 ppm of 
Na+, K+-ATPase with and without OMA at -25°C. The OMA peak is expected at 100 
ppm. Black spectrum shows Na4, K+-ATPase alone (background). Red spectrum shows 
Na+, K+-ATPase with OMA.
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Figure 6.24. 13C Spectra of Na+, K+-ATPase samples with OMA at 118-95 ppm of 
Na+, K+-ATPase with and without OMA at 4°C. The OMA peak is expected at 100 
ppm. Black spectrum shows Na+, K -ATPase alone (background). Red spectrum shows 
Na\ K+-ATPase with OMA.
In another control ouabain was added to Na+, K -ATPase before adding 
OMA. Ouabain should displace OMA and reduce total OMA binding. At - 
25°C as the sample is frozen and both bound and unbound OMA will be 
observed in the spectra. Figure 6.25 reveals little change between the Na+, 
K+-ATPase samples with OMA alone and Na+, K+-ATPase with ouabain 
and OMA as a result of this. This was repeated with Na', K-ATPase
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samples with no phosphate which should reduce binding. Slightly less 
intense peaks are observed for both OMA (blue) and Ouabain/OMA (pink) 
with no phosphate; again a large change would not be expected at this 
temperature as unbound OMA will still be observed. Figure 6.26. shows 
the same set of four' Na+, K+~ATPase samples with OMA or Ouabain and 
OMA both in the presence and absence of phosphate at 4DC. At this 
temperature unbound OMA will not be observed in the NMR spectra. 
Indeed the OMA peak is observed in the Na+, K+-ATPase with OMA 
spectrum but not in the spectrum where ouabain is also present suggesting 
ouabain is displaces the OMA. This confirms OMA is binding at the same 
site as ouabain as expected. Interestingly OMA still binds albeit slightly 
less so in the absence of phosphate. This binding can also be prevented by 
the binding of ouabain.
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Figure 6.25. 13C Spectra of Na+, K+-ATPase samples with OMA at 118-95 ppm of 
Na+, K+-ATPase with and without OMA at -25°C. The OMA peak is expected at 100 
ppm. Black spectrum shows Na+, K+-ATPase with OMA. Red spectrum shows Na+, K+- 
ATPase with ouabain and OMA. Blue and Pink spectra are identical to Black and Red 
respectively with no phosphate added.
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Figure 6.26. ,3C Spectra of Na+, K+-ATPase samples with OMA at 118-95 ppm of 
Na+, K+-ATPase with and without OMA at 4°C. The OMA peak is expected at 100 
ppm. Black spectrum shows Na+, K+-ATPase with OMA. Red spectrum shows Na+, K+- 
ATPase with ouabain and OMA. Blue and Pink spectra are identical to Black and Red 
respectively with no phosphate added shows Spectra are the result of accumulating 
102,400 transients in 5 blocks of 20,480 transients with a spinning rate of 4000 Hz. 
Spectra are normalised to the lipid methyl peak.
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Figure 6.27. and Figure 6.28 (-25°C and 4°C respectively) show the effect 
of manganese on the OMA peak which reduces with increased manganese 
concentrations as expected. This meant a system was in place to obtain 
distance data for both ODA peaks separately with similar experiments.
OMA 
2 mM Mn 
5 mM Mn
115 110 105 T 100 95
13C chemical shift (ppm)
Figure 6.27 UC Spectra of Na+, K+-ATPase samples at 118-95 ppm at -25°C. The
OMA peak is expected at 100 ppm. Spectra indicate the effect of various manganese 
concentrations on the OMA peak.
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Figure 6.28 ,3C Spectra of Na+, K+-ATPase samples at 118-95 ppm at 4°C. Spectra 
indicate the effect of various manganese concentrations on the OMA peak.
Similar experiments were next attempted with ODA. Figure 6.29 shows the 
region where the ODA signal is expected at -25°C. Unlike OMA at this 
temperature the resolution is poor in this region and no peaks can be 
assigned. This suggests there could be a range of orientations of ODA that 
give rise to a distribution of frequencies that cause the signal to broaden.
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The effect of manganese on other regions of the spectrum was similar to 
what had been observed previously in OMA and is discussed later.
ODA
0.25
0.5
1.5
2.0
C chemical shift (ppm)
Figure 6.29 The effect of manganese on UC Spectra of ISa+, K+-ATPase samples with 
ODA at 118-95 ppm at -25°C. The ODA peaks are expected at 100 and HOppm. 
Resolution is too poor to see either peak and therefore determine the effects of manganese. 
To improve resolution and signal to noise whilst keeping the sample below 
freezing for preservation the temperature was raised to -10°C. It appears at 
-25°C both bound and unbound ODA is being observed so the
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experimental temperature needed to be increased. The spinning frequency 
was increased to 8000 Hz as increased spinning rate will remove more of 
the effects of chemical shift anisotropy and improve signal strength. This 
improved resolution can be seen in Figure 6.30 where a Na+, K+-ATPasc 
spectrum without ODA (labelled background) is compared to a spectrum 
of Na+, K+-ATPase with ODA (labelled ODA) to highlight the peaks 
derived from ODA The steroid peak is as expected like in OMA at 100 
ppm however the steroid peak expected at 110 ppm is hard to distinguish 
unlike previous observations (Middleton et al, 2000). This is either due to 
ODA degrading during or after the Na+, K+-ATPase sample preparation or 
ODA binding in a different location to ouabain and OMA. The spectra of 
Na+, K+-ATPase and ODA with 0, 0.25, 0.5 and 1.0 mM manganese are 
shown in Figure 6.31. The steroid peak is completely lost at 0.25 mM Mn 
whereas the effects on the rhamnose peak are difficult to determine. In 
OMA the steroid peak was still present at 5 mM Mn. This suggests ODA is 
binding at the surface of the protein as the steroid peak is lost at such low 
Mn concentrations.
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Figure 6.30.13C Spectra of Na+, K+-ATPase samples with ODA at 118-95 ppm of Na+, 
K+-ATPase with and without OMA at -10°C. The ODA peaks is expected at 100 and 
110 ppm. Black spectrum shows Na+, K+-ATPase alone (background). Red spectrum 
shows Na+, K+-ATPase with OMA.
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Figure 6.31.13C Spectra of Na+, K+-ATPase samples with ODA at various manganese 
concentrations at -10oC. The ODA peaks are expected at 100 and 110 ppm. Spectra 
indicate the effect of various manganese concentrations on the OMA peaks.
295
For this system to be successful, similar effects by manganese on the 
natural abundance 13C peaks from lipid and the Na+, K+-ATPase must be 
observed. The OMA spectra of the key regions that represent the different 
carbon types observed are shown in Figure 6.19-22 at both -25°C and 4°C. 
Figure 6.32-35 show the ODA spectra in the same region at -25°C and 
-10°C. The peak intensities of the peaks indicated by the arrows on these 
spectra were calculated as percentages relative to the manganese free 
spectra (i.e. OMA or ODA alone) and plotted against manganese 
concentration to see the reproducibility of the effects of manganese on 
natural abundance 13C. Figure 6.36 and Figure 6.37 show these plots and 
reveal similar effects of manganese to peak intensities in each case with the 
exception of the peak at 69 ppm which is veiy different at -25 °C. This is in 
the lipid headgroup region and may be due to the different properties of the 
membrane at particularly cold temperatures. This does show that there is 
consistency above -10°C making the system reproducible.
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Figure 6.32 13C Spectra of Na+, K+-ATPase samples with ODA at various manganese 
concentrations at -25°C and -10°C in the 50-0 ppm range where lipid chain and 
protein side groups occur. Spectra are the result of accumulating 102,400 transients in 5 
blocks of 20,480 transients with a spinning rate of 4000 Hz at -25°C and 8000 Hz at -10°C. 
Spectra are normalised to the lipid methyl peak.
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Figure 6.33 13C Spectra of Na+, K+-ATPase samples with ODA at various manganese 
concentrations at -25°C and -10°C in the 80-50 ppm range where protein Ca and 
lipid headgroups occur. Spectra are the result of accumulating 102,400 transients in 5 
blocks of 20,480 transients with a spinning rate of 4000 Hz at -25°C and 8000 Hz at -10°C. 
Spectra are normalised to the lipid methyl peak.
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Figure 6.34 l3C Spectra of Na+, K+-ATPase samples with OMA at various manganese 
concentrations at -25°C and -10°C in the 140-115 ppm range where C=C occur.
Spectra are the result of accumulating 102,400 transients in 5 blocks of 20,480 transients 
with a spinning rate of 4000 Hz at -25°C and 8000 Hz at -10°C. Spectra are normalised to 
the lipid methyl peak.
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Figure 6.35 UC Spectra of Na+, K+-ATPase samples with ODA at various manganese 
concentrations at -25°C and -10°C in the 185-160 ppm range where CO occur.
Spectra are the result of accumulating 102,400 transients in 5 blocks of 20,480 transients 
with a spinning rate of 4000 Hz at -25°C and 8000 Hz at -10°C. Spectra are normalised to 
the lipid methyl peak.
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Figure 6.36 Scattergraphs to show relative peak intensities at 30 and 69 ppm against 
manganese concentration for all experiments performed. Experiments were performed 
at a range of manganese concentrations (0-5 mM) with both OMA and ODA at various 
temperatures indicated on the graphs.
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Figure 6.37 Scattergraphs to show relative peak intensities at 172 and 128 ppm 
against manganese concentration for all experiments performed. Experiments were 
performed at a range of manganese concentrations (0-5 mM) with both OMA and ODA at 
various temperatures indicated on the graphs.
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6.4. Discussion
This final chapter shifts focus from the physiological inhibitors, the FXYD 
proteins to the pharmacological inhibitors the cardiac glycosides. Although 
all experiments shown here are on just one member of the cardiac 
glycosides known as ouabain, their identical steroid backbones indicate 
their mechanism is likely veiy similar. Although the work presented here 
fails to give a real insight into how cardiac glycosides bind to the Na+, K+- 
ATPase the aim to develop a novel method of probing the location of 
ligands within transmembrane regions of proteins was successful. ODA 
gave unusual results in that previously it gave rise to a signature pair of 
peaks in the NMR spectra (Middleton et ah, 2000) whereas in the data 
presented here it either appeared as one broad peak (Figure 6.29.) in the 
case of -25°C experiments or only the steroid peak appeared as expected 
whereas the rhamnose peak was hard to distinguish in the case of -10°C 
experiments (Figure 6.30.). Although the steroid peak appears at -10°C it 
diminishes in manganese concentrations as low as 0.25 mM (Figure 6.31.) 
at which only a small effect is observed on lipid headgroups (Figure 6.33.). 
In OMA experiments this peak has not fully diminished in manganese 
concentrations as high as 5 mM (Figure 6.25-26.). This suggests OMA and 
ODA are binding in different locations within the NaH', K+-ATPase with 
OMA binding within the protein near the surface whereas ODA binds on 
the surface itself leaving the 13C nuclei very prone to the effects of 
manganese on T2 relaxation times. It is unclear why ODA is acting in this
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way when it has not done previously. Fresh ODA would need to be 
produced to see if ODA possibly degraded during or after the preparation 
of Na+, K+-ATPasc samples for NMR which could explain its unusual 
binding. There is a possibility ODA binds to a surface site as it is shown as 
a possibility in GOLD experiments (Figure 6.14.). If these problems can be 
overcome the system is in place to determine the accessibility of both ODA 
peaks. As shown in Figures 6.36-37 the peak intensities of natural 
abundance 13C reduce as a result of increased manganese concentration in a 
similar manner in all cases apart from -25 °C lipid headgroups. Slight 
deviations have to be expected due to the methods of purification of the 
Na+, K+-ATPase samples it is impossible to have the same quantity of 
protein between samples.
Since these experiments were performed a high ouabain affinity Na+, K+ - 
ATPase structure with bound ouabain has been solved (Yatime et al, 
2011). Unlike the low ouabain affinity structure (Ogawa et al, 2009) 
where the Na+, K+-ATPase was crystallised before soaking ouabain into 
the ciystal this structure stabilised the Na+, K+-ATPase with ouabain itself 
before crystallisation. This meant that ouabain bound to the Na+, K+- 
ATPase whilst still active. This structure reveals two key things. Firstly it 
reveals the homology model (Figure 6.11) is unrepresentative of the true 
E2P conformation as revealed by the alignment of the homology model 
with the high ouabain affinity structure in Figure 6.38. For any further
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homology models to be used with Naf, K4-ATPase better strategies will 
have to be developed.
Figure 6.38. Alignment of high ouabain affinity Na+, K+-ATPase with EjP homology 
model. This alignment highlights the clear differences between the E2P homology model 
of the a-subunit (red) presented in this work (using SERCA as a template) and the high 
ouabain affinity E2P Na*, K+-ATPase (green, cyan and magenta PDB1D: 3N23).
Secondly it reveals the differences between the high and low ouabain 
affinity structures of the Na', K^-ATPase. Figure 6.39. is an alignment of 
both Na+, Kf-ATPase structures with bound ouabain. Although very 
similar there is a clear difference between the two. It is unclear if this 
difference is due to the different affinities or the different species used as
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the low ouabain affinity structure is from spiny dogfish rectal gland and the 
high ouabain affinity structure is from pig kidney. The possibility of 
differences between species is also brought into question by the GOLD 
Na+, K+-ATPase/ouabain docking presented here. Whilst the distance from 
the centre of mass of the Na+, K+-ATPase to the centre of mass of ouabain 
modelled by GOLD is similar between species (Figure 6.9) the orientation 
of ouabain within the Na+, K+-ATPase is noticeably different (Figure 6.10). 
By solving high ouabain affinity spiny dogfish rectal gland and low 
ouabain affinity pig kidney Na+, K+-ATPase it could be confirmed if there 
really are differences between species. Additionally by overcoming the 
problems with ODA the NMR experiments presented here could provide 
more evidence and hold the advantage over x-ray crystallography of being 
performed on active protein.
306
Figure 6.39. Alignment of Na+, K+-ATPase bound to ouabain in low and high affinity 
conformations. Low ouabain affinity Na\ K -ATPase from spiny dogfish (green a- 
subunit, cyan P-subunit, magenta FXYD protein (FXYD10) with brown ouabain PDB1D: 
3A3Y) is shown aligned to high ouabain affinity Na', K4-ATPase (red a-subunit, yellow 
P-subunit, orange FXYD protein (FXYD 10) with blue ouabain PDBID: 3N23).
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Chapter 7
7.1. General Discussion
The general aim of this project was to gain a better understanding of two 
classes of regulators of the Na+, K!-ATPase, one physiological and one 
pharmacological, using a range of biophysical and biochemical techniques. 
The first class of regulators are the FXYD proteins which are a family of 
small transmembrane proteins that are expressed tissue specifically and 
form a complex with the Na+, K+-ATPase (Garty and Karlish, 2005). The 
second class of regulators are the cardiac glycosides, which are very potent 
pharmacological inhibitors of the Na+, K+-ATPase and have been 
administered as drugs for over 200 years.
This was a timely project for analysis of regulators of Na+, K+-ATPase as 
four different structures of the protein (Morth et a!., 2007; Ogawa et al, 
2009; Shinoda et al, 2009; Yatime et al, 2011) were solved and published 
dining the course of the work. The results presented in this thesis have 
provided new insights into the how the cytoplasmic region of both PLM 
and the long isoform of Mat-8 interact with the Na+, K+-ATPase and cell 
membranes. For cardiac glycosides additional insights into the orientation 
of ouabain within the Na+, K+-ATPase have been made. Moreover, the 
methodology developed in this thesis will enable further examination of 
FXYD proteins and cardiac glycosides. For FXYD proteins, the short
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isoform of Mat-8 was successfully expressed and purified and a new solid- 
state NMR based method has been developed to probe the depths of 
ligands within the binding pockets of transmembrane proteins.
7.2. Conclusions
7.2.1. FXYD Proteins
At the outset of the project the aim was to develop an expression and 
purification system for the production of milligram quantities of I5N and 
13C labelled FXYD proteins for NMR. Although this has yet to be achieved 
much progress has been made toward this goal. Membrane proteins are 
notoriously difficult to express and purify (Grisshammer and Tateu, 1995). 
Indeed, another group has reported specific problems in expressing and 
purifying FXYD proteins, which was addressed by designing the pBCL 
vector which requires the mutation of methionine residues to leucine 
residues to facilitate CNBr cleavage (Thai et aL, 2005). As Mat-8 contains 
two methionine residues in its transmembrane region this construct is not 
ideal and attempts to recreate the system were unsuccessful. By developing 
a new system in the pMAL plasmid (Riggs, 2001), Mat-8 was successfully 
expressed and purified in LB. This system produces Mat-8 as a fusion 
protein with MBP. The procedure incurred many problems as the 
purification procedure required soluble protein. The insolubility of Mat-8 
caused by its hydrophobic transmembrane region meant that detergent was
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required as an aid to solubility. This meant many methods had to be 
attempted to remove the detergent after purification of Mat-8 and cleavage 
from its fusion partner MBP. A successful method was reached by 
purifying the Mat-8/MBP fusion protein in the amylose column, cleaving 
with TEVP, precipitating protein with chloroform methanol precipitation 
and purifying by HPLC after dissolving the protein in guanidium chloride. 
This large number of purification steps may be why when the process was 
repeated in labelled minimal media, not enough protein was present to 
produce an NMR signal. Nevertheless a system is now in place to produce 
Mat-8 and with appropriate optimisation may yield enough labelled protein 
for NMR.
Although the lack of labelled protein prevented structural analysis of full- 
length FXYD proteins by NMR, several other methods were employed to 
gain structural insights into the soluble cytoplasmic regions of FXYD 
proteins. CD revealed the a-helical content of PLM.3s.72 (Clayton et al, 
2005), Mat-Ssfss-e?, Mat-81f38-9o and CHIF3S-69 to be approximately 15%, 
0%, 8% and 7% respectively. This shows that the diversity of amino acid 
sequence between FXYD proteins in the cytoplasmic region is also 
reflected in the structure of the cytoplasmic region of FXYD proteins 
providing further evidence they confer the tissue specific features of 
FXYD proteins. The level of a-helical content of PLM38-72 estimated by 
CD is around half the level of a-helical content solved by solution NMR in
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SDS micelles. Further CD presented here shows that SDS induces 
additional a-helical content in PLM38-72. This is most likely because SDS is 
a highly negative detergent which is not a suitable proxy for a cell 
membrane which is a bilayer with a much lower surface charge.
As the cytoplasmic region is the most varied part of the FXYD proteins 
work was undertaken to understand the function and interactions of this 
region within PLM and Mat-8. One of the questions addressed in this 
thesis is whether the cytoplasmic domains of FXYD proteins interact 
directly with Na+,K+-ATPase, or are stabilised by interactions with the 
phospholipid membrane surface, or whether both interactions occur in 
dynamic equilibrium. PLM is particularly interesting in the cytoplasmic 
region as it has two PKA/PKC phosphorylation sites at Ser 63 and Ser 68 
(Palmer et ah, 1991; Mounsey et al, 2000). The PLM cytoplasmic domain 
alone partially inhibits Na+, K+-ATPase but when Ser 68 is phosphorylated 
in PLMs4_72 the Na+, K' -ATPase activity is stimulated to a level above that 
in the absence of the peptide (Pavlovic et al, 2007). It would also appear 
that phosphorylation reduces the affinity of the cytoplasmic region of PLM 
for negatively charged membranes as shown here by ITC and also reduces 
the potency of the PLM cytoplasmic region as an inhibitor of the Na+, K+- 
ATPase. This suggests that phosphorylation regulates the function of the 
cytoplasmic region as an inhibitor of the Na+, K+-ATPase as it reduces the 
affinity of PLM38-72 for both the Na+, K+-ATPase and phospholipids which
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is supported by the fact that the cytoplasmic region of the short isoform of 
Mat-8 and CHIP have no effect on Na+, K+ -ATPase function and are not 
phosphorylated by PKA or PKC. By testing the binding of PLM38-72 in the 
presence of the Na+, K+-ATPase it would appear that the interaction with 
cell membranes is much weaker than previously reported (Clayton et al, 
2005). This suggests that the role of PLM phosphorylation in regulating the 
Na+, K+ -ATPase is largely caused by reducing its affinity for the binding 
site on the protein and the reduction of binding to negatively charged cell 
membranes obseived in PPLM38-72 over PLM3S-72 is insubstantial especially 
since native membranes have a much lower surface charge (Akio, 1971) 
than the 2:1 DMPC DOPG membranes which were used in these NMR 
experiments. This interaction could still be crucial to the stability of the 
cytoplasmic region of PLM. An interesting finding of this work is that the 
cytoplasmic region of the long isoform of Mat-8 is a weak inhibitor of the 
Na+, K+-ATPase, albeit to a smaller degree than PLM. This isoform is a 
relatively new discoveiy and thus poorly understood (Bibert et al, 2006), it 
is not known if it is physiologically phosphorylated. It does have three 
predicted phosphorylation sites not present in the short isoform of Mat-8 
which may mean phosphorylation plays a role in its regulation like in 
PLM.
Bioinformatics was also used to gain insights into how the cytoplasmic 
region of PLM and long form Mat-8 might interact with the Na+, K+-
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ATPase with the spiny dogfish rectal gland structure (Shinoda et al., 2009) 
being used in the studies. This led to the discovery of the motif SxxRxS 
using DiLiMOT which is present in the cytoplasmic region of PLM and 
long form Mat-8 but no other FXYD proteins. It is also present in several 
other proteins that interact with the Na+3 ATPase. Whilst the motif is 
predicted to be at the end of a helix in both PLM and long form Mat-8 it is 
only predicted to be disordered in PLM. Disorder has proved to be a 
common feature in small linear motifs with the premise of becoming 
ordered upon binding (Davey et al, 2012). Another common feature of 
short linear motif is conservation. The long isoform of Mat-8 has currently 
only been discovered in humans so its conservation is unclear. However 
the motif is preserved in all known instances of PLM, which include 
mammals and amphibians. Finding a potential location for this motif on the 
surface of the Na+, K+-ATPase proved more difficult. This is because a 
major method of predicting binding locations is to analyse the surface of a 
target protein for conservation. Unfortunately the number of species known 
to express FXYD proteins is relatively small and thus the majority of the 
Na+, K+-ATPase surface is conserved across these species. Other methods 
were limited by the fact the Na+, K+-ATPase is a membrane protein and the 
hydrophobic membrane region is calculated as potential binding sites for 
peptides which is inaccessible to the cytoplasmic region of a FXYD 
protein. Anchorsmap is a more motif specific method for analysing protein 
surfaces for binding sites in that it finds locations for specific amino acid
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residues. This revealed a potential binding site for the SxxRxS motif which 
is located on the surface of the Na+, K+-ATPase in close proximity of the 
cytoplasmic cell membrane surface. This binding site is in a similar 
location to where is appears in the proposed model within helix 4 of PLM 
(Teriete et ah, 2007; Teriete et al., 2009). By modelling the cytoplasmic 
helix of PLM from the solved structure into this site it reveals it is both 
sterically and electrostatically compatible. Furthermore the side chain of an 
arginine residue in the random coil structure at the C-terminus of this helix 
is able to interact with the membrane surface which provides a possible 
explanation for how the cytoplasmic region of PLM may interact with both 
the Na+, K!-ATPase and the membrane surface.
This interaction would occur at the N-terminus of helix M5 of the Na+, K+- 
ATPase. It would therefore appear when the cytoplasmic region of PLM 
binds to the Na1, K+-ATPase it causes a movement of helix M5. This 
movement causes the C-terminus of helix M5 to move away from the third 
Na+ binding site which located at the C-terminus of helix M5, M6 and M9 
(Morth et a!,, 2007). This would surely have an effect on the affinity for 
Na+ of the third binding site which would explain the inhibitory effects of 
the cytoplasmic region of PLM on Na+, K+-ATPase activity.
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Anchorsmap calculated another binding site that would place the a-helix in 
a similar location to the one proposed in a recent model as an alternative 
PLM orientation induced by phosphorylation (Teriete et al, 2009). 
However analysis of the protein surface at this location reveals it is 
unlikely to be a real site as the pocket appears too small to accommodate 
an a-helix.
There appears to be a direct relationship between the structural and 
functional studies of FXYD cytoplasmic domains earned out in this thesis. 
PLM38-72 has the greatest effect on the function of the Na+, K+~ATPase and 
has the highest affinity for cell membranes of all the FXYD proteins tested, 
and also has the largest a-helical content. Mat-81f38-93 also has an effect on 
the function of the Na+, K+-ATPase and has an affinity for phospholipid 
membranes but Mat-Ssfss-e? has no significant effect on Na+, K’ -ATPase or 
affinity for membranes. Interestingly Mat-Ssfsg-e? is essentially 
unstructured whereas Mat-81f38-93 has approximately 8% a-helical content 
suggesting that the inhibitory function of the long isoform of Mat-8 and 
inactivity of the short isoform of Mat-8 could be related to structure. The 
proposed interaction between the SxxRxS motif in PLM and Na+, K+- 
ATPase also shows how the cytoplasmic region of PLM can interact with 
both the Na+, K'-ATPase and cell membranes simultaneously which 
supports the observation of PLM38,-72 binding to cell membranes in the 
presence of the Na+, K+-ATPase.
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7.2.2. Cardiac Glycosides
Further understanding of the interaction of cardiac glycosides with the Na+, 
K+-ATPase has been gained with both solid-state NMR and computer 
prediction methods. By analysing the low-ouabain affinity Na+, K+- 
ATPase stractures with GOLD, the possibility of ouabain occupying 
slightly different orientations in different species was revealed. This was 
surprising given the high specificity of ouabain to the Na+, K+-ATPase 
(Jewell et aL, 1992). Work has begun to confirm this observation 
experimentally by developing a novel solid-state NMR method for 
determining the depth of ligands within its binding site. By using cross- 
polarisation, 13C signals from a I3C labelled derivative of ouabain bound to 
Na+,K+-ATPase can be detected. These signals along with peaks from 
specific locations in the membrane and Na+, K+-ATPase such as lipid 
headgroups and C=C are reduced by the paramagnetic broadening agent 
manganese. Manganese will bind to membrane and protein surfaces and 
reduce the relaxation times of the nuclear spins in its local proximity. The 
effect on each spin is dependent on the distance from the manganese in that 
the closer it is the larger the effect on broadening. This means each I3C 
peak of the Na+, K+-ATPase is diminished based on accessibility to Mn2+, 
so whilst lipid headgronp signals will diminish at low quantities of 
manganese due to their ease of accessibility, less accessible signals like the
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lipid methyl which is found in the middle of the lipid bilayer will not be 
significantly affected by manganese. By adding a ligand such as ouabain 
labelled with 13C at two chemically and magnetically distinct sites, the 
relative effects of Mn2+ on these two peaks can be analysed to give 
information about the ligand orientation in the binding site. By comparing 
the broadening of the two 13C peaks on ouabain to the broadening of the 
natural abundance peaks in the Na+, K+-ATPase membranes, the 
accessibility of the two 13C label sites on ouabain can be estimated 
separately. This means if one site is closer to the protein surface than the 
other and therefore more exposed, its NMR peak will be more affected by 
manganese. The labelling method used in these experiments involved 
forming acetonide bridges at two locations on ouabain at the steroid moiety 
and rhamnose moiety. This produced OMA (steroid moiety label only) and 
ODA (steroid and rhamnose moiety labelled). Experiments with OMA 
proved very successful and appeared to show that ouabain was bound to 
the Na+, K+-ATPase and close to the protein surface. To understand the 
orientation of ouabain ODA needs to be used as it has two distinguishable 
sites that can be analysed. Unfortunately, ODA behaved very differently to 
OMA as the steroid 13C peak was completely diminished at a veiy low 
manganese concentration suggesting it was binding to a different site on 
the surface. The rhamnose peak appeared veiy differently to what had been 
obseived previously (Middleton et al, 2000) suggesting it was occupying a 
range of orientations. Experiments run on ODA before the NMR
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experiments showed it binds competitively with ouabain which suggests it 
was binding to the same site. This suggests an issue arose during sample 
preparation and the ODA possibly degraded preventing it from binding to 
the cardiac glycoside binding site in the Na+, K' -ATPase. Nevertheless the 
system is in place to repeat the method with fresh sample.
7.3. Future Work
7.3.1. Further Development of the pMAL expression system for FXYD 
proteins
The work presented here lays the foundations for many other experimental 
possibilities. With the successful expression and purification of Mat-8 its 
role in regulation of the Na+, K+-ATPase can be further investigated. 
Initially the Na' , K+-ATPase could be reconstituted with Mat-8 in synthetic 
membranes. The ATPase activity could be then measured and compared to 
activity of the Na+, K+-ATPase reconstituted without Mat-8 to gain further 
insights into the effect of full length Mat-8 as a regulator of the Na+, K+ - 
ATPase (Crambert et al, 2005). As preparations of the Na+, K+-ATPase 
contain y-subimit or FXYD 10 this will not be ideal as they will bind to the 
Na+, K+-ATPase in the same location. If a method to purify FXYD-protein 
free native Na+, K+-ATPase or a method to express and purify the Na* K+- 
ATPase could be developed this could solve this problem. However the 
expression, and purification of a heterodimeric membrane protein would be
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extremely difficult. SERCA has been successfully expressed in yeast and 
purified (Jidenko et ah, 2006) which is promising due to its homology with 
the a-subunit of the Na+, K+-ATPase. The p-subunit is likely to cause many 
additional problems as it will need to be co-expressed and form a complex 
with the a-subunit which is not an issue in SERCA.
There were several purification steps involved in the production of Mat-8 
which meant insufficient quantities of labelled protein were produced for 
NMR. By reducing the number of steps the yield may be improved enough 
to produce an NMR signal, hi addition alternative detergents with higher 
critical micellar concentrations could be used to solubilise the fusion 
protein, facilitating full removal of the detergent by dialysis and possibly 
allowing precipitation of pine Mat-8. Alternatively this could also be 
achieved by using a different chloroform precipitation method that has 
successfully removed small transmembrane proteins from detergents and 
impurities (Hu et al., 2007). An alternative expression construct with a 
different fusion partner may also be investigated to improve the solubility 
of the fusion protein and eliminate the requirement for detergents. Upon 
successful expression and purification of 13C/15N labelled short form Mat-8 
it could then be possible to reconstitute it into synthetic lipid bilayers with 
a similar composition to native membranes and solve the structure by 
NMR as has been done for the small membrane protein kaliotoxin (Lange 
et at, 2005). This would be a superior method to what has been employed
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for PLM (Teriete et al, 2007) and CHIP (Franzin et ah, 2007d) which 
were solved in SDS micelles which are a highly negatively charged 
monolayer unlike the slightly negatively charged bilayer observed in cell 
membranes. With a successful system in place for Mat-8 work could then 
be done to apply it to other FXYD proteins, particularly the long isoform 
of Mat-8 so the structural differences between the two isoforms could be 
compared.
7.3.2. The cytoplasmic regions of PLM and long form Mat-8 as Na+, 
K-AIPase inhibitors
As the ATPase assays of PLM38-72 on Na+, K+-ATPase reconstituted into 
2:1 DMPC:DOPG at 100 mM Na+ showed much less inhibition than in 
native membranes, a full Na+ titration curve needs to be produced to see if 
there is a reduction on K0.5 or Vmax- If there is a reduction in these 
parameters then it would suggest that PLM38-72 does not immobilise DOPG 
as previously reported (Clayton et ah, 2005) and rather binds to lipid 
membrane surfaces. It would also be interesting to perform experiments in 
DMPC DOPS membranes as PLM38-72 binds more strongly to DOPS 
which is a eukaryotic lipid than DOPG which is a prokaryotic lipid. It is 
possible that the nature of the experiments that show PLM38-72 immobilised 
DOPG are flawed as they are performed in LMVs which could mean a 
high local concentration of peptide in the interbilayer space could increase 
the effect of PLM38-72 on DOPG. However it is possible that the stronger
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interaction between PLM38.72 and DOPS could be significant as if it 
immobilised DOPS in Na+, K+-ATPase reconstituted in DMPC:DOPS it 
would increase the local concentration of DMPC around the Na+, K+- 
ATPase which would not support function.
7.3.3. Further Bioinformatics
The Na+ activation curve of the Na+5 K+-ATPase in the presence of the 
long isoform of Mat-8 revealed an increase in K0.5. It also failed to reach 
maximal activity but Hill curve fitting suggested there was no effect on 
Vmax- To confirm this additional experiments would need to be performed 
at higher Na+ concentrations to produce a full curve where VmBX is reached.
Although the cytoplasmic helix of PLM was modelled onto the surface of 
the Na+, K+-ATPase this hypothesis could be strengthened by modelling 
the foil length protein. This could be achieved using Modeller which can 
model loops using a satisfaction of spatial restraints method. (Fiser et al, 
2000). If the structure of long form Mat-8 could be solved then similar 
methods could be employed to model the interaction of its cytoplasmic 
region with the Na+, K+-ATPase
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7.3.4. The orientation of ouabain bound to the Na+, K+-ATPase 
Finally, with the system in place to analyse the depths of acetonide bridges
on ouabain by solid-state NMR, the ODA experiments need to be repeated
to determine the orientation of ouabain in the Na+, K'! -ATPase. By doing
this in both pig kidney and spiny dogfish rectal gland Na+, K+-ATPase
membranes it can be determined if there really are differences between
species in the orientation of ouabain bound to the Na+, K+-ATPase as
ouabain is a veiy potent and specific inhibitor of the Na+, K+-ATPase if
there is a variations of orientations between species the interaction may not
be as specific as first thought. It would also be advantageous to perform
solution-state NMR on both OMA and ODA to confirm how they are
observed on an NMR spectrum when not constrained by being bound to
the Na1, K+-ATPase.
In conclusion, this work has not only provided insights into the mechanism 
of the cytoplasmic regions of FXYD proteins it has also developed several 
novel methods for the analysis of both FXYD proteins and cardiac 
glycosides; inhibitors of the Na+, K+-ATPase and opens up many 
possibilities for further study.
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APPENDIX A
CLUSTAL 2.1 multiple sequence alignment
alpha-1
MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDELHRKYGTDL 
S 60
alpha-3 MG---- DKKD-----
DKDSPKKNKGKERRDLDDLKKEVAMTEHKMSVEEVCRKYNTDCV 50 
alpha-2 MGRGAGREYSPAATTAENGGGKKKQ—
KEKELDELKKEVAMDDRKLSLDELGRKYQVDLS 58
SERCA1 ----------------------------------------
MEAAHAKTTEECLAYFGVSET 21
SERCA2 ----------------------------------------
MENAHTKTVEEVLGHFGVNES 21
SERCA3 ----------------------------------------
MEAAHLLPAADVLRHFSVTAE 21
alpha-1
RGLTSARAAEILARDGPNALTPPPTTPEWIKFCRQLFGGFSMLLWIGAILCFLAYSIQAA 120
alpha-3
QGLTHSKAQEILARDGPNALTPPPTTPEWVKFCRQLFGGFSILLWIGAILCFLAYGIQA
G 110
alpha-2
KGLTNQRAQDVLARDGPNALTPPPTTPEWVKFCRQLFGGFSILLWIGAILCFLAYGIQA
A 118
SERCA1
TGLTPDQVKRNLEKYGLNELPAEEGKTLWELVIEQFEDLLVRILLLAACISFVLAWFEE
G 81
SERCA2
TGLSLEQVKKLKERWGSNELPAEEGKTLLELVIEQFEDLLVRILLLAACISFVLAWFEE
G 81
SERCA3
GGLSPAQVTGARERYGPNELPSEEGKSLWELVLEQFEDLLVRILLLAALVSFVLAWFEE G 81
alpha-1
TEEEPQNDNLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEK—
M 178
alpha-3
TEDDPSGDNLYLGIVLAAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIREGEK— 
M 168
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alpha-2
MEDEPSNDNLYLGVVLAAVVIVTGCFSYYQEAKSSKIMDSFKNMVPQQALVIREGEK— 
M 176
SERCA1 EE--
TITAFVEPFVILLILIANAIVGVWQERNAENAIEALKE YE PEMGKVYRADRKSVQ 138 
SERCA2 EE--
TITAFVEPFVILLILVANAIVGVWQERNAENAIEALKE YE PEMGKVYRQDRKSVQ 138 
SERCA3 EE--
TTTAFVEPLVIMLILVANAIVGVWQERNAESAIEALKEYEPEMGKVIRSDRKGVQ 138
alpha ~1 SINAEEVVVGDLVEVKGGDRIPADLRIISANG—
CKVDNSSLTGESEPQTRSPDFTNEN- 235
alpha-3 QVNAEEVVVGDLVEIKGGDRVPADLRIISAHG—
CKVDNSSLTGESEPQTRSPDCTHDN- 225
alpha-2 QINAEEVVVGDLVEVKGGDRVPADLRIISSHG—
CKVDNSSLTGESEPQTRSPEFTHEN- 233
SERCA1
RIKARDIVPGDIVEVAVGDKVPADIRILAIKSTTLRVDQSILTGESVSVIKHTEPVPDP
R 198
SERCA2
RIKAKDIVPGDIVEIAVGDKVPADIRLTSIKSTTLRVDQSILTGESVSVIKHTDPVPDP
R 198
SERCA3
RIRARDIVPGDIVEVAVGDKVPADLRLIEIKSTTLRVDQSILTGESVSVTKHTEAIPDP 
R 198
alpha-1
PLETRNIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAAEIEHFIH
293
alpha-3
PLETRNITFFSTNCVEGTARGVVVATGDRTVMGRIATLASGLEVGKTPIAIEIEHFIQ
283
alpha-2
PLETRNICFFSTNCVEGTARGIVIATGDRTVMGRIATLASGLEVGRTPIAMEIEHFIQ
291
SERCA1
AVNQDKKNMLFSGTNIAAGKALGIVATTGVGTEIGKIRDQMAATEQDKTPLQQKLDEFG
E 258
SERCA2
AVNQDKKNMLFSGTNIAAGKAMGVVVATGVNTEIGKIRDEMVATEQERTPLQQKLDEFG
E 258
SERCA3
AVNQDKKNMLFSGTNITSGKAVGVAVATGLHTELGKIRSQMAAVEPERTPLQRKLDEFG 
R 258
alpha-1 IITGVAVFLGVSFFILSL------
ILEYTWLEAVIFLIGIIVAN--- VPEGLLATVTVC 343
alpha-3 LITGVAVFLGVSFFILSL------
ILGYTWLEAVIFLIGIIVAN--- VPEGLLATVTVC 333
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alpha-2 LITGVAVFLGVSFFVLSL------
ILGYSWLEAVIFLIGIIVAN--- VPEGLLATVTVC 341
SERCA1
QLSKVISLICVAVWLINIGHFNDPVHGGSWFRGAIYYFKIAVALAVAAIPEGLPAVITT
C 318
SERCA2
QLSKVISLICIAVWIINIGHFNDPVHGGSWIRGAIYYFKIAVALAVAAIPEGLPAVITT
C 318
SERCA3
QLSHAISVICVAVWVINIGHFADPAHGGSWLRGAVYYFKIAVALAVAAIPEGLPAVITT 
C 318
alpha-1
LTLTAKRMARKNCLVKNLEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTT 403
alpha-3
LTLTAKRMARKNCLVKNLEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADT
T 393
alpha-2
LTLTAKRMARKNCLVKNLEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADT
T 401
SERCA1
LALGTRRMAKKNAIVRSLPSVETLGCTSVICSDKTGTLTTNQMSVCKMFIIDKVDGDICL 378
SERCA2
LALGTRRMAKKNAIVRSLPSVETLGCTSVICSDKTGTLTTNQMSVCRMFILDRVEGDTC
S 378
SERCA3
LALGTRRMARKNAIVRSLPSVETLGCTSVICSDKTGTLTTNQMSVCRMFVVAEADAGSC 
L 378
*** •m'k'k'ki'frit -^r ****** ** **********
***•* •*«
alpha-1 ENQSGVSFDKTSA-----------------
TWLALSRIAGLCNRAVFQANQENLPILKRA 446
alpha-3 EDQSGTSFDKSSH-----------------
TOTALSHIAGLCNRAVFKGGQDNIPVLKRD 436
alpha-2 EDQSGATFDKRSP-----------------
TWTALSRIAGLCNRAVFKAGQENISVSKRD 444 
SERCA1
LNEFSITGSTYAPEGEVLKNDKPVRPGQYDGLVELATICALCNDSSLDFNEAKGVYEKV
G 438
SERCA2
LNEFTITGSTYAPIGEVHKDDKPVNCHQYDGLVELATICALCNDSALDYNEAKGVYEKV
G 438
SERCA3
LHE FTIS GTTYTPEGEVRQGDQPVRCGQFDGLVELATICALCNDSALDYNEAKGVYEKV 
G 438
alpha-1 VAGDASESALLKCIELC
CGSVKEMRERYAKIVEIPFNSTNKYQLS 491
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alpha-3 VAGDASESALLKCIELS---------------
SGSVKLMRERNKKVAEIPFNSTNKYQLS 481
alpha-2 TAGDASESALLKCIELS----------------
CGSVRKMRDRNPKVAEIPFNSTNKYQLS 489 
SERCA1
EATETALTTLVEKMNVFNTDVRSLSKVERANACNSVIRQLMKKEFTLEFSRDRKSMSVY
C 498
SERCA2
EATETALTCLVEKMNVFDTELRGLSKIERANACNSVIKQLMKKEFTLEFSRDRKSMSVY
C 498
SERCA3
EATETALTCLVEKMNVFDTDLQALSRVERAGACNTVIKQLMRKEFTLEFSRDRKSMSVY 
C 498
* ... . * *
* .
alpha-1
IHKNPNTSEPQHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQNAYLELGGLGE
R 551
alpha-3
IHETEDPNDNRYLLVMKGAPERILDRCSTILLQGKEQPLDEEMKEAFQNAYLELGGLGE 
R 541
alpha-2 IHEREDSPQS-
HVLVMKGAPERILDRCSTILVQGKEIPLDKEMQDAFQNAYMELGGLGER 548 
SERCA1
SPAKSSRAAVGNKMFVKGAPEGVIDRCNYVRVGTTRVPLTGPVKEKIMAVIKEWGTGRD 
T 558
SERCA2 TPNKPSRTSMS-
KMFVKGAPEGVIDRCTHIRVGSTKVPMTSGVKQKIMSVIREWGSGSDT 557 
SERCA3
TPTRPHPTGQGSKMFVKGAPESVIERCSSVRVGSRTAPLTPTSREQILAKIRDWGSGSD 
T 558
. *
alpha-1 VLGFCHLFLPDEQFPEGFQFDTDDVNFPIDN-
LCFVGLISMIDPPRAAVPDAVGKCRSAG 610
alpha-3 VLGFCHYYLPEEQFPKGFAFDCDDVNFTTDN-
LCFVGLMSMIDPPRAAVPDAVGKCRSAG 600
alpha-2 VLGFCQLNLPSGKFPRGFKFDTDELNFPTEK-
LCFVGLMSMIDPPRAAVPDAVGKCRSAG 607
SERCAl
LRCLALATRDTPPKREEMVLDDSARFLEYETDLTFVGVVGMLDPPRKEVTGSIQLCRDA
G 618
SERCA2
LRCLALATHDNPLRREEMHLEDSANFIKYETNLTFVGCVGMLDPPRIEVASSVKLCRQA
G 617
SERCA3
LRCLALATRDAPPRKEDMELDDCSKFVQYETDLTFVGCVGMLDPPRPEVAACITRCYQA 
G 618
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alpha-1
IKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDAKACVVHGSD
L 670
alpha-3
IKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDAKACVIHGTD
L 660
alpha-2
IKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPMSQVNPREAKACVVHGSD 
L 667
SERCA1 IRVIMITGDNKGTAIAICRRIGIFGENE--------------
---- EVADRAYTGREF 658
SERCA2 IRVIMITGDNKGTAVAICRRIGIFGQDE--------------
---- DVTSKAFTGREF 657
SERCA3 IRVVMITGDNKGTAVAICRRLGIFGDTE--------------
---- DVAGKAYTGREF 658
* * . .
alpha-1
KDMTSEQLDDILKYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKKAD 
I 730
alpha-3
KDFTSEQIDEILQNHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKKAD
I 720
alpha-2
KDMTSEQLDEILKNHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKKAD I 727
SERCA1 DDLPLAEQREACR—
RACCFARVEPSHKSKIVEYLQSYDEITAMTGDGVNDAPALKKAEI 716 
SERCA2 DELNPSAQRDACL—
NARCFARVEPSHKSKIVEFLQSFDEITAMTGDGVNDAPALKKAEI 715 
SERCA3 DDLSPEQQRQACR—
TARCFARVEPAHKSRIVENLQSFNEITAMTGDGVNDAPALKKAEI 716
'k 'k 'k k • k -k k k k
k k • k k k k k k k • k k k k k k • k
alpha-1
GVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTLTSNIPEITP
F 790
alpha-3
GVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTLTSNIPEITP
F 780
alpha-2
GIAMGISGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTLTSNIPEITP F 787
SERCAl GIAMGS-
GTAVAKTASEMVLADDNFSTIVAAVEEGRAIYNNMKQFIRYLISSNVGEVVCI 775 
SERCA2 GIAMGS-
GTAVAKTASEMVLADDNFS TIVAAVEEGRAIYNNMKQFIRYLIS SNVGEVVCI 774 
SERCA3 GIAMGS-
GTAVAKSAAEMVLSDDNFASIVAAVEEGRAIYSNMKQFIRYLISSNVGEVVCI 775
k * k k k k • k • k k * + k • k kkkk*»kk* k k k k k
k * * k * k • k k
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alpha-1
LIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPKTDKLVNERL
I 850
alpha-3
LLFIMANIPLPLGTITILCIDLGTDMVPAISLAYEAAESDIMKRQPRNPRTDKLVNERL
I 840
alpha-2
LLFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEAAESDIMKRQPRNSQTDKLVNERL
I 847
SERCAl
FLTAALGLPEALIPVQLLWVNLVTDGLPATALGFNPPDLDIMDRPPRSPKEPLISGWLF
F 835
SERCA2
FLTAALGFPEALIPVQLLWVNLVTDGLPATALGFNPPDLDIMNKPPRNPKEPLISGWLF
F 834
SERCA3
FLTAILGLPEALIPVQLLWVNLVTDGLPATALGFNPPDLDIMEKLPRSPREALISGWLF 
F 835
alpha-1
SMAYGQIGMIQALGGFFTYFVILAENGFLPIHLLGLRVDWDDRWINDVEDSYGQQWTYE
Q 910
alpha-3
SMAYGQIGMIQALGGFFSYFVILAENGFLPGNLVG1RLNWDDRTVNDLEDSYGQQWTYE
Q 900
alpha-2
SMAYGQIGMIQALGGFFTYFVILAENGFLPSRLLGIRLDWDDRTMNDLEDSYGQEWTYE 
Q 907
SERCAl RYMAIGGYVGAATVGAAAWWFLYAEDGPH------
VNYSQLTHFMQCTEDNTHFEGIDCE 889
SERCA2 RYLAIGCYVGAATVGAAAWWFIAADGGPR------
VSFYQLSHFLQCKEDNPDFEGVDCA 888
SERCA3 RYLAIGVYVGLATVAAATWWFVY DAE GPH------
INFYQLRNFLKCSEDNPLFAGIDCE 889
* :
. . **
alpha-1
RKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFEETALAAFLS
Y 970 
alpha-3
RKVVEFTCHTAFFVSIWVQWADLIICKTRRNSVFQQGMKNKILIFGLFEETALAAFLS
Y 960 
alpha-2
RKVVEFTCHTAFFASIVVVQWADLIICKTRRNSVFQQGMKNKILIFGLLEETALAAFLS
Y 967 
SERCAl
VFEAPEPMTMALSVLVTIEMCNALNSLSENQSLLRMPPWVNIWLLGSICLSMSLHFLIL
Y 949 
SERCA2
IFESPYPMTMALSVLVTIEMCNALNSLSENQSLLRMPPWENIWLVGSICLSMSLHFLIL
Y 948
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SERCA3
VFESRFPTTMALSVLVTIEMCNALNSVSENQSLLRMPPWMNPWLLVAVAMSMALHFLIL 
L 949
alpha-1
CPGMGVALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKETYY-----
- 1023 
alpha-3
CPGMDVALRMYPLKPSWWFCAFPYSFLIFVYDEIRKLILRRNPGGWVEKETYY-----
- 1013 
alpha-2
CPGMGVALRMYPLKVTWWFCAFPYSLLIFIYDEVRKLILRRYPGGWVEKETYY-----
- 1020 
SERCA1
VDPLPMIFKLRALDLTQWLMVLKISLPVIGLDEILKFVARNYLEDPEDE—RRK----
- 1001 
SERCA2
VEPLPLIFQITPLNVTQWLMVLKISLPVILMDETLKFVARNYLEPGKEC—
VQPATKSCS 1006
SERCA3
VPPLPLIFQVTPLSGRQWVVVLQISLPVILLDEALKYLSRNHMHACLYPGLLRTVSQAW 
S 1009
alpha-1
alpha-3
alpha-2
SERCA1
SERCA2
SERCA3
FSACTDGISWPFVLLIMPLVIWVYSTDTNFSDMFWS 1042 
RQPLTTSWTPDHTGRNEPEVSAGNRVESPVCTSD— 1043
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APPENDIX B
DtfJMoT
Below we show all motifs, including those that appear in regions or proteins not 
used for the P-/Scons calculation (i.e. in filtered domains, or duplicate homologous 
regions). Filtered regions appear in a lower case letters. An asterix in the alignment 
indicates that the motif is present in that species, in addition to the original
sequence (ORG)_________________________ (help)
You can download sequences below in fasta format (download).
The proteins below contain the SxxRxS motif.
>Adducin
MNGDSRAAVVTSPPPTTAPHKERYFDRVDENNPEYLRERNMAPDLRQDFNMMEQKKRVS 
MILQSPAFCEELESMIQEQFKKGKNPTGLLALQQIADFMTTNVPNVYPAAPQGGMAALN 
MSLGMVTPVNDLRGSDSIAYDKGEKLLRCklaafyrladlfgwsqliynhittrvnseq 
ehflivpfgllysevtasslvkinlqgdivdrgstnlgvnqagftlhsaiyaarpdvkc 
vvhihtpagaavsamkcgllpispealslgevayhdyhgilvdeeekvliqknlgpksk 
vlilrnhglvsvgesveeafyyihnlvvaceiqvrtlasaggpdnlvllnpEKYKAKSR 
SPGSPVGEGTGSPPKWQIGEQEFEALMRMLDNLGYRTGYPYRYPALREKSKKYSDVEVP 
ASVTGYSFASDGDSGTCSPLRHSFQKQQREKTRWLNSGRGDEASEEGQNGSSPKSKTKW 
TKEDGHRTSTSAVPNLFVPLNTNPKEVQEMRNKIREQNLQDIKTAGPQSQVLCGVVMDR 
SLVQGELVTASKAIlEKEYQPHVIVSTTGPNPFTTLTdreleeyrreverkqkgseenl 
deareqkeksPPDQPAVPHPPPSTPIKLEEDLVPEPTTGDDSDAATFKPTLPDLSPDEP 
SEALGFPMLEKEEEAHRPPSPTEAPTEASPEPAPDPAPVAEEAAPSAVEEGAAADPGSD 
GSPGKSPSKKKKKFRTPSFLKKSKKKSDS
>Mat8
MQKVTLGLLVFLAGFPVLDANDLEDKNSPFYYDWhslqvgglicagvlcamgiiivMSE
WRSSGEQAGRGWGSPPLTTQLSPTGAKCKCKFGQKSGHHPGETPPLITPGSAOS
>PI3K
MAASGVPRGCDILIVYSPDAEEWCQYLQTLFLSSRQVRSQKILTHRLGPEASFSAEDLS 
LFLSTRCVVVLLSAELVQHFHKPALLPLLQRAFHPPHRVVRLLCGVRDSEEFLDFFPDW 
AHWQELTCDDEPETYVAAVKKAISEDSGCDSVTDTEPEDEKVVSYSKQQNLPTVTSPGN 
LMVVQPDRIRCGAETTVYVIVRCKLDDRVATEAEFSPEDSPSVRMEAKVENEYTISVKA 
PNLSSGNVSLKIYSGDLWCETVISYYTDMEEIGNLLSNAANPVEFMCQAFKIVPYNTE 
TLDKLLTESLKNNIPASGLHLFGINQLEEEDMMTNQRDEELPTLLHFAAKYGLKNLTAL 
LLTCPGALQAYSVANKHGHYPNTIAEKHGFRDLRQFIDEYVETVDMLKSHIKEELMHGE 
EADAVYESMAHLSTDLLMKCSLNPGCDEDLYESMAAFVPAATEDLYVEMLQASTSNPIP 
GDGFSRATKDSMIRKFLEGNSMGMTNLERDQCHLGQEEDVYHTVDDDEAFSVDLASRPP 
VPVPRPETTAPGAHQLPDNEPYIFKVFAEKSQERPGNFYVSSESIRKGPPVRPWRDRPQ 
SSIYDPFAGMKTPGQRQLITLQEQVKLGIVNVDEAVLHFKEWQLNQKKRSESFRFQQEN 
LKRLRDSITRRQREKQKSGKQTDLEITVPIRHSQHLPAKVEFGVYESGPRKSVIPPRTE 
LRRGDWKTDSTSSTASSTSNRSSTRSLLSVSSGMEGDNEDNEVPEVTRSRSPGPPQVDG 
TPTMSLERPPRVPPRAASQRPPTRETFHPPPPVPPRGR
>PLM
Maslghilvfcvglltmakaespkehdpftydyqslqigglviagilfilgilivlsrr 
crckfnqqqrtgepdEEEGTFRSSIRRLSTRRR
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>SRC
MGSNKSKPKDASQRRRSLEPAENVHGAGGGAFPASQTPSKPASADGHRGPSAAFAPAAA 
EPKLFGGFNSSDTVTSPQRAGPLAGGVTtfvalydyesrtetdlsfkkgerlqivnnte 
gdwwlahslstgqtgyipsnyvapsdSIQAEewyfgkitrreserlllnaenprgtfIv 
resettkgayclsvsdfdnakglnvkhykirkldsggfyitsrtqfnslqqlvayyskh 
adgLCHRLTTVCPTSKPQTQGLAKDAWEIPRESLrlevklgqgcfgevwragtwngttrv 
aiktlkpgtmspeafIqeaqvmkklrheklvqlyavvseepiyivteymskgslldfIk 
getgkylrlpqlvdmaaqiasgmayvermnyvhrdlraanilvgenlvckvadfglarl 
iedneytarqgakfpikwtapeaalygrftiksdvwsfgilltelttkgrvpypgmvnr 
evldqvergyrmpcppecpeslhdlmcqcwrkepeerptfeylqaf1EDYFTSTEPQYQ 
PGENL
The proteins below do not contain the SxxRxS motif.
>Ank
MPYSVGFREADaatsfIraarsgnldkaldhlrngvdintCNQNglnglhlaskeghvkm 
vvellhkeiiletttkKgntalhiaalagqdevvrelvnyganvnaqsqKgftplymaaq 
enhlevvkfllenganqnvateDgftplavalqqghenvvahlinygtkgkvrlpalhia 
arnddtrtaavllqndpnpdvlskTgftplhiaahyenlnvaqlllnrgasvnftpqNgi 
tplhiasrrgnvimvrllldrgaqietktkDeltplhcaarnghvriseilldhgapiqa 
ktkNglspihmaaqgdhldcvrlllqydaeidditlDhltplhvaahcghhrvakvlldk 
gakpnsralNgftplhiackknhvrvmelllktgasidavteSgltplhvasfmghlpiv 
knllqrgaspnvsnvKvetplhmaaraghtevakyllqnkakvnakakDdqtplhcaari 
ghtnmvklllennanpnlattAghtplhiaareghvetvlallekeasqacmtkKgftpl 
hvaakygkvrvaelllerdahpnaagkNgltplhvavhhnnldivklllprggsphspaw 
NgytplhiaakqnqvevarsllqyggsanaesvQgvtplhlaaqeghaemvalllskqan 
gnlgnkSgltplhlvaqeghvpvadvlikhgvmvdattrMgytplhvashygniklvkf1 
IqhqadvnaktkLgysplhqaaqqghtdivtlllkngaspnevssDGTTPLAIAKRLGYI 
SVTDVLKWTDETSFVLVSDKHRMSFPETVDEILDVSEDEGEELISFKAERRDSRDVDEE 
KELLDFVPKLDQWESPAIPRIPCAMPETWIRSEEQEQASKEYDEDSLIPSSPATETSD 
NISPVASPVHTgfIvsfmvdarggsmrgsrhnglrvvipprtcaaptritcrlvkpqkls 
tppplaeeeglasriialgptgaqfIspviveiphfashgrgdrelvvlrsengsVWKEH 
RSRYGESYLDQILNGMDEELGSLEELEKKRVCRIITTDFPLYFVIMSRLCQDYDTIGPEG 
GSLKSKLVPLVQATFPENAVTKRVKLALQAQPVPDELVTKLLGNQATFSPIVTVEPRRRK 
FHRPIGLRIPLPPSWTDNPRDSGEGDTTSLRLLCSVIGGTDQAQWEDITGTTKLVYANEC 
ANFTTNVSARFWLSDCPRTAEAVNFATLLYKELTAVPYMAKFVIFAKMNDPREGRLRCYC 
MTDDKVDKTLEQHENFVEVARSRDIEVLEGMSLFAELSGNLVPVKKAAQQRSFHFQSFRE 
NRLAMPVKVRDSSREPGGSLSFLRKAMKYEDTQHILCHLNITMPPCAKGSGAEDRRRTPT 
PLALRYSILSESTpgslsgteqaemkmavisehlglswaelarelqfsvedinrirvenp 
nslleqsvallnlwviregqnanmenlytalqsidrgeivnmlegsgRQSRNLKPDRRHT 
DRDYSLSPSQMNGYSSLQDELLSPASLGCALSSPLRADQYWNEVAVLDAIPLAATEHDTM 
LEMSDMQVWSAGLTPSLVTAEDSSLECSKAEDSDATGHEWKLEGALSEEPRGPELGSLEL 
VEDDTVDSDATNGLIDLLEQEEGQRSEEKLPGSKRQDDATGAGQDSENEVSLVSGHQRGQ 
ARITHSPTVSQVTERSQDRLQDWDADGSIVSYLQDAAQGSWQEEVTQGPHSFQGTSTMTE 
GLEPGGSQEYEKVLVSVSEHTWTEQPEAESSQADRDRRQQGQEEQVQEAKNTFTQWQGN 
EFQNIPGEQVTEEQFTDEQGNIVTKKIIRKWRQIDLSSADAAQEHEEVTVEGPLEDPSE 
LEVDIDYFMKHSKDHTSTPNP
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